

# CITATION REPORT

List of articles citing

**Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria**

**DOI: 10.1016/s1474-4422(07)70178-3**  
**Lancet Neurology, The, 2007, 6, 734-46.**

**Source:** <https://exaly.com/paper-pdf/42995749/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2281	Integrated care pathways in dementia: a challenge to National Institute for Health and Clinical Excellence/Social Care Institute for Excellence guidance. <b>2007</b> , 11, 95-99		6
2280	Editorial comment on 'Prevalence of dementia in the United States: the aging, demographics, and memory study' by Plassman et al. <b>2007</b> , 29, 133-5		10
2279	Clinical prediction of Alzheimer disease dementia across the spectrum of mild cognitive impairment. <b>2007</b> , 64, 1443-50		126
2278	Role of imaging techniques in the diagnosis of dementia. <b>2007</b> , 80 Spec No 2, S71-7		75
2277	Imaging in dementia. <b>2007</b> , 19, 133-141		
2276	Clinicopathological concordance and discordance in three monozygotic twin pairs with familial Alzheimer's disease. <b>2007</b> , 78, 1039		1
2275	Visual rating and ROI-based parametric analysis of rCBF SPECT in patients with mild or questionable dementia: a comparative study. <b>2007</b> , 24, 429-33		7
2274	Commentary on "The Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia, 2006.". <b>2007</b> , 3, 444-5		1
2273	Distinguishing Lewy body dementias from Alzheimer's disease. <b>2007</b> , 7, 1499-516		22
2272	Still debating a cause and diagnostic criteria for Alzheimer's disease. <b>2007</b> , 11, 1225-6		7
2271	A new framework for the diagnosis of Alzheimer's disease. <i>Lancet Neurology, The</i> , <b>2007</b> , 6, 667-9	24.1	19
2270	Prevention of progression to dementia in the elderly: rationale and proposal for a health-promoting memory consultation (an IANA Task Force). <b>2008</b> , 12, 520-9		19
2269	Apports de la biologie dans le diagnostic des démences. <b>2008</b> , 28, 29-33		
2268	Apport des biomarqueurs au diagnostic de la maladie de Parkinson. <b>2008</b> , 28, 34-37		
2267	Molecular imaging in dementia. <b>2008</b> , 35 Suppl 1, S1-3		10
2266	Individual cerebral metabolic deficits in Alzheimer's disease and amnesic mild cognitive impairment: an FDG PET study. <b>2008</b> , 35, 1357-66		83
2265	Principal component analysis of FDG PET in amnesic MCI. <b>2008</b> , 35, 2191-202		64

2264	[Antidementia drugs--response or non-response?]. <b>2008</b> , 49, 353-9	4
2263	[Treatment and care strategies for Alzheimer's disease and related dementias]. <b>2008</b> , 79, 617-28, quiz 629	6
2262	[New perspectives in the laboratory diagnosis of dementia]. <b>2008</b> , 79 Suppl 3, 139-46; quiz 147-8	0
2261	La maladie d'Alzheimer: une maladie du cerveau et une maladie de l'esprit. <b>2008</b> , 6, 57-59	
2260	L'apport de la neuro-imagerie dans la maladie d'Alzheimer. <b>2008</b> , 6, 68-75	
2259	The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias. <b>2008</b> , 38, 1-15	81
2258	Therapeutic strategies for Alzheimer's disease. <b>2008</b> , 37, 171-86	102
2257	Alzheimer's disease and other dementing conditions. <b>2008</b> , 29 Suppl 3, 301-7	12
2256	Brain SPECT in subtypes of mild cognitive impairment. Findings from the DESCRIPA multicenter study. <b>2008</b> , 255, 1344-53	50
2255	Clinical proteomics of the cerebrospinal fluid: Towards the discovery of new biomarkers. <b>2008</b> , 2, 428-36	69
2254	A 2-year follow-up of 233 very mild (CDR 0.5) Alzheimer's disease patients (REAL.FR cohort). <b>2008</b> , 23, 460-5	13
2253	Current awareness in geriatric psychiatry. <b>2008</b> , 23, i-xii	
2252	Prodromal Alzheimer's disease: successive emergence of the clinical symptoms. <b>2008</b> , 64, 492-8	477
2251	White matter lesion severity is associated with reduced cognitive performances in patients with normal CSF Abeta42 levels. <b>2008</b> , 118, 373-8	9
2250	Neuroscience: The plaque plan. <b>2008</b> , 456, 161-4	44
2249	Cognitive syndrome of the thalamus: a misleading differential diagnosis of Alzheimer's disease. <b>2008</b> , 56, 1970-1	0
2248	Two-year progression from mild cognitive impairment to dementia: to what extent do different definitions agree?. <b>2008</b> , 56, 1424-33	174
2247	Hypertension after acute ischemic stroke in older patients: effect on neurological outcome. <b>2008</b> , 56, 1971-3	2

2246	Current and future therapy in Alzheimer's disease. <b>2008</b> , 22, 265-74		112
2245	MRI-based automated computer classification of probable AD versus normal controls. <b>2008</b> , 27, 509-20		115
2244	Association between the interleukin-1beta polymorphisms and Alzheimer's disease: a systematic review and meta-analysis. <b>2008</b> , 59, 155-63		94
2243	The potential role of nutritional components in the management of Alzheimer's Disease. <b>2008</b> , 585, 197-207		29
2242	A life course of adiposity and dementia. <b>2008</b> , 585, 163-75		86
2241	Intravenous immunoglobulin: a first-line treatment in CIDP?. <i>Lancet Neurology, The</i> , <b>2008</b> , 7, 115-6	24.1	6
2240	Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. <i>Lancet Neurology, The</i> , <b>2008</b> , 7, 129-35	24.1	551
2239	Imaging of amyloid comes of age. <i>Lancet Neurology, The</i> , <b>2008</b> , 7, 114-5	24.1	3
2238	Current and future uses of neuroimaging for cognitively impaired patients. <i>Lancet Neurology, The</i> , <b>2008</b> , 7, 161-72	24.1	110
2237	Endpoints for trials in Alzheimer's disease: a European task force consensus. <i>Lancet Neurology, The</i> , <b>2008</b> , 7, 436-50	24.1	123
2236	Revised research diagnostic criteria for Alzheimer's disease. <i>Lancet Neurology, The</i> , <b>2008</b> , 7, 668-70	24.1	18
2235	Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. <i>Lancet Neurology, The</i> , <b>2008</b> , 7, 779-86	24.1	577
2234	Biomarkers for early diagnosis of Alzheimer disease: 'ALzheimer ASsociated gene'--a new blood biomarker?. <b>2008</b> , 12, 1094-117		37
2233	Functional abnormalities of the medial temporal lobe memory system in mild cognitive impairment and Alzheimer's disease: insights from functional MRI studies. <b>2008</b> , 46, 1624-35		285
2232	Recollection and familiarity in amnesic mild cognitive impairment: a global decline in recognition memory. <b>2008</b> , 46, 1965-78		88
2231	Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. <b>2008</b> , 46, 1688-97		239
2230	Increased biomagnetic activity in the ventral pathway in mild cognitive impairment. <b>2008</b> , 119, 1320-7		27
2229	Early diagnosis and treatment of Alzheimer's disease. <b>2008</b> , 8, 769-80		20

2228	Colostrinin: a naturally occurring compound derived from mammalian colostrum with efficacy in treatment of neurodegenerative diseases, including Alzheimer's. <b>2008</b> , 9, 2553-9	6
2227	Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. <b>2008</b> , 24, 2561-74	106
2226	Mild cognitive impairment: challenging issues. <b>2008</b> , 16, 339-42	2
2225	SPECT neuroimaging in translational research of CNS disorders. <b>2008</b> , 52, 352-62	29
2224	[A new conception of Alzheimer disease]. <b>2008</b> , 29, 763-5	1
2223	[Near a biological diagnosis of Alzheimer's disease and related disorders]. <b>2008</b> , 29, 785-93	2
2222	Cognition in REM sleep behavior disorder - A window into preclinical dementia?. <b>2008</b> , 9, 341-2	10
2221	Neuro-archaeology: pre-symptomatic architecture and signature of neurological disorders. <b>2008</b> , 31, 626-36	98
2220	Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. <b>2008</b> , 213, 315-25	282
2219	Realizing the potential of positron emission tomography with 18F-fluorodeoxyglucose to improve the treatment of Alzheimer's disease. <b>2008</b> , 4, S29-36	20
2218	Prevention therapeutics of dementia. <b>2008</b> , 4, S122-30	11
2217	Current challenges for the successful treatment and prevention of Alzheimer's disease: treating the pathologies of the disease to change its clinical course. <b>2008</b> , 4, S119-21	7
2216	Current and future management of Alzheimer's disease. <b>2008</b> , 4, S48-50	7
2215	Dementia of the Alzheimer type. <b>2008</b> , 30, 15-34	94
2214	Investigation of Nonneoplastic Neurologic Disorders with PET and MRI. <b>2008</b> , 3, 317-34	3
2213	Research criteria for the diagnosis of Alzheimer's disease: genetic risk factors, blood biomarkers and olfactory dysfunction. <b>2008</b> , 20, 853-5	13
2212	Diagnostic and prognostic needs in neurodegenerative disorders: focus on proteomics. <b>2008</b> , 5, 153-6	3
2211	. <b>2008</b> ,	7

2210	Mild cognitive impairment: believe it or not?. <b>2008</b> , 20, 357-63	34
2209	The Japanese MCI screen for early detection of Alzheimer's disease and related disorders. <b>2008</b> , 23, 162-6	25
2208	Usability of cerebrospinal fluid biomarkers in a tertiary memory clinic. <b>2008</b> , 25, 553-8	8
2207	Differential hypometabolism patterns according to mild cognitive impairment subtypes. <b>2008</b> , 26, 490-8	15
2206	Multi-center comparison of medial temporal atrophy in patients with Alzheimer's disease--data from the ICTUS study. <b>2008</b> , 26, 314-22	5
2205	PENN biomarker core of the Alzheimer's disease Neuroimaging Initiative. <b>2008</b> , 16, 19-23	42
2204	Acetylcholinesterase inhibitor and N-methyl-D-aspartic acid receptor antagonist use among hospice enrollees with a primary diagnosis of dementia. <b>2008</b> , 11, 738-45	20
2203	Treatment options in Alzheimer's disease: maximizing benefit, managing expectations. <b>2008</b> , 25, 408-22	86
2202	Cerebrospinal fluid biomarkers in the evaluation of Alzheimer disease. <b>2008</b> , 54, 1589-91	5
2201	Alzheimer's disease drug development: old problems require new priorities. <b>2008</b> , 7, 499-511	20
2200	Voxel-based morphometry in Alzheimer's disease. <b>2008</b> , 8, 1691-702	95
2199	Controversies in Alzheimer's disease drug development. <b>2008</b> , 20, 389-95	17
2198	Alzheimer's disease drug development in 2008 and beyond: problems and opportunities. <b>2008</b> , 5, 346-57	44
2197	Atrophy accelerates with conversion from mild cognitive impairment to Alzheimer disease. <b>2008</b> , 70, 1728-9	3
2196	Issues in Design and Conduct of Clinical Trials for Cognitive-Enhancing Drugs. <b>2008</b> , 21-76	2
2195	Geographical differences in the occurrence of Alzheimer's disease mortality: United States versus Puerto Rico. <b>2008</b> , 23, 462-9	6
2194	Cognitive impairment no dementia - neuropsychological and neuroimaging characterization of an amnesic subgroup. <b>2008</b> , 25, 238-47	15
2193	Tau as a biomarker of neurodegenerative diseases. <b>2008</b> , 2, 363-84	61

2192	Functional MRI in the early diagnosis of Alzheimer's disease: is it time to refocus?. <b>2008</b> , 8, 169-75	11
2191	Diagnosis and treatment of dementia: 3. Mild cognitive impairment and cognitive impairment without dementia. <b>2008</b> , 178, 1273-85	93
2190	Development of screening guidelines and clinical criteria for predementia Alzheimer's disease. The DESCRIPA Study. <b>2008</b> , 30, 254-65	64
2189	Towards an objective assessment of alzheimer's disease. <b>2008</b> ,	4
2188	Neurobiology of sleep disturbances in neurodegenerative disorders. <b>2008</b> , 14, 3430-45	45
2187	Safety and efficacy of galantamine in subjects with mild cognitive impairment. <b>2008</b> , 70, 2024-35	198
2186	Biomarker bei neurodegenerativen Demenzen. <b>2008</b> , 35, 526-538	1
2185	Subjective memory complaints and concurrent memory performance in older patients of primary care providers. <b>2008</b> , 14, 1004-13	54
2184	Potential for misclassification of mild cognitive impairment: a study of memory scores on the Wechsler Memory Scale-III in healthy older adults. <b>2008</b> , 14, 463-78	119
2183	[Clinical approach and pathological cascade of dementia]. <b>2008</b> , 48, 467-75	1
2182	Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?. <b>2008</b> , 15, 303-25	97
2181	Mild cognitive impairment: a concept ready to move on?. <b>2008</b> , 21, 529-32	15
2180	Brain Diffusion Changes in Patients Diagnosed with Alzheimers Disease. <b>2008</b> , 4, 226-230	2
2179	Genetic assessment and management of dementia. <b>2008</b> , 8, 618-21	0
2178	Integrating symptomatic- and disease-modifying treatments. <b>2008</b> , 13, 28-30	3
2177	Lessons learned from failed and discontinued clinical trials for the treatment of Alzheimer's disease: future directions. <b>2008</b> , 15, 327-38	21
2176	Plasma biomarkers of Alzheimer's disease. <b>2008</b> , 21, 260-7	27
2175	Towards an earlier diagnosis of Alzheimer disease (Proceedings of the 5th MCI Symposium, 2007). <b>2008</b> , 22, 99-110	7

2174	Bibliography. Current world literature. Addictive disorder. <b>2008</b> , 21, 303-11	
2173	Diagnostic uncertainty in a severely demented male patient: a case report. <b>2008</b> , 1, 250	
2172	Early identification of Alzheimer's disease: what have we learned from mild cognitive impairment?. <b>2008</b> , 13, 4-7	2
2171	Taking the next steps in the treatment of Alzheimer's disease: disease-modifying agents. <b>2008</b> , 13, 11-4	
2170	Disease modifying trials in Alzheimer's disease: perspectives for the future. <b>2008</b> , 15, 289-301	13
2169	Combining functional scales and cognitive tests in screening for mild cognitive impairment at a university-based memory clinic in Brazil. <b>2008</b> , 30, 346-9	30
2168	. <b>2009</b> ,	3
2167	CSF studies facilitate DNA diagnosis in familial Alzheimer's disease due to a presenilin-1 mutation. <b>2009</b> , 17, 53-7	5
2166	Applying new research criteria for diagnosis of early Alzheimer's disease: sex and intelligence matter. <b>2009</b> , 2009,	1
2165	Telemedicine and Alzheimer's disease from studio-based videoconferencing to mobile handheld cell phones. <b>2009</b> , 1, 39-43	6
2164	Diffusion tensor imaging for Alzheimer's disease: A review of concepts and potential clinical applicability. <b>2009</b> , 3, 268-274	5
2163	Approach to the Patient with Abnormal Cerebrospinal Fluid Protein Content. <b>2009</b> , 287-294	2
2162	Brain imaging and neuropathologic mechanisms in Alzheimer's disease: vascular versus neurodegenerative and amyloid-beta versus tau. <b>2009</b> , 18, 419-27	1
2161	Structural Neuroimaging in the Detection and Prognosis of Pre-Clinical and Early AD. <b>2009</b> , 21, 3-12	38
2160	Applications of Neuroimaging to Disease-Modification Trials in Alzheimer's Disease. <b>2009</b> , 21, 129-136	16
2159	Large-Scale Functional Brain Network Abnormalities in Alzheimer's Disease: Insights from Functional Neuroimaging. <b>2009</b> , 21, 63-75	140
2158	Fully-Automated Volumetric MRI with Normative Ranges: Translation to Clinical Practice. <b>2009</b> , 21, 21-28	83
2157	Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer's disease. <b>2009</b> , 4, e6501	269



2156	Interactive exploration of neuroanatomical meta-spaces. <b>2009</b> , 3, 38	11
2155	Sleep, Breathing, and Neurologic Disorders. <b>2009</b> , 436-498	2
2154	Increased total TAU but not amyloid-beta(42) in cerebrospinal fluid correlates with short-term memory impairment in Alzheimer's disease. <b>2009</b> , 18, 907-18	24
2153	The emergence of cognitive discrepancies in preclinical Alzheimer's disease: a six-year case study. <b>2009</b> , 15, 278-93	9
2152	Cholesterol-modifying strategies for Alzheimer's disease. <b>2009</b> , 9, 695-709	27
2151	Brain metabolic correlates of cerebrospinal fluid beta-amyloid 42 and tau in Alzheimer's disease. <b>2009</b> , 27, 474-80	11
2150	Alterations in regional brain volume and individual MRI-guided perfusion in normal control, stable mild cognitive impairment, and MCI-AD converter. <b>2009</b> , 22, 35-45	18
2149	Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging. <b>2009</b> , 50, 818-22	175
2148	Diagnostic evaluation of dementia in the secondary health care sector. <b>2009</b> , 27, 534-42	22
2147	Cognitive reserve in relation to abeta42 in patients converting from MCI to dementia - a follow-up report. <b>2009</b> , 28, 110-5	11
2146	Performance of FDG PET for detection of Alzheimer's disease in two independent multicentre samples (NEST-DD and ADNI). <b>2009</b> , 28, 259-66	58
2145	'Attended alone' sign: validity and reliability for the exclusion of dementia. <b>2009</b> , 38, 476-8	28
2144	Nanotechnology, Nanostructure, and Nervous System Disorders. <b>2009</b> , 177-226	1
2143	Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. <b>2009</b> , 66, 382-9	607
2142	Personality features in subjective cognitive impairment and mild cognitive impairment--early indicators of dementia?. <b>2009</b> , 28, 528-35	21
2141	Mini-mental state examination is sensitive to brain atrophy in Alzheimer's disease. <b>2009</b> , 28, 252-8	31
2140	Diagnosis of mild cognitive impairment revisited after one year. Preliminary results of a prospective study. <b>2009</b> , 27, 224-31	26
2139	Minimizing misdiagnosis: psychometric criteria for possible or probable memory impairment. <b>2009</b> , 27, 439-50	44

2138	Cortical thickness analysis to detect progressive mild cognitive impairment: a reference to Alzheimer's disease. <b>2009</b> , 28, 404-12	40
2137	Early intervention for mild cognitive impairment: a randomised controlled trial. <b>2009</b> , 80, 730-6	151
2136	Early diagnosis of Alzheimer's disease using cortical thickness: impact of cognitive reserve. <b>2009</b> , 132, 2036-47	318
2135	Do amyloid-lowering strategies work clinically?. <b>2009</b> , 2, 3-6	2
2134	Creutzfeldt-jakob, Parkinson, lewy body dementia and Alzheimer diseases: from diagnosis to therapy. <b>2009</b> , 9, 2-11	6
2133	Personalized healthcare: how to improve outcomes by increasing benefit and decreasing risk through the use of biomarkers. <b>2009</b> , 3, 701-9	5
2132	Predicting the time of conversion to MCI in the elderly: role of verbal expression and learning. <b>2009</b> , 73, 1436-42	49
2131	The neuropsychiatric mental status examination. <b>2009</b> , 29, 185-93	4
2130	Diagnostic imaging of patients in a memory clinic: comparison of MR imaging and 64-detector row CT. <b>2009</b> , 253, 174-83	97
2129	Cerebrospinal fluid beta-amyloid and dynabridging in Alzheimer's disease drug development. <b>2009</b> , 3, 711-21	7
2128	New perspectives for the diagnosis of Alzheimer's disease. <b>2009</b> , 4, 160-81	11
2127	Alzheimer's disease and CSF biomarkers: key challenges for broad clinical applications. <b>2009</b> , 3, 735-7	19
2126	Chronic kidney disease definition and classification: no need for a rush to judgment. <b>2009</b> , 75, 1015-8	19
2125	Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia. <b>2009</b> , 66, 81-7	52
2124	Functional imaging in mild cognitive impairment and early Alzheimer's disease: is it pertinent?. <b>2009</b> , 24, 30-38	2
2123	Clinical syndromes associated with posterior atrophy: early age at onset AD spectrum. <b>2009</b> , 73, 1571-8	196
2122	Detection of MCI in the clinic: evaluation of the sensitivity and specificity of a computerised test battery, the Hopkins Verbal Learning Test and the MMSE. <b>2009</b> , 38, 455-60	78
2121	Cracking the therapeutic nut in mild cognitive impairment: better nuts and better nutcrackers. <b>2009</b> , 72, 1542-3	

2120	Proteomic analysis of Alzheimer's disease cerebrospinal fluid from neuropathologically diagnosed subjects. <b>2009</b> , 6, 399-406	25
2119	Current concepts of mild cognitive impairment and their applicability to persons at-risk for familial Alzheimer's disease. <b>2009</b> , 6, 341-6	17
2118	Structural and functional MRI in mild cognitive impairment. <b>2009</b> , 6, 179-85	82
2117	Mild cognitive impairment does entail retrograde amnesia for public events. <b>2009</b> , 31, 48-56	10
2116	Amyloid PET and MRI in Alzheimer's disease and mild cognitive impairment. <b>2009</b> , 6, 312-9	12
2115	Adult neurogenesis, neural stem cells and Alzheimer's disease: developments, limitations, problems and promises. <b>2009</b> , 6, 461-70	51
2114	Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease. <b>2009</b> , 73, 935-40	59
2113	Adherence to a Mediterranean diet, cognitive decline, and risk of dementia. <b>2009</b> , 302, 638-48	522
2112	Failure to report financial disclosure information. <b>2009</b> , 302, 2433-4	2
2111	Differential association of [11C]PIB and [18F]FDDNP binding with cognitive impairment. <b>2009</b> , 73, 2079-85	38
2110	Biomarkers in relation to cognitive reserve in patients with mild cognitive impairment--proof of concept. <b>2009</b> , 27, 194-200	24
2109	Minute effects of sex on the aging brain: a multisample magnetic resonance imaging study of healthy aging and Alzheimer's disease. <b>2009</b> , 29, 8774-83	92
2108	Patterns of brain atrophy on magnetic resonance imaging and the boundary between ageing and Alzheimer's disease. <b>2009</b> , 19, 295-307	4
2107	Improving the care of people with dementia at the end of life: The role of hospice and the US experience. <b>2009</b> , 8, 377-389	10
2106	Alzheimer's disease: on the verges of treatment and prevention. <i>Lancet Neurology, The</i> , <b>2009</b> , 8, 4-5	24.1 20
2105	Will CSF analysis become routine in people with memory complaints?. <i>Lancet Neurology, The</i> , <b>2009</b> , 8, 595-6	24.1 3
2104	Cognitive deficits in middle-aged and older adults with bipolar disorder and cognitive complaints: comparison with mild cognitive impairment. <b>2009</b> , 24, 624-31	8
2103	Voxel based morphometry features and follow-up of amnesic patients at high risk for Alzheimer's disease conversion. <b>2009</b> , 24, 875-84	15

2102	Structural MRI biomarkers for preclinical and mild Alzheimer's disease. <b>2009</b> , 30, 3238-53	172
2101	Discriminating accuracy of medial temporal lobe volumetry and fMRI in mild cognitive impairment. <b>2009</b> , 19, 166-75	29
2100	Fully automatic hippocampus segmentation and classification in Alzheimer's disease and mild cognitive impairment applied on data from ADNI. <b>2009</b> , 19, 579-87	227
2099	Neurochemical biomarkers in the differential diagnosis of movement disorders. <b>2009</b> , 24, 1411-26	31
2098	Gibt es einen Goldstandard ff.die Diagnose von Demenzen?. <b>2009</b> , 12, 24-33	
2097	Criteria for the neuropathological diagnosis of dementing disorders: routes out of the swamp?. <b>2009</b> , 117, 101-10	41
2096	The role of proteomics in dementia and Alzheimer's disease. <b>2009</b> , 118, 181-95	47
2095	To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer's disease. <b>2009</b> , 259, 248-56	41
2094	Alzheimer's disease, but not ageing or depression, affects dual-tasking. <b>2009</b> , 256, 1860-8	27
2093	Update on amyloid imaging: from healthy aging to Alzheimer's disease. <b>2009</b> , 9, 345-52	51
2092	Amyloid imaging in Alzheimer's disease and other dementias. <b>2009</b> , 3, 246-61	23
2091	Early detection of patients in the pre demented stage of Alzheimer's disease: the Pre-Al Study. <b>2009</b> , 13, 21-6	16
2090	Biomarkers for Alzheimer's disease trials--biomarkers for what? A discussion paper. <b>2009</b> , 13, 334-6	10
2089	Interest of the new criteria for drug trials in AD. <b>2009</b> , 13, 356-7	5
2088	Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy. <b>2009</b> , 13, 367-9	75
2087	Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: the ALZHEMED (Tramiprosate) experience. <b>2009</b> , 13, 370-2	23
2086	Mild Alzheimer's disease: a "position paper". <b>2009</b> , 13, 503-19	8
2085	Diagnostic prŕoche de la maladie d'Alzheimer. <b>2009</b> , 1, 42-47	1

2084	Frontières entre confusion et démence. <b>2009</b> , 1, 114-117	
2083	[Current status of cognition-based interventions in Alzheimer's disease]. <b>2009</b> , 80, 273-87	6
2082	[Informant report of cognitive changes in the elderly. A first evaluation of the German version of the IQCODE]. <b>2009</b> , 80, 1176, 1178-80, 1182-9	6
2081	Effects of medial temporal lobe degeneration on brain perfusion in amnesic MCI of AD type: deafferentation and functional compensation?. <b>2009</b> , 36, 1101-12	33
2080	EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. <b>2009</b> , 36, 2103-10	377
2079	Human freedom and the brain. <b>2009</b> , 21 Suppl 2, 1-6	
2078	CSF biomarkers: pinpointing Alzheimer pathogenesis. <b>2009</b> , 1180, 28-35	54
2077	Imaging biomarkers in Alzheimer's disease. <b>2009</b> , 1180, 20-7	7
2076	Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels. <b>2009</b> , 1180, 56-67	84
2075	AZD2184: a radioligand for sensitive detection of beta-amyloid deposits. <b>2009</b> , 108, 1177-86	111
2074	The NOS3 G894T (Glu298Asp) polymorphism is a risk factor for frontotemporal lobar degeneration. <b>2009</b> , 16, 37-42	20
2073	Classification and diagnosis of dementia: a mechanism-based approach. <b>2009</b> , 16, 168-73	10
2072	Differences in grey and white matter atrophy in amnesic mild cognitive impairment and mild Alzheimer's disease. <b>2009</b> , 16, 468-74	41
2071	EFNS guidelines on disease-specific CSF investigations. <b>2009</b> , 16, 760-70	65
2070	Current concepts in Alzheimer's disease: a multidisciplinary review. <b>2009</b> , 24, 95-121	193
2069	A systematic review of Instrumental Activities of Daily Living scales in dementia: room for improvement. <b>2009</b> , 80, 7-12	174
2068	[Diagnostic criteria for mild cognitive impairment in a cohort of 100 subjects]. <b>2009</b> , 165, 1062-70	0
2067	Alzheimer disease: Visual rating of atrophy aids diagnostic accuracy. <b>2009</b> , 5, 243-4	2

2066	Current Hypotheses and Research Milestones in Alzheimer's Disease. <b>2009</b> ,	1
2065	Application of pet imaging to diagnosis of Alzheimer's disease and mild cognitive impairment. <b>2009</b> , 84, 133-49	21
2064	Linking vascular disorders and Alzheimer's disease: potential involvement of BACE1. <b>2009</b> , 30, 1535-44	30
2063	[What should be done and not done throughout the process of dementia? Dialogue and aid]. <b>2009</b> , 44 Suppl 2, 15-21	
2062	Fish, docosahexaenoic acid and Alzheimer's disease. <b>2009</b> , 48, 239-56	224
2061	Assessing neuronal networks: understanding Alzheimer's disease. <b>2009</b> , 89, 125-33	92
2060	Neural correlates of delayed episodic memory in patients with mild cognitive impairment--a FDG PET study. <b>2009</b> , 467, 100-4	13
2059	Increase of theta/gamma ratio is associated with memory impairment. <b>2009</b> , 120, 295-303	67
2058	Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection. <b>2009</b> , 283, 119-26	14
2057	Biological fluid biomarkers in neurodegenerative parkinsonism. <b>2009</b> , 5, 561-70	54
2056	Clinical investigations in primary care. <b>2009</b> , 24, 1-11	16
2055	Case Studies. 63-192	
2054	The Italian Brain Normative Archive of structural MR scans: norms for medial temporal atrophy and white matter lesions. <b>2009</b> , 21, 266-76	28
2053	fMRI Techniques and Protocols. <b>2009</b> ,	11
2052	Alzheimer's disease therapeutic research: the path forward. <b>2009</b> , 1, 2	36
2051	[Update on Alzheimer's disease]. <b>2009</b> , 67, 116-26	3
2050	Impaired social cognition in mild Alzheimer disease. <b>2009</b> , 22, 130-40	100
2049	Redox-reactive antiphospholipid antibody differences between serum from Alzheimer's patients and age-matched controls. <b>2009</b> , 42, 646-52	11

2048	MAPK, beta-amyloid and synaptic dysfunction: the role of RAGE. <b>2009</b> , 9, 1635-45	48
2047	Quantitative evaluation of Alzheimer's disease. <b>2009</b> , 6, 569-88	12
2046	Hippocampal volume and cortical sources of EEG alpha rhythms in mild cognitive impairment and Alzheimer disease. <b>2009</b> , 44, 123-35	116
2045	Relating one-year cognitive change in mild cognitive impairment to baseline MRI features. <b>2009</b> , 47, 1363-70	73
2044	Multidimensional classification of hippocampal shape features discriminates Alzheimer's disease and mild cognitive impairment from normal aging. <b>2009</b> , 47, 1476-86	288
2043	Neural correlates of Alzheimer's disease and mild cognitive impairment: a systematic and quantitative meta-analysis involving 1351 patients. <b>2009</b> , 47, 1196-206	239
2042	Development and validation of the Memory Performance Index: reducing measurement error in recall tests. <b>2009</b> , 5, 295-306	18
2041	Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Facilitating Alzheimer's disease drug development in the United States. <b>2009</b> , 5, 125-7	3
2040	Commentary on "A roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Who may benefit from disease-modifying studies in Alzheimer's disease?. <b>2009</b> , 5, 147-8	
2039	Early risk assessment for Alzheimer's disease. <b>2009</b> , 5, 182-96	33
2038	Maximizing the Alzheimer's Disease Neuroimaging Initiative II. <b>2009</b> , 5, 271-5	15
2037	Markers of Alzheimer's disease in a population attending a memory clinic. <b>2009</b> , 5, 307-17	49
2036	Scales as outcome measures for Alzheimer's disease. <b>2009</b> , 5, 324-39	32
2035	Can we do better in developing new drugs for Alzheimer's disease?. <b>2009</b> , 5, 489-91	21
2034	The Diagnosis of Dementia in Subjects with Heterogeneous Educational Levels. <b>2009</b> , 229-236	
2033	CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. <b>2009</b> , 302, 385-93	758
2032	Association of plasma amyloid beta with risk of dementia: the prospective Three-City Study. <b>2009</b> , 73, 847-53	111
2031	Blood protein signature for the early diagnosis of Alzheimer disease. <b>2009</b> , 66, 161-5	39

2030	Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. <i>Lancet Neurology, The</i> , <b>2009</b> , 8, 619-27	24.1	473
2029	Les troubles cognitifs de la maladie d'Alzheimer et des syndromes apparentés : pourquoi et comment les explorer ?. <b>2009</b> , 9, 183-190		
2028	P2a-5 Validation de la valeur prédictive du rapport A $\beta$ 42/A $\beta$ 40 du LCS pour le diagnostic de la maladie d'Alzheimer. <b>2009</b> , 165, 67-68		
2027	[CSF biomarkers: proteomics investigations and clinical applications in neurodegenerative disorders]. <b>2009</b> , 165, 213-22		9
2026	Mettre la maladie d'Alzheimer en images. <b>2009</b> , 9, 196-202		
2025	Évolution du concept de mild cognitive impairment. <b>2009</b> , 9, 11-16		0
2024	[Validation of a brief screening scale evaluating praxic abilities for use in memory clinics. Evaluation in 419 controls, 127 mild cognitive impairment and 320 demented patients]. <b>2009</b> , 165, 560-7		64
2023	Design, synthesis, and testing of difluoroboron-derivatized curcumins as near-infrared probes for in vivo detection of amyloid-beta deposits. <b>2009</b> , 131, 15257-61		325
2022	Cerebrospinal fluid analysis for diagnosis of noninflammatory, dementive and psychiatric diseases. <b>2009</b> , 21 Suppl 2, 58-61		25
2021	Near-infrared spectroscopy of blood plasma for diagnosis of sporadic Alzheimer's disease. <b>2009</b> , 17, 391-7		35
2020	Mild Cognitive Impairment and Functional Imaging. <b>2009</b> , 98, 1378-1384		
2019	Current and future treatments for Alzheimer's disease. <b>2009</b> , 14, 4-7; discussion 16-8		6
2018	Antibiotics and antivirals for dementia and mild cognitive impairment. <b>2009</b> ,		
2017	Testosterone supplementation for mild cognitive impairment and dementia. <b>2009</b> ,		
2016	Frontotemporal dementia and dementia with Lewy bodies in a case-control study of Alzheimer's disease. <b>2009</b> , 21, 688-95		14
2015	Alzheimer's disease: from pathogenesis to novel therapeutic approaches. <b>2009</b> , 6, 259-277		1
2014	Risk of incident Alzheimer's disease in diabetic patients: a systematic review of prospective trials. <b>2009</b> , 16, 677-85		157
2013	Relevance of the evaluation criteria used in clinical trials for Alzheimer's disease. <b>2009</b> , 64, 139-8		5



2012	Pertinence des critères d'évaluation utilisés dans les essais cliniques sur la maladie d'Alzheimer. <b>2009</b> , 64, 139-143	4
2011	SPECT predictors of cognitive decline and Alzheimer's disease in mild cognitive impairment. <b>2009</b> , 17, 761-72	36
2010	Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story. <b>2009</b> , 4, 91-106	23
2009	MCP-1 A-2518G polymorphism: effect on susceptibility for frontotemporal lobar degeneration and on cerebrospinal fluid MCP-1 levels. <b>2009</b> , 17, 125-33	17
2008	Microglial upregulation of progranulin as a marker of motor neuron degeneration. <b>2010</b> , 69, 1191-200	55
2007	Syndrome dmentiel : diagnostic et prise en charge. <b>2010</b> , 5, 1-10	
2006	Genetic and Genomic Aspects of Alzheimer's Disease. <b>2010</b> , 19, 334-341	
2005	The concept of dementia: retain, reframe, rename or replace?. <b>2010</b> , 22, 37-42	18
2004	Screening for mental disorders in residential aged care facilities. <b>2010</b> , 22, 1107-20	19
2003	Diagnosis of prodromal Alzheimer's disease: do you really want to know?. <b>2010</b> , 37, 2	2
2002	Diagnosis disclosure of prodromal Alzheimer disease-ethical analysis of two cases. <b>2010</b> , 37, 67-75	15
2001	Evidence of syntaxin 1A involvement in migraine susceptibility: a Portuguese study. <b>2010</b> , 67, 422-7	10
2000	Preliminary evidence of validity of the revised criteria for Alzheimer disease diagnosis: report of 2 cases. <b>2010</b> , 24, 108-14	10
1999	Patient management problem. <b>2010</b> , 16, 212-23	
1998	Adenosine A2A receptor expression in peripheral blood mononuclear cells of patients with mild cognitive impairment. <b>2010</b> , 20, 991-6	17
1997	Clinically different stages of Alzheimer's disease associated by amyloid deposition with [11C]-PIB PET imaging. <b>2010</b> , 21, 995-1003	38
1996	The neuropsychological presentation of Alzheimer's disease and other neurodegenerative disorders. <b>2010</b> , 561-584	
1995	Plasma carbonic anhydrase II protein is elevated in Alzheimer's disease. <b>2010</b> , 21, 939-45	27

1994	[Not Available]. <b>2010</b> , 65, 277-83	1
1993	Biomarkers for the early stages of clinical development in Alzheimer's disease. <b>2010</b> , 65, 285-90, 277-283	1
1992	[The Alzheimer's disease: how to estimate the impact of the pathology and the treatment?]. <b>2010</b> , 65, 423-8	
1991	Conceptual evolution in Alzheimer's disease: implications for understanding the clinical phenotype of progressive neurodegenerative disease. <b>2010</b> , 19, 253-72	63
1990	Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years. <b>2010</b> , 21, 1119-28	94
1989	The amnesic syndrome of hippocampal type in Alzheimer's disease: an MRI study. <b>2010</b> , 22, 285-94	114
1988	Combination treatments in Alzheimer's disease: risks and benefits. <b>2010</b> , 10, 693-702	14
1987	Mapping brain morphological and functional conversion patterns in amnesic MCI: a voxel-based MRI and FDG-PET study. <b>2010</b> , 37, 36-45	82
1986	Brain perfusion SPECT correlates with CSF biomarkers in Alzheimer's disease. <b>2010</b> , 37, 589-93	19
1985	Molecular imaging in cognitive impairment: the relevance of cognitive reserve, importance of multisite longitudinal trials and challenges of standardised analysis. <b>2010</b> , 37, 399-404	2
1984	Does registration of serial MRI improve diagnosis of dementia?. <b>2010</b> , 52, 987-95	2
1983	Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. <b>2010</b> , 119, 669-78	140
1982	Visual short-term memory binding in Alzheimer's disease and depression. <b>2010</b> , 257, 1160-9	63
1981	Reduced benefit from mnemonic strategies in early-stage Alzheimer's disease: a brief testing-the-limits paradigm for clinical practice. <b>2010</b> , 257, 1718-26	5
1980	The new Alzheimer's criteria in a naturalistic series of patients with mild cognitive impairment. <b>2010</b> , 257, 2004-14	38
1979	Cortical excitability in very mild Alzheimer's disease: a long-term follow-up study. <b>2010</b> , 257, 2078-85	24
1978	Sharpening the boundaries of Parkinson-associated dementia: recommendation for a neuropsychological diagnostic procedure. <b>2010</b> , 117, 353-67	7
1977	The potential and limits for clinical trials for early Alzheimer's disease and some recommendations. <b>2010</b> , 14, 295-8	22

1976	Evolving early (pre-dementia) Alzheimer's disease trials: suit the outcomes to the population and study design. <b>2010</b> , 14, 299-302		2
1975	Clinical trials for early (pre-dementia) Alzheimer's disease: a case for mild cognitive impairment. <b>2010</b> , 14, 304-5		6
1974	Seeing with new eyes: finding a path to early intervention trials in Alzheimer's disease. <b>2010</b> , 14, 306-9		8
1973	Functional alterations in memory networks in early Alzheimer's disease. <b>2010</b> , 12, 27-43		389
1972	Alterations of the sphingolipid pathway in Alzheimer's disease: new biomarkers and treatment targets?. <b>2010</b> , 12, 331-40		95
1971	Efficacy of akatinol memantine in moderate cognitive impairments. <b>2010</b> , 40, 926-33		8
1970	Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. <i>Lancet Neurology, The</i> , <b>2010</b> , 9, 119-28	24.1	2982
1969	Alzheimer's disease: clinical trials and drug development. <i>Lancet Neurology, The</i> , <b>2010</b> , 9, 702-16	24.1	836
1968	The diagnosis of young-onset dementia. <i>Lancet Neurology, The</i> , <b>2010</b> , 9, 793-806	24.1	340
1967	Revising the definition of Alzheimer's disease: a new lexicon. <i>Lancet Neurology, The</i> , <b>2010</b> , 9, 1118-27	24.1	1354
1966	Neurofilament ELISA validation. <b>2010</b> , 352, 23-31		69
1965	Is the presence of mild to moderate cognitive impairment associated with self-report of non-cancer pain? A cross-sectional analysis of a large population-based study. <b>2010</b> , 39, 734-42		23
1964	Increased hippocampal head diffusivity predicts impaired episodic memory performance in early Alzheimer's disease. <b>2010</b> , 48, 1447-53		26
1963	Manual validation of FreeSurfer's automated hippocampal segmentation in normal aging, mild cognitive impairment, and Alzheimer Disease subjects. <b>2010</b> , 181, 219-25		79
1962	Early-onset Alzheimer disease: the contribution of neuroimaging for the diagnosis. <b>2010</b> , 182, 287-8		5
1961	MRI correlates of episodic memory in Alzheimer's disease, mild cognitive impairment, and healthy aging. <b>2010</b> , 184, 57-62		86
1960	A changing landscape for advance directives in dementia research. <b>2010</b> , 70, 623-30		34
1959	Recruitment methods in Alzheimer's disease research: general practice versus population based screening by mail. <b>2010</b> , 10, 35		19

1958	Diagnosis and biomarkers of predementia in Alzheimer's disease. <b>2010</b> , 8, 89	76
1957	Memory complaints and increased rates of brain atrophy: risk factors for mild cognitive impairment and Alzheimer's disease. <b>2010</b> , 25, 1119-26	11
1956	Retrospective evaluation of revised criteria for the diagnosis of Alzheimer's disease using a cohort with post-mortem diagnosis. <b>2010</b> , 25, 988-97	24
1955	Detecting prodromal Alzheimer's disease in mild cognitive impairment: utility of the CAMCOG and other neuropsychological predictors. <b>2010</b> , 25, 1280-7	39
1954	3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI. <b>2010</b> , 31, 786-97	79
1953	Assessment of white matter tract damage in mild cognitive impairment and Alzheimer's disease. <b>2010</b> , 31, 1862-75	102
1952	Amyloid and tau proteins in cortical brain biopsy and Alzheimer's disease. <b>2010</b> , 68, 446-53	98
1951	Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid A $\beta$ 1-42. <b>2010</b> , 68, 825-34	123
1950	Optimization protocol for amyloid- $\beta$ peptides detection in human cerebrospinal fluid using SELDI TOF MS. <b>2010</b> , 4, 352-7	26
1949	Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe. <b>2010</b> , 17, 90-6	53
1948	EFNS guidelines for the diagnosis and management of Alzheimer's disease. <b>2010</b> , 17, 1236-48	329
1947	Computerized visuo-spatial memory test as a supplementary screening test for dementia. <b>2010</b> , 10, 77-82	18
1946	An update on clinical proteomics in Alzheimer's research. <b>2010</b> , 112, 1386-414	70
1945	Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease. <b>2010</b> , 122, 270-7	13
1944	Risk factors for incident mild cognitive impairment--results from the German Study on Ageing, Cognition and Dementia in Primary Care Patients (AgeCoDe). <b>2010</b> , 121, 260-72	94
1943	Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future. <b>2010</b> , 16, 1223-6	63
1942	Alzheimer's disease: strategies for disease modification. <b>2010</b> , 9, 387-98	808
1941	Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. <b>2010</b> , 9, 560-74	446

1940	Design considerations in long-term intervention studies for the prevention of cognitive decline or dementia. <b>2010</b> , 68 Suppl 1, S16-21	21
1939	The clinical approach to the person with dementia. 137-140	
1938	Structural imaging of Alzheimer's disease. 313-331	
1937	New developments in the diagnosis of dementia. <b>2010</b> , 107, 677-83	30
1936	In vivo imaging biomarkers in mouse models of Alzheimer's disease: are we lost in translation or breaking through?. <b>2010</b> , 2010,	11
1935	CSF Biomarkers for Alzheimer's Disease Diagnosis. <b>2010</b> , 2010,	61
1934	Diagnostic tests for Alzheimer's disease: rationale, methodology, and challenges. <b>2010</b> , 2010,	6
1933	Clinical and biological predictors of Alzheimer's disease in patients with amnesic mild cognitive impairment. <b>2010</b> , 32, 216-22	36
1932	Preclinical diagnosis of Alzheimer's disease: Prevention or prediction?. <b>2010</b> , 4, 259-261	2
1931	Of course it is (the delusion that's really true). <b>2010</b> , 197, 140-140	
1930	Does Retirement Affect Cognitive Functioning?. <b>2010</b> ,	15
1929	Role of cognitive reserve in progression from mild cognitive impairment to dementia. <b>2010</b> , 4, 28-34	25
1928	Late onset Alzheimer's disease in older people. <b>2010</b> , 5, 307-11	64
1927	Treatment of Alzheimer's disease: symptomatic and disease-modifying approaches. <b>2010</b> , 3, 46-56	36
1926	Combined Analysis of CSF Tau, A $\beta$ 42, A $\beta$ 1-42% and A $\beta$ 1-40% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia. <b>2010</b> , 2010,	13
1925	Scintigraphie c $\beta$ brale de perfusion et d $\beta$ mences d $\beta$ gh $\beta$ atives. <b>2010</b> , 2, 96-99	
1924	The 7th Leonard Berg Symposium, part 2. <b>2010</b> , 20, 1255-60	
1923	Place des biomarqueurs du liquide c $\beta$ halorachidien dans le diagnostic de la maladie d'Alzheimer. <b>2010</b> , 2, 92-95	

1922	Does the source of subjects matter?: absolutely!. <b>2010</b> , 74, 1754-5	10
1921	Target-specific PET probes for neurodegenerative disorders related to dementia. <b>2010</b> , 51, 1418-30	47
1920	Errors in Table in: Evidence of Syntaxin 1A Involvement in Migraine Susceptibility: A Portuguese Study. <b>2010</b> , 67, 920	
1919	Cerebrospinal fluid tau protein levels and 18F-fluorodeoxyglucose positron emission tomography in the differential diagnosis of Alzheimer's disease. <b>2010</b> , 30, 245-53	7
1918	What's new in dementia?. <b>2010</b> , 10, 391-4	9
1917	Nonstroke cardiovascular disease and risk of Alzheimer disease and dementia. <b>2010</b> , 24, 213-9	29
1916	Complex calculations: ethical issues in involving at-risk healthy individuals in dementia research. <b>2010</b> , 36, 553-7	16
1915	Could clinical profile influence CSF biomarkers in early-onset Alzheimer disease?. <b>2010</b> , 24, 278-83	17
1914	Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease. <b>2010</b> , 24, 269-77	38
1913	Combined clinical and cognitive criteria to identify mild cognitive impairment in a southern Chinese community. <b>2010</b> , 24, 343-7	14
1912	Tau-proteins as gender-specific state markers in amnesic mild cognitive impairment. <b>2010</b> , 30, 93-100	9
1911	Galantamine for Alzheimer's disease. <b>2010</b> , 6, 345-54	51
1910	Validity of the free and cued selective reminding test in predicting dementia: the 3C study. <b>2010</b> , 74, 1760-7	57
1909	CSF biomarker utilisation and ethical considerations of biomarker assisted diagnosis and research in dementia: perspectives from within the European Alzheimer's Disease Consortium (EADC). <b>2010</b> , 81, 124-5	6
1908	CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease. <b>2010</b> , 30, 2088-101	164
1907	New research criteria for the diagnosis of Alzheimer's disease applied in a memory clinic population. <b>2010</b> , 30, 1-7	35
1906	Lack of accuracy for the proposed 'Dubois criteria' in Alzheimer's disease: a validation study from the Swedish brain power initiative. <b>2010</b> , 30, 374-80	24
1905	An exploration of cognitive subgroups in Alzheimer's disease. <b>2010</b> , 16, 233-43	24

1904	Validating the Chinese version of the Verbal Learning Test for screening Alzheimer's disease. <b>2010</b> , 16, 244-51	72
1903	Predicting cognitive decline and conversion to Alzheimer's disease in older adults using the NAB List Learning test. <b>2010</b> , 16, 651-60	13
1902	Hierarchical cognitive and psychosocial predictors of amnesic mild cognitive impairment. <b>2010</b> , 16, 721-9	3
1901	Nanoneuroscience. <b>2010</b> ,	12
1900	Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. <b>2010</b> , 74, 956-64	309
1899	Prosocial capabilities in Alzheimer's patients. <b>2010</b> , 65B, 119-28	13
1898	Frontotemporal dementia presenting as pathological gambling. <b>2010</b> , 6, 347-52	47
1897	. <b>2010</b> ,	
1896	Cerebral glucose metabolism in preclinical and prodromal Alzheimer's disease. <b>2010</b> , 10, 1667-73	94
1895	Correlation between cognitive impairment and CSF biomarkers in amnesic MCI, non-amnesic MCI, and Alzheimer's disease. <b>2010</b> , 22, 971-80	37
1894	Quantitative structural MRI for early detection of Alzheimer's disease. <b>2010</b> , 10, 1675-88	45
1893	Circulating levels of brain-derived neurotrophic factor: correlation with mood, cognition and motor function. <b>2010</b> , 4, 871-87	116
1892	White matter diffusivity predicts memory in patients with subjective and mild cognitive impairment and normal CSF total tau levels. <b>2010</b> , 16, 58-69	24
1891	Spatial working memory in aging and mild cognitive impairment: effects of task load and contextual cueing. <b>2010</b> , 17, 556-74	38
1890	Dementia diagnostics 2.0--transfer from research studies into routine clinical practice. <b>2010</b> , 56, 152-3	1
1889	Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. <b>2010</b> , 133, 3336-48	377
1888	Serial MRI and CSF biomarkers in normal aging, MCI, and AD. <b>2010</b> , 75, 143-51	117
1887	Relationship of dementia screening tests with biomarkers of Alzheimer's disease. <b>2010</b> , 133, 3290-300	77

1886	High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters. <b>2010</b> , 7, 56-66	90
1885	MCI patients declining and not-declining at mid-term follow-up: FDG-PET findings. <b>2010</b> , 7, 287-94	37
1884	Absolute diffusivities define the landscape of white matter degeneration in Alzheimer's disease. <b>2010</b> , 133, 529-39	320
1883	Clinical Nanomedicine: Nanomedical approaches in Alzheimer's disease. <b>2010</b> , 3,	1
1882	Novel CSF biomarkers for frontotemporal lobar degenerations. <b>2010</b> , 75, 2079-86	77
1881	The association between noncancer pain, cognitive impairment, and functional disability: an analysis of the Canadian study of health and aging. <b>2010</b> , 65, 880-6	28
1880	Predicting outcome in mild cognitive impairment: 4-year follow-up study. <b>2010</b> , 197, 135-40	31
1879	Cerebrospinal Fluid Biomarkers in Diagnosing Alzheimer's Disease in Clinical Practice: An Illustration with 3 Case Reports. <b>2010</b> , 2, 5-11	2
1878	Clinical Reasoning: a 59-year-old man who became lost in his own home. <b>2010</b> , 74, e66-8	
1877	Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. <b>2010</b> , 67, 217-23	72
1876	Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. <b>2010</b> , 67, 949-56	344
1875	Family history of Alzheimer's disease and hippocampal structure in healthy people. <b>2010</b> , 167, 1399-406	53
1874	General intellectual decline and daily living skills. <b>2010</b> , 24, 80-94	3
1873	Frñdiagnose der mñglichen Alzheimer-Erkrankung anhand neuer Forschungskriterien. <b>2010</b> , 41, 106-115	
1872	Prñvention von Demenzen. <b>2010</b> , 4, 361-372	
1871	Beyond the dawning of the age of biomarkers. <b>2010</b> , 18, 955-8	2
1870	Sindrome demenziale: diagnosi e gestione. <b>2010</b> , 12, 1-10	
1869	[Alzheimer disease, memory and estrogen]. <b>2010</b> , 166, 377-88	5



1868	Biomarkers in Alzheimer's disease: past, present and future. <b>2010</b> , 4, 15-26	47
1867	Diagnosis of Alzheimer's disease using neuropsychological testing improved by multivariate analyses. <b>2010</b> , 32, 793-808	35
1866	The clinical use of structural MRI in Alzheimer disease. <b>2010</b> , 6, 67-77	1131
1865	Informed consent in dementia research. Legislation, theoretical concepts and how to assess capacity to consent. <b>2010</b> , 1, 58-63	19
1864	From mild cognitive impairment to prodromal Alzheimer disease: A nosological evolution. <b>2010</b> , 1, 146-154	4
1863	Rapid cerebral amyloid binding by A $\beta$ antibodies infused into $\beta$ -amyloid precursor protein transgenic mice. <b>2010</b> , 68, 971-4	11
1862	Information about medications may cause misunderstanding in older adults with cognitive impairment. <b>2010</b> , 298, 46-51	19
1861	Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer's disease. <b>2010</b> , 51, 1345-59	203
1860	Measurement of hippocampal atrophy using 4D graph-cut segmentation: application to ADNI. <b>2010</b> , 52, 109-18	113
1859	Autobiographical memory retrieval in patients with Alzheimer's disease. <b>2010</b> , 53, 331-40	45
1858	Head size, age and gender adjustment in MRI studies: a necessary nuisance?. <b>2010</b> , 53, 1244-55	313
1857	Clinical features of rapidly progressive Alzheimer's disease. <b>2010</b> , 29, 371-8	59
1856	Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study. <b>2010</b> , 81, 1123-7	61
1855	Functional representation of olfactory impairment in early Alzheimer's disease. <b>2010</b> , 22, 581-91	52
1854	Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. <b>2010</b> , 20, 881-91	113
1853	Quantification of $\beta$ synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. <b>2010</b> , 4, 683-99	101
1852	A novel presenilin 1 mutation (Ser169del) in a Chinese family with early-onset Alzheimer's disease. <b>2010</b> , 468, 34-7	21
1851	Early event-related potentials changes during simple mental calculation in Chinese older adults with mild cognitive impairment: A case-control study. <b>2010</b> , 475, 29-32	5

1850	□Amyloid precursor protein and tau protein levels are differently regulated in human cerebellum compared to brain regions vulnerable to Alzheimer's type neurodegeneration. <b>2010</b> , 485, 162-6	22
1849	[Perfusion brain SPECT and Alzheimer disease]. <b>2010</b> , 39, 1127-31	1
1848	Scintigraphie cĕbrale de perfusion et troubles cognitifs d'origine vasculaire. <b>2010</b> , 34, 406-412	
1847	Increased sensitivity to proactive interference in amnesic mild cognitive impairment is independent of associative and semantic impairment. <b>2010</b> , 72, 325-31	11
1846	A new approach for modeling episodic memory from rodents to humans: the temporal order memory. <b>2010</b> , 215, 172-9	37
1845	Theta rhythm heterogeneity in humans. <b>2010</b> , 121, 456-7	7
1844	Slowing of EEG correlates with CSF biomarkers and reduced cognitive speed in elderly with normal cognition over 4 years. <b>2010</b> , 31, 215-23	65
1843	Subregional hippocampal atrophy predicts Alzheimer's dementia in the cognitively normal. <b>2010</b> , 31, 1077-88	210
1842	Distinctive alterations of the cingulum bundle during aging and Alzheimer's disease. <b>2010</b> , 31, 1582-92	51
1841	Amnesic MCI future clinical status prediction using baseline MRI features. <b>2010</b> , 31, 1606-17	30
1840	Added diagnostic value of CSF biomarkers in differential dementia diagnosis. <b>2010</b> , 31, 1867-76	53
1839	Integrating ADNI results into Alzheimer's disease drug development programs. <b>2010</b> , 31, 1481-92	44
1838	Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment. <b>2010</b> , 31, 1443-51, 1451.e1	45
1837	Probing the biology of Alzheimer's disease in mice. <b>2010</b> , 66, 631-45	334
1836	[Alzheimer's and related diseases: toward earlier and more accurate diagnosis]. <b>2010</b> , 31, 846-53	0
1835	Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. <b>2010</b> , 6, 131-44	1328
1834	CSF biomarkers predict a more malignant outcome in Alzheimer disease. <b>2010</b> , 74, 1531-7	141
1833	Sĕndrome demencial: diagnĕstico y tratamiento. <b>2010</b> , 14, 1-10	

1832	Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. <b>2010</b> , 223, 334-46	120
1831	An unbiased, staged, multicentre, validation strategy for Alzheimer's disease CSF tau levels. <b>2010</b> , 223, 432-8	8
1830	Early dementia diagnosis and the risk of suicide and euthanasia. <b>2010</b> , 6, 75-82	89
1829	Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. <b>2010</b> , 6, 230-8	209
1828	Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. <b>2010</b> , 6, 367-77	36
1827	Correlations between soluble $\beta$ forms of amyloid precursor protein and A $\beta$ 8, 40, and 42 in human cerebrospinal fluid. <b>2010</b> , 1357, 175-83	64
1826	Differential effects of global and cerebellar normalization on detection and differentiation of dementia in FDG-PET studies. <b>2010</b> , 49, 1490-5	102
1825	CSF biomarker pathology correlates with a medial temporo-parietal network affected by very mild to moderate Alzheimer's disease but not a fronto-striatal network affected by healthy aging. <b>2010</b> , 49, 1820-30	23
1824	Automated detection of brain atrophy patterns based on MRI for the prediction of Alzheimer's disease. <b>2010</b> , 50, 162-74	230
1823	Automated 3D mapping of baseline and 12-month associations between three verbal memory measures and hippocampal atrophy in 490 ADNI subjects. <b>2010</b> , 51, 488-99	71
1822	Cognitive intervention in Alzheimer disease. <b>2010</b> , 6, 508-17	117
1821	The use of PET in Alzheimer disease. <b>2010</b> , 6, 78-87	274
1820	Molecular imaging in the diagnosis of Alzheimer's disease: visual assessment of [ $^{11}\text{C}$ ]PIB and [ $^{18}\text{F}$ ]FDDNP PET images. <b>2010</b> , 81, 882-4	47
1819	Low incidence of post-lumbar puncture headache in 1,089 consecutive memory clinic patients. <b>2010</b> , 63, 326-30	85
1818	[Imaging of dementia in clinical routine. Recommendations of SFNR]. <b>2010</b> , 37, 122-6	7
1817	Early-versus late-onset Alzheimer's disease: more than age alone. <b>2010</b> , 19, 1401-8	282
1816	Structural brain changes in aging: courses, causes and cognitive consequences. <b>2010</b> , 21, 187-221	503
1815	Sharpen that needle. <b>2010</b> , 67, 918-20	34

1814	Screening and case-finding tools for the detection of dementia. Part II: evidence-based meta-analysis of single-domain tests. <b>2010</b> , 18, 783-800	33
1813	Assessing the progression of mild cognitive impairment to Alzheimer's disease: current trends and future directions. <b>2010</b> , 2, 28	70
1812	Role of structural MRI in Alzheimer's disease. <b>2010</b> , 2, 23	76
1811	Pro: Can biomarkers be gold standards in Alzheimer's disease?. <b>2010</b> , 2, 17	9
1810	Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?. <b>2010</b> , 2, 8	16
1809	Differences in medication use in the Alzheimer's disease neuroimaging initiative: analysis of baseline characteristics. <b>2010</b> , 27, 677-86	17
1808	CSF neurofilament proteins levels are elevated in sporadic Creutzfeldt-Jakob disease. <b>2010</b> , 21, 569-76	34
1807	Sleep well, think well: sleep-wake disturbance in mild cognitive impairment. <b>2010</b> , 23, 123-30	84
1806	Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease. <b>2010</b> , 107, 10256-61	172
1805	Altered serum glycomics in Alzheimer disease: a potential blood biomarker?. <b>2010</b> , 13, 439-44	25
1804	Monoclonal antibodies against $\beta$ -amyloid (A $\beta$ ) for the treatment of Alzheimer's disease: the A $\beta$ target at a crossroads. <b>2011</b> , 11, 679-86	35
1803	Can event-related potential predict the progression of mild cognitive impairment?. <b>2011</b> , 28, 625-32	40
1802	PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's disease. <b>2011</b> , 3, 11	32
1801	Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development. <b>2011</b> , 3, 34	36
1800	Patient self-report for evaluating mild cognitive impairment and prodromal Alzheimer's disease. <b>2011</b> , 3, 35	33
1799	Structural and functional brain imaging in the assessment of prodromal Alzheimer's disease. <b>2011</b> ,	
1798	Use of biomarkers in clinical trials of Alzheimer disease: from concept to application. <b>2011</b> , 15, 313-25	15
1797	Exploring the role of cognitive reserve in early-onset dementia. <b>2011</b> , 26, 139-44	14

1796	The 10-word learning task in the differential diagnosis of early Alzheimer's disease and elderly depression: A cross-sectional pilot study. <b>2011</b> , 15, 113-21	8
1795	[Building and validation of a test evaluating verbal recognition memory: The Forty test (f40)]. <b>2011</b> , 167, 324-30	
1794	Neuroanatomical correlates of cognitive reserve in Alzheimer disease. <b>2011</b> , 14, 143-51	51
1793	Molecular Imaging. <b>2011</b> ,	2
1792	[Use of CSF biomarkers in the diagnosis of Alzheimer's disease in clinical practice]. <b>2011</b> , 167, 474-84	10
1791	Human platelets tau: a potential peripheral marker for Alzheimer's disease. <b>2011</b> , 25, 103-9	60
1790	Troubles de la mmoire d'installation progressive chez un homme de 62 ans. <b>2011</b> , 2, 139-148	
1789	[Diagnostic norms of RAPID neuropsychological battery tests for subjects aged 60 to 89 years with Alzheimer's disease]. <b>2011</b> , 167, 495-504	7
1788	[Pure progressive amnesia, isolated for 16 years with focal hippocampus atrophy]. <b>2011</b> , 167, 622-5	2
1787	Development and cross-validation of the UPSA short form for the performance-based functional assessment of patients with mild cognitive impairment and Alzheimer disease. <b>2011</b> , 19, 915-22	37
1786	Intff du dosage des biomarqueurs du LCR dans les dñences dñhfatives. <b>2011</b> , 2, 256-263	
1785	La mayorfa de edad de la potenciación de larga duración: plasticidad sináptica y diagnóstico temprano del Alzheimer. <b>2011</b> , 3, 117-119	
1784	Enfermedad de Alzheimer. Guía de práctica clínica. <b>2011</b> , 3, 120-137	5
1783	Relación entre hipertensión arterial y la demencia. <b>2011</b> , 28, 182-195	0
1782	Folate and homocysteine in the cerebrospinal fluid of patients with Alzheimer's disease or dementia: a case control study. <b>2011</b> , 65, 270-8	31
1781	Cerebrospinal fluid biomarkers for Alzheimer's disease: the present and the future. <b>2011</b> , 8, 413-20	35
1780	What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 2: chronic progressive and relapsing disease. <b>2011</b> , 5, 393-410	3
1779	APOE4 is associated with greater atrophy of the hippocampal formation in Alzheimer's disease. <b>2011</b> , 55, 909-19	99

1778	Impact of EEG-vigilance on brain glucose uptake measured with [(18)F]FDG and PET in patients with depressive episode or mild cognitive impairment. <b>2011</b> , 56, 93-101	40
1777	Fast and robust extraction of hippocampus from MR images for diagnostics of Alzheimer's disease. <b>2011</b> , 56, 185-96	84
1776	Sex differences in grey matter atrophy patterns among AD and aMCI patients: results from ADNI. <b>2011</b> , 56, 890-906	62
1775	Associative encoding deficits in amnesic mild cognitive impairment: a volumetric and functional MRI study. <b>2011</b> , 56, 1743-8	25
1774	MRI detection of tissue pathology beyond atrophy in Alzheimer's disease: introducing T2-VBM. <b>2011</b> , 56, 1946-53	20
1773	Local MRI analysis approach in the diagnosis of early and prodromal Alzheimer's disease. <b>2011</b> , 58, 469-80	127
1772	Long-term consequences of repetitive brain trauma: chronic traumatic encephalopathy. <b>2011</b> , 3, S460-7	332
1771	The MTHFD1L gene rs11754661 marker is associated with susceptibility to Alzheimer's disease in the Chinese Han population. <b>2011</b> , 308, 32-4	7
1770	[Mild cognitive impairment in clinical practice]. <b>2011</b> , 137, 414-8	4
1769	Automatic classification of patients with Alzheimer's disease from structural MRI: a comparison of ten methods using the ADNI database. <b>2011</b> , 56, 766-81	689
1768	Interactive effects of physical activity and APOE- $\epsilon$ 4 on BOLD semantic memory activation in healthy elders. <b>2011</b> , 54, 635-44	87
1767	Multivariate analysis of MRI data for Alzheimer's disease, mild cognitive impairment and healthy controls. <b>2011</b> , 54, 1178-87	104
1766	Contribution of 1H spectroscopy to a brief cognitive-functional test battery for the diagnosis of mild Alzheimer's disease. <b>2011</b> , 32, 351-61	9
1765	Review of cerebral microangiopathy and Alzheimer's disease: relation between white matter hyperintensities and microbleeds. <b>2011</b> , 32, 367-78	37
1764	Data mining methods in the prediction of Dementia: A real-data comparison of the accuracy, sensitivity and specificity of linear discriminant analysis, logistic regression, neural networks, support vector machines, classification trees and random forests. <b>2011</b> , 4, 299	207
1763	A novel blood test for the early detection of Alzheimer's disease. <b>2011</b> , 23, 121-9	56
1762	Association between syncope and cognitive impairment. <b>2011</b> , 7, 143-153	0
1761	Alzheimer's Disease. <b>2011</b> , 1-91	7

1760	Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy. <b>2011</b> , 178, 1509-16	77
1759	A single nucleotide polymorphism in LRP2 is associated with susceptibility to Alzheimer's disease in the Chinese population. <b>2011</b> , 412, 268-70	22
1758	Cortical sources of resting state electroencephalographic rhythms in Parkinson's disease related dementia and Alzheimer's disease. <b>2011</b> , 122, 2355-64	68
1757	The role of gene expression profiling in drug discovery. <b>2011</b> , 11, 549-56	21
1756	Nutrition and Alzheimer's disease: the detrimental role of a high carbohydrate diet. <b>2011</b> , 22, 134-40	67
1755	Brain aging, Alzheimer's disease, and mitochondria. <b>2011</b> , 1812, 1630-9	206
1754	Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. <b>2011</b> , 25, 997-1019	141
1753	Cerebral lobar microhemorrhages detection by high magnetic field susceptibility weighted image: a potential diagnostic neuroimage technique of Alzheimer's disease. <b>2011</b> , 76, 840-2	6
1752	Hippocampal atrophy rates in Alzheimer's disease: automated segmentation variability analysis. <b>2011</b> , 495, 6-10	13
1751	L'imagerie TEP-traceurs des plaques amyloïdes : le point de vue du clinicien. <b>2011</b> , 35, 608-612	1
1750	Tip-of-the-tongue for proper names in mild cognitive impairment. Semantic or post-semantic impairments?. <b>2011</b> , 24, 636-651	22
1749	Diet and Alzheimer's disease risk factors or prevention: the current evidence. <b>2011</b> , 11, 677-708	180
1748	ANCA: A Family of Fluorescent Probes that Bind and Stain Amyloid Plaques in Human Tissue. <b>2011</b> , 2, 249-255	62
1747	Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. <b>2011</b> , 34, 430-42	235
1746	Biomarkers for Alzheimer's disease therapeutic trials. <b>2011</b> , 95, 579-93	100
1745	Development of Alzheimer-disease neuroimaging-biomarkers using mouse models with amyloid-precursor protein-transgene expression. <b>2011</b> , 95, 547-56	30
1744	The future of Alzheimer's disease: the next 10 years. <b>2011</b> , 95, 718-28	156
1743	Ethical considerations of biomarker use in neurodegenerative diseases--a case study of Alzheimer's disease. <b>2011</b> , 95, 517-9	21

1742	Novel insights for the treatment of Alzheimer's disease. <b>2011</b> , 35, 373-9	63
1741	Brain perfusion SPECT with an automated quantitative tool can identify prodromal Alzheimer's disease among patients with mild cognitive impairment. <b>2011</b> , 32, 15-23	60
1740	MCI patients' EEGs show group differences between those who progress and those who do not progress to AD. <b>2011</b> , 32, 563-71	68
1739	Cortical thickness and voxel-based morphometry in posterior cortical atrophy and typical Alzheimer's disease. <b>2011</b> , 32, 1466-76	138
1738	Neurostructural predictors of Alzheimer's disease: a meta-analysis of VBM studies. <b>2011</b> , 32, 1733-41	159
1737	Mild cognitive impairment: instructions for use at Neurobiology of Aging. <b>2011</b> , 32, 761-762	2
1736	Amyloid beta 1-42 in cerebrospinal fluid is associated with cognitive plasticity. <b>2011</b> , 190, 132-6	2
1735	[Introduction. Alzheimer's disease before dementia]. <b>2011</b> , 46 Suppl 1, 31-2	
1734	[The diagnostic approach to early Alzheimer's disease. What are we talking about? Conceptual considerations]. <b>2011</b> , 46 Suppl 1, 33-8	0
1733	[Role of biomarkers in the early diagnosis of Alzheimer's disease]. <b>2011</b> , 46 Suppl 1, 39-41	2
1732	[Neuropsychology and early diagnosis]. <b>2011</b> , 46 Suppl 1, 42-6	1
1731	[Predementia Alzheimer's disease. Benefits of early diagnosis]. <b>2011</b> , 46 Suppl 1, 47-54	2
1730	[Ethical considerations in the presymptomatic diagnosis of Alzheimer's disease]. <b>2011</b> , 46 Suppl 1, 55-9	0
1729	[Predictive signs of Alzheimer's disease]. <b>2011</b> , 32 Suppl 1, S12-3	
1728	Epidemiology of cognitive aging and Alzheimer's disease: contributions of the cache county utah study of memory, health and aging. <b>2012</b> , 10, 3-31	11
1727	Amyloid- $\beta$ and $\beta$ biomarkers in Parkinson's disease-dementia. <b>2011</b> , 310, 25-30	26
1726	The legacy of nanotechnology: revolution and prospects in neurosurgery. <b>2011</b> , 9, 608-14	25
1725	Alzheimer's Disease. <b>2011</b> , 43-64	



1724	Association study of clusterin polymorphism rs11136000 with late onset Alzheimer's disease in Chinese Han population. <b>2011</b> , 26, 627-30	34
1723	Florbetaben to trace amyloid- $\beta$ in the Alzheimer brain by means of PET. <b>2011</b> , 26 Suppl 3, 117-21	46
1722	The merits of FDDNP-PET imaging in Alzheimer's disease. <b>2011</b> , 26 Suppl 3, 135-45	40
1721	Longitudinal changes of CSF biomarkers in Alzheimer's disease. <b>2011</b> , 25, 583-94	64
1720	Current perspectives on pharmacotherapy of Alzheimer's disease. <b>2011</b> , 12, 335-50	56
1719	Report of the task force on designing clinical trials in early (predementia) AD. <b>2011</b> , 76, 280-6	134
1718	Advances in perfusion magnetic resonance imaging in Alzheimer's disease. <b>2011</b> , 7, 185-96	30
1717	AMPA workshop on challenges faced by investigators conducting Alzheimer's disease clinical trials. <b>2011</b> , 7, e109-17	12
1716	Harmonization of magnetic resonance-based manual hippocampal segmentation: a mandatory step for wide clinical use. <b>2011</b> , 7, 171-4	74
1715	Volumetric and visual rating of magnetic resonance imaging scans in the diagnosis of amnesic mild cognitive impairment and Alzheimer's disease. <b>2011</b> , 7, e101-8	49
1714	Operationalizing diagnostic criteria for Alzheimer's disease and other age-related cognitive impairment-Part 1. <b>2011</b> , 7, 15-34	44
1713	Sources of variability in estimates of the prevalence of Alzheimer's disease in the United States. <b>2011</b> , 7, 74-9	60
1712	Reducing case ascertainment costs in U.S. population studies of Alzheimer's disease, dementia, and cognitive impairment-Part 2. <b>2011</b> , 7, 110-23	25
1711	Revision of the criteria for Alzheimer's disease: A symposium. <b>2011</b> , 7, e1-12	27
1710	Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <b>2011</b> , 7, 257-62	1166
1709	The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <b>2011</b> , 7, 263-9	8211
1708	Commentary on "Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease." A Canadian perspective. <b>2011</b> , 7, 330-2	29
1707	The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <b>2011</b> , 7, 270-9	5630

1706	Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. <b>2011</b> , 7, 474-485.e4	139
1705	Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease: cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden--regulatory considerations by European Medicines Agency focusing in improving benefit/risk in regulatory trials. <b>2011</b> , 21, 781-8	45
1704	Enfermedad de Alzheimer. <b>2011</b> , 10, 5129-5137	
1703	Alzheimer's disease. <b>2011</b> , 377, 1019-31	1645
1702	The usefulness of biological and neuroimaging markers for the diagnosis of early-onset Alzheimer's disease. <b>2011</b> , 2011, 296374	8
1701	Morphological Factor Estimation via High-Dimensional Reduction: Prediction of MCI Conversion to Probable AD. <b>2011</b> , 2011, 914085	11
1700	Biomarkers of Alzheimer's disease: from central nervous system to periphery?. <b>2010</b> , 2011, 342980	3
1699	Focal Cortical Presentations Genetically Proven Alzheimer Disease. <b>2011</b> ,	
1698	Hemiparesis followed by dementia. 47-54	
1697	Penicillin for dementia in a young man. 165-171	
1696	Subjective cognitive complaint. 6-12	
1695	Woman with visual complaints. 59-63	
1694	Association between the c. 2495 A>G ATP7B Polymorphism and Sporadic Alzheimer's Disease. <b>2011</b> , 2011, 973692	23
1693	Adenosine A(2A) Receptor and IL-10 in Peripheral Blood Mononuclear Cells of Patients with Mild Cognitive Impairment. <b>2011</b> , 2011, 484021	5
1692	Biomarkers to measure treatment effects in Alzheimer's disease: what should we look for?. <b>2011</b> , 2011, 598175	3
1691	Impact of early intervention and disease modification in patients with predementia Alzheimer's disease: a Markov model simulation. <b>2011</b> , 3, 189-95	31
1690	Molecular Neuroimaging of the Dementias. <b>2011</b> , 557-574	
1689	Clinical features and multidisciplinary approaches to dementia care. <b>2011</b> , 4, 125-47	81

1688	Biomarkers predicting Alzheimer's disease in cognitively normal aging. <b>2011</b> , 7, 60-8	26
1687	Cerebrospinal fluid tau in frontotemporal lobar degeneration: clinical, neuroimaging, and prognostic correlates. <b>2011</b> , 23, 505-12	7
1686	Alzheimer's Diseases: Towards Biomarkers for an Early Diagnosis. <b>2011</b> ,	
1685	Criteria for the diagnosis of Alzheimer's disease: Recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology. <b>2011</b> , 5, 146-152	21
1684	Neuroimaging in Alzheimer's disease: current role in clinical practice and potential future applications. <b>2011</b> , 66 Suppl 1, 19-24	40
1683	Combinatorial markers of mild cognitive impairment conversion to Alzheimer's disease--cytokines and MRI measures together predict disease progression. <b>2011</b> , 26 Suppl 3, 395-405	43
1682	Detection of Soluble Amyloid- $\beta$ Oligomers and Insoluble High-Molecular-Weight Particles in CSF: Development of Methods with Potential for Diagnosis and Therapy Monitoring of Alzheimer's Disease. <b>2011</b> , 2011, 151645	14
1681	Magnetoencephalography as a putative biomarker for Alzheimer's disease. <b>2011</b> , 2011, 280289	40
1680	Brain functional network in Alzheimer's disease: diagnostic markers for diagnosis and monitoring. <b>2011</b> , 2011, 481903	21
1679	Decreased sAPP $\beta$ , A $\beta$ 38, and A $\beta$ 40 cerebrospinal fluid levels in frontotemporal dementia. <b>2011</b> , 26, 553-63	56
1678	Increasing the predictive accuracy of amyloid- $\beta$ blood-borne biomarkers in Alzheimer's disease. <b>2011</b> , 24, 47-59	14
1677	Inflammation and oxidative damage in Alzheimer's disease: friend or foe?. <b>2011</b> , 3, 252-66	47
1676	Combined Imaging Markers Dissociate Alzheimer's Disease and Frontotemporal Lobar Degeneration - An ALE Meta-Analysis. <b>2011</b> , 3, 10	44
1675	Exercise-induced cognitive plasticity, implications for mild cognitive impairment and Alzheimer's disease. <b>2011</b> , 2, 28	119
1674	Biomarkers in Alzheimer's disease. <b>2011</b> , 2, 46	14
1673	A disease state fingerprint for evaluation of Alzheimer's disease. <b>2011</b> , 27, 163-76	65
1672	Sensitivity and specificity of medial temporal lobe visual ratings and multivariate regional MRI classification in Alzheimer's disease. <b>2011</b> , 6, e22506	87
1671	Prediction of dementia in primary care patients. <b>2011</b> , 6, e16852	87

1670	Combined evaluation of FDG-PET and MRI improves detection and differentiation of dementia. <b>2011</b> , 6, e18111	106
1669	Impaired visual recognition memory in amnesic mild cognitive impairment is associated with mesiotemporal metabolic changes on magnetic resonance spectroscopic imaging. <b>2010</b> , 22, 1269-79	20
1668	Is brain SPECT useful in degenerative dementia diagnosis?. <b>2011</b> , 35, 1-3	16
1667	Negative amyloid PET imaging in a patient with probable Alzheimer's disease. <b>2011</b> , 36, 1120-1	4
1666	Alzheimer's disease vaccines: promises and pitfalls. <b>2011</b> , 1, 969-988	1
1665	Should electroconvulsive therapy be more routinely used in the treatment of depression in elderly patients with cognitive disturbances?. <b>2011</b> , 1, 403-407	1
1664	Editorial neuroAIDS review. <b>2011</b> , 25, 123-41	63
1663	Focusing on atypical symptoms for improved diagnosis of early-onset Alzheimer's disease. <b>2011</b> , 6, 575-578	3
1662	Evolution of the diagnostic criteria for degenerative and cognitive disorders. <b>2011</b> , 24, 532-41	32
1661	Cholesterol and LDL relate to neuritic plaques and to APOE4 presence but not to neurofibrillary tangles. <b>2011</b> , 8, 303-12	25
1660	Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials. <b>2011</b> , 17, 508-20	44
1659	Genetic polymorphisms in sigma-1 receptor and apolipoprotein E interact to influence the severity of Alzheimer's disease. <b>2011</b> , 8, 765-70	43
1658	Clinical use of neuroimaging in dementia: an international perspective. <b>2011</b> , 23 Suppl 2, S3-5	2
1657	Perfusion SPECT and FDG-PET. <b>2011</b> , 23 Suppl 2, S25-31	29
1656	The use of CT in dementia. <b>2011</b> , 23 Suppl 2, S6-12	21
1655	Revised NIA-AA criteria for the diagnosis of Alzheimer's disease: a step forward but not yet ready for widespread clinical use. <b>2011</b> , 23, 1191-6	26
1654	Using cognitive decline in novel trial designs for primary prevention and early disease-modifying therapy trials of Alzheimer's disease. <b>2011</b> , 23, 1376-85	10
1653	Structural MRI. <b>2011</b> , 23 Suppl 2, S13-24	26

1652	Verbal memory in drug-naive, newly diagnosed Parkinson's disease. The retrieval deficit hypothesis revisited. <b>2011</b> , 25, 114-24	71
1651	Current conceptions of the etiology and risk factors for Alzheimer's disease and their possible implications on the design of dementia clinical trials. <b>2011</b> , 1, 1491-1503	
1650	Cholinesterase inhibitors for rarer dementias. <b>2011</b> ,	1
1649	Using MRI neuroimaging methods to detect treatment responses in Alzheimer's disease. <b>2011</b> , 1, 235-243	1
1648	Striving for an integrated drug-development process for neurodegeneration: the coalition against major diseases. <b>2011</b> , 1, 379-385	12
1647	Ask the experts: PET amyloid imaging: can its diagnostic potential be effectively realized in the clinic?. <b>2011</b> , 1, 445-451	
1646	Effects of a newly developed cognitive intervention in amnesic mild cognitive impairment and mild Alzheimer's disease: a pilot study. <b>2011</b> , 25, 679-94	96
1645	Survey of protocols for the manual segmentation of the hippocampus: preparatory steps towards a joint EADC-ADNI harmonized protocol. <b>2011</b> , 26 Suppl 3, 61-75	111
1644	Nutrition and brain aging: role of fatty acids with an epidemiological perspective. <b>2011</b> , 18, 228-235	
1643	Gender differences in the prodromal signs of dementia: memory complaint and IADL-restriction. a prospective population-based cohort. <b>2011</b> , 27, 39-47	46
1642	Long-term stability of Alzheimer's disease biomarker proteins in cerebrospinal fluid. <b>2011</b> , 26, 255-62	23
1641	A gene expression pattern in blood for the early detection of Alzheimer's disease. <b>2011</b> , 23, 109-19	77
1640	Which memory system is impaired first in Alzheimer's disease?. <b>2011</b> , 27, 11-22	95
1639	Cerebrospinal fluid biomarkers in Progranulin mutations carriers. <b>2011</b> , 27, 781-90	42
1638	Prediction of preclinical Alzheimer's disease: longitudinal rates of change in cognition. <b>2011</b> , 25, 707-17	36
1637	Experiences with cerebrospinal fluid analysis in Dutch memory clinics. <b>2011</b> , 18, 1014-6	5
1636	A figurative proverb test for dementia: rapid detection of disinhibition, excuse and confabulation, causing discommunication. <b>2011</b> , 11, 205-11	8
1635	Yamaguchi fox-pigeon imitation test (YFPIT) for dementia in clinical practice. <b>2011</b> , 11, 221-6	6

1634	The world of dementia beyond 2020. <b>2011</b> , 59, 923-7		50
1633	Neuromyelitis optica with very late onset. <b>2011</b> , 59, 1138-40		9
1632	"Reversible" Alzheimer's disease?. <b>2011</b> , 59, 1137-8		1
1631	Autonomic dysfunction in mild cognitive impairment: a transcranial Doppler study. <b>2011</b> , 124, 403-9		12
1630	Sleep disturbance in mild cognitive impairment: differential effects of current and remitted depression. <b>2011</b> , 23, 167-72		27
1629	White matter lesion load increases the risk of low CSF A $\beta$ 42 in apolipoprotein E-e4 carriers attending a memory clinic. <b>2011</b> , 21, e78-82		9
1628	PET/CT in diagnosis of dementia. <b>2011</b> , 1228, 81-92		54
1627	Event-based prospective memory failure in amnesic mild cognitive impairment. <b>2011</b> , 49, 2209-16		12
1626	Hippocampal dysfunction in patients with mild cognitive impairment: a functional neuroimaging study of a visuospatial paired associates learning task. <b>2011</b> , 49, 2060-70		117
1625	Auditory object cognition in dementia. <b>2011</b> , 49, 2755-65		49
1624	Brain fuel metabolism, aging, and Alzheimer's disease. <b>2011</b> , 27, 3-20		374
1623	Dissociating behavioral disorders in early dementia-An FDG-PET study. <b>2011</b> , 194, 235-244		51
1622	Dementia: challenges and promising developments. <i>Lancet Neurology, The</i> , <b>2011</b> , 10, 7-9	24.1	4
1621	Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study. <i>Lancet Neurology, The</i> , <b>2011</b> , 10, 213-20	24.1	138
1620	$\beta$ Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. <i>Lancet Neurology, The</i> , <b>2011</b> , 10, 230-40	24.1	459
1619	New lexicon and criteria for the diagnosis of Alzheimer's disease. <i>Lancet Neurology, The</i> , <b>2011</b> , 10, 299-300; author reply 300-1	24.1	3
1618	New lexicon and criteria for the diagnosis of Alzheimer's disease âAuthors' reply. <i>Lancet Neurology, The</i> , <b>2011</b> , 10, 300-301	24.1	6
1617	Cerebral amyloid- $\beta$ PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. <i>Lancet Neurology, The</i> , <b>2011</b> , 10, 424-35	24.1	400

1616	Revised criteria for Alzheimer's disease: what are the lessons for clinicians?. <i>Lancet Neurology, The</i> , <b>2011</b> , 10, 598-601	24.1	20
1615	The Translational Medicine Ontology and Knowledge Base: driving personalized medicine by bridging the gap between bench and bedside. <b>2011</b> , 2 Suppl 2, S1		55
1614	Staging of the cognitive decline in Alzheimer's disease: insights from a detailed neuropsychological investigation of mild cognitive impairment and mild Alzheimer's disease. <b>2012</b> , 27, 423-32		25
1613	Visual assessment of posterior atrophy development of a MRI rating scale. <b>2011</b> , 21, 2618-25		223
1612	HSV1 in Alzheimer's disease: Myth or reality?. <b>2011</b> , 2,		3
1611	Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease. <b>2012</b> , 10, 187-212		37
1610	The balance between cognitive reserve and brain imaging biomarkers of cerebrovascular and Alzheimer's diseases. <b>2011</b> , 134, 3687-96		92
1609	Disease-modifying treatments for Alzheimer's disease. <b>2011</b> , 4, 203-16		91
1608	Quantitation of amyloid beta peptides A $\beta$ (1-38), A $\beta$ (1-40), and A $\beta$ (1-42) in human cerebrospinal fluid by ultra-performance liquid chromatography-tandem mass spectrometry. <b>2011</b> , 419, 133-9		93
1607	Tau mediated neurodegeneration: an insight into Alzheimer's disease pathology. <b>2011</b> , 36, 1329-35		42
1606	Category cued recall following controlled encoding as a neuropsychological tool in the diagnosis of Alzheimer's disease: a review of the evidence. <b>2011</b> , 21, 54-65		50
1605	Prospective memory impairment in mild cognitive impairment: an analytical review. <b>2011</b> , 21, 390-404		49
1604	Relationships between hippocampal microstructure, metabolism, and function in early Alzheimer's disease. <b>2011</b> , 216, 219-26		13
1603	Free and Cued Selective Reminding Test: an Italian normative study. <b>2011</b> , 32, 1057-62		50
1602	Non-verbal memory measured by Rey-Osterrieth Complex Figure B: normative data. <b>2011</b> , 32, 1081-9		28
1601	Normative data for a battery of free recall, cued recall and recognition tests in the elderly Italian population. <b>2011</b> , 32, 1103-14		4
1600	Different profiles of Alzheimer's disease cerebrospinal fluid biomarkers in controls and subjects with subjective memory complaints. <b>2011</b> , 118, 259-62		41
1599	Mild cognitive impairment exists in Parkinson's disease. <b>2011</b> , 118, 1179-83		6

1598	S-propargyl-cysteine (ZYZ-802), a sulphur-containing amino acid, attenuates beta-amyloid-induced cognitive deficits and pro-inflammatory response: involvement of ERK1/2 and NF- $\kappa$ B pathway in rats. <b>2011</b> , 40, 601-10	37
1597	ESMRMB 2011, 28th Annual Scientific Meeting, Leipzig, Germany, 6-8 October: Abstracts, Saturday. <b>2011</b> , 24, 183-270	2
1596	MEG connectivity analysis in patients with Alzheimer's disease using cross mutual information and spectral coherence. <b>2011</b> , 39, 524-36	30
1595	[Diagnosis without therapy: early diagnosis of Alzheimer's disease in the stage of mild cognitive impairment]. <b>2011</b> , 82, 1151-9	6
1594	[The future of biomarkers in dementia diagnostics]. <b>2011</b> , 82, 1385-6, 1388, 1390, passim	2
1593	Individualized quantification of brain $\beta$ -amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls. <b>2011</b> , 38, 1702-14	77
1592	Functional implications of hippocampal degeneration in early Alzheimer's disease: a combined DTI and PET study. <b>2011</b> , 38, 2219-27	28
1591	Segmentation ciblè d'images IRM et maladie d'Alzheimer. <b>2011</b> , 32, 19-26	3
1590	Positron emission tomography with Pittsburgh compound B in diagnosis of early stage Alzheimer's disease. <b>2011</b> , 59, 57-62	2
1589	Brain-derived neurotrophic factor and Alzheimer's disease: physiopathology and beyond. <b>2011</b> , 13, 217-22	139
1588	A Critical Analysis of the MND Criteria for Feigned Cognitive Impairment: Implications for Forensic Practice and Research. <b>2011</b> , 4, 147-156	25
1587	Designing clinical trials for early (pre-dementia) Alzheimer's disease: determining the appropriate population for treatment. <b>2011</b> , 15, 22-4	8
1586	Co-morbidity and drug treatment in Alzheimer's disease. A cross sectional study of participants in the dementia study in northern Norway. <b>2011</b> , 11, 58	49
1585	Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. <b>2011</b> , 69, 570-80	310
1584	Cerebral amyloid angiopathy in the elderly. <b>2011</b> , 70, 871-80	367
1583	Alzheimer's CSF markers in older schizophrenia patients. <b>2011</b> , 26, 640-8	21
1582	Lack of awareness of symptoms in people with dementia: the structural and functional basis. <b>2011</b> , 26, 783-92	45
1581	Neuropsychological profile of prodromal Alzheimer's disease (Prd-AD) and their radiological correlates. <b>2011</b> , 52, 190-6	20



1580	Similar amyloid- $\beta$ burden in posterior cortical atrophy and Alzheimer's disease. <b>2011</b> , 134, 2036-43	96
1579	New diagnostic criteria for Alzheimer's disease. <b>2011</b> , 5, 407-9	4
1578	Delineating Alzheimer's disease progression with MGAT3, a biomarker for improved prognosis and personalized therapy. <b>2011</b> , 5, 645-7	2
1577	Using biomarkers to improve detection of Alzheimer's disease. <b>2011</b> , 1, 127-139	22
1576	Alzheimer's disease: from pathogenesis to disease-modifying approaches. <b>2011</b> , 10, 163-74	30
1575	Screening for dementia: an opportunity for debate. <b>2011</b> , 11, 1347-9	2
1574	Detecting hippocampal shape changes in Alzheimer's disease using statistical shape models. <b>2011</b> ,	
1573	Evidence of neuronal compensation during episodic memory in subjective memory impairment. <b>2011</b> , 68, 845-52	107
1572	Recent approaches targeting beta-amyloid for therapeutic intervention of Alzheimer's disease. <b>2011</b> , 6, 222-33	16
1571	Nuclear medicine imaging in dementia: a practical overview for hospitalists. <b>2011</b> , 39, 149-60	7
1570	Suspected early dementia. <b>2011</b> , 343, d5568	2
1569	A multi-task learning formulation for predicting disease progression. <b>2011</b> ,	115
1568	Interacting with $\beta$ -secretase for treating Alzheimer's disease: from inhibition to modulation. <b>2011</b> , 18, 5430-47	24
1567	Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer's disease. <b>2011</b> , 26, 627-45	179
1566	Early and presenting symptoms of dementia with lewy bodies. <b>2011</b> , 32, 202-8	62
1565	Functional impairment in the diagnosis of mild cognitive impairment. <b>2011</b> , 25, 225-9	7
1564	Diversity and disparity in dementia: the impact of ethnoracial differences in Alzheimer disease. <b>2011</b> , 25, 187-95	203
1563	Joint model with latent state for longitudinal and multistate data. <b>2011</b> , 12, 723-36	23

1562	Memantine: a treatment for Alzheimer's disease with a new formulation. <b>2011</b> , 7, 349-362	2
1561	Acute Neuromuscular Respiratory Failure—Reply. <b>2011</b> , 68, 395	
1560	Bihemispheric cerebral FDG PET correlates of cognitive dysfunction as assessed by the CERAD in Alzheimer's disease. <b>2011</b> , 42, 71-6	18
1559	β-secretase inhibitors for treating Alzheimer's disease: rationale and clinical data. <b>2011</b> , 1, 1175-1194	2
1558	Salivary tau species are potential biomarkers of Alzheimer's disease. <b>2011</b> , 27, 299-305	111
1557	Acute neuromuscular respiratory failure. <b>2011</b> , 68, 398-9; author reply 399	1
1556	Use of florbetapir-PET for imaging beta-amyloid pathology. <b>2011</b> , 305, 275-83	760
1555	New lessons from the Alzheimer's Disease Neuroimaging Initiative. <b>2011</b> , 68, 19-21	2
1554	Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative. <b>2011</b> , 68, 58-66	111
1553	Modeling of pathological traits in Alzheimer's disease based on systemic extracellular signaling proteome. <b>2011</b> , 10, M111.008862	36
1552	Primum non nocere. <b>2011</b> , 68, 397-8; author reply 398	2
1551	Mapping out biomarkers for Alzheimer disease. <b>2011</b> , 305, 304-5	18
1550	CSF amyloid β8 as a novel diagnostic marker for dementia with Lewy bodies. <b>2011</b> , 82, 160-4	38
1549	Comparison of immunosorbent assays for the quantification of biomarkers for Alzheimer's disease in human cerebrospinal fluid. <b>2011</b> , 31, 139-45	14
1548	Memory for emotional pictures in patients with Alzheimer's dementia: comparing picture-location binding and subsequent recognition. <b>2011</b> , 2011, 409364	14
1547	The clinical utility of gene testing for Alzheimer's disease. <b>2011</b> , 3, e1	10
1546	Alzheimer's disease: a review of recent developments. <b>2011</b> , 10, 73-9	14
1545	Comparison between Alzheimer's disease and subcortical vascular dementia: attentional cortex study in functional magnetic resonance imaging. <b>2011</b> , 39, 1413-9	10

1544	The neuroanatomical substrate of lexical-semantic decline in MCI APOE $\epsilon$ carriers and noncarriers. <b>2011</b> , 25, 230-41	7
1543	Primum non nocereâReply. <b>2011</b> , 68, 395	4
1542	Amyloid $\beta$ (A $\beta$ ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease. <b>2011</b> , 49, 367-74	51
1541	Pre-dementia memory impairment is associated with white matter tract affection. <b>2011</b> , 17, 143-53	16
1540	Progression from mild to pronounced MCI is not associated with cerebrospinal fluid biomarker deviations. <b>2011</b> , 32, 193-7	10
1539	What do people with dementia and their carers really need?. <b>2011</b> , 1, 37-42	
1538	Performance on the RI-48 Cued Recall Test Best Predicts Conversion to Dementia at the 5- and 10-Year Follow-Ups. <b>2011</b> , 1, 258-66	10
1537	Long latency and high variability in accuracy-speed of prosaccades in Alzheimer's disease at mild to moderate stage. <b>2011</b> , 1, 318-29	26
1536	Dementia screening, biomarkers and protein misfolding: Implications for public health and diagnosis. <b>2011</b> , 5, 16-21	20
1535	Voice processing in dementia: a neuropsychological and neuroanatomical analysis. <b>2011</b> , 134, 2535-47	52
1534	Glaucoma and Alzheimer's disease in the elderly. <b>2011</b> , 7, 719-733	10
1533	Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. <b>2011</b> , 52, 1210-7	267
1532	CSF Alzheimer's disease-like pattern in corticobasal syndrome: evidence for a distinct disorder. <b>2011</b> , 82, 834-8	31
1531	Mild cognitive impairment: differential atrophy in the hippocampal subfields. <b>2011</b> , 32, 1658-61	80
1530	Neurodegenerative processes in Alzheimer's disease: an overview of pathogenesis with strategic biomarker potential. <b>2011</b> , 6, 173-185	
1529	Improved generation of probabilistic atlases for the expectation maximization classification. <b>2011</b> ,	4
1528	Development of memory clinics in the Netherlands: 1998 to 2009. <b>2011</b> , 15, 34-9	22
1527	Challenges in the development of companion diagnostics for neuropsychiatric disorders. <b>2011</b> , 11, 829-37	8

1526	Structural and functional network connectivity breakdown in Alzheimer's disease studied with magnetic resonance imaging techniques. <b>2011</b> , 24, 455-74	62
1525	Dementia in 2010: Paving the way for Alzheimer disease drug development. <b>2011</b> , 7, 65-6	6
1524	The Little Black Book of Neuropsychology. <b>2011</b> ,	49
1523	Dysexecutive versus amnesic phenotypes of very mild Alzheimer's disease are associated with distinct clinical, genetic and cortical thinning characteristics. <b>2011</b> , 82, 45-51	106
1522	A window into the heterogeneity of human cerebrospinal fluid A $\beta$ peptides. <b>2011</b> , 2011, 697036	12
1521	Evaluation of apparent diffusion coefficient mappings in amnesic mild cognitive impairment using an image analysis software brain search. <b>2011</b> , 52, 1147-54	10
1520	The clinical diagnosis of early-onset dementias: diagnostic accuracy and clinicopathological relationships. <b>2011</b> , 134, 2478-92	178
1519	The role of clusterin, complement receptor 1, and phosphatidylinositol binding clathrin assembly protein in Alzheimer disease risk and cerebrospinal fluid biomarker levels. <b>2011</b> , 68, 207-13	69
1518	White matter damage in Alzheimer disease and its relationship to gray matter atrophy. <b>2011</b> , 258, 853-63	212
1517	PiTaSu: wearable interface for assisting senior citizens with memory problems. <b>2011</b> , 10,	6
1516	New tools for the study of Alzheimer's disease: what are biomarkers and morphometric markers teaching us?. <b>2011</b> , 17, 592-605	10
1515	Overtime reliability of medial temporal lobe atrophy rating in a clinical setting. <b>2012</b> , 53, 318-23	33
1514	Ethical issues in Alzheimer's disease: an overview. <b>2012</b> , 12, 557-67	16
1513	Stage-dependent agreement between cerebrospinal fluid proteins and FDG-PET findings in Alzheimer's disease. <b>2012</b> , 9, 241-7	13
1512	The profile of hippocampal metabolites differs between Alzheimer's disease and subcortical ischemic vascular dementia, as measured by proton magnetic resonance spectroscopy. <b>2012</b> , 32, 805-15	34
1511	Alzheimer's disease and environmental exposure to lead: the epidemiologic evidence and potential role of epigenetics. <b>2012</b> , 9, 563-73	131
1510	Platelet immunoglobulin and amyloid precursor protein as potential peripheral biomarkers for Alzheimer's disease: findings from a pilot study. <b>2012</b> , 41, 408-12	19
1509	Early-onset Alzheimer disease clinical variants: multivariate analyses of cortical thickness. <b>2012</b> , 79, 80-4	63

1508	White matter damage along the uncinate fasciculus contributes to cognitive decline in AD and DLB. <b>2012</b> , 9, 326-33	24
1507	Dementia has a categorical, not dimensional, latent structure. <b>2012</b> , 27, 791-7; author reply 798-800	6
1506	Mitochondrial- and endoplasmic reticulum-associated oxidative stress in Alzheimer's disease: from pathogenesis to biomarkers. <b>2012</b> , 2012, 735206	97
1505	Anosognosia: patients' distress and self-awareness of deficits in Alzheimer's disease. <b>2012</b> , 27, 339-45	35
1504	[Consensus 2012--diagnosis and treatment of patients with dementia in Switzerland]. <b>2012</b> , 101, 1239-49	3
1503	Comparison between visual assessment of MTA and hippocampal volumes in an elderly, non-demented population. <b>2012</b> , 53, 573-9	28
1502	Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment. <b>2012</b> , 79, 1332-9	207
1501	Development of a questionnaire on everyday navigational ability to assess topographical disorientation in Alzheimer's disease. <b>2012</b> , 27, 65-72	15
1500	Management of Alzheimer's disease using disease-modifying drugs. <b>2012</b> , 2, 375-378	1
1499	Associative and semantic memory deficits in amnesic mild cognitive impairment as revealed by functional magnetic resonance imaging. <b>2012</b> , 25, 195-215	12
1498	Correlation of amyloid PET ligand florbetapir F 18 binding with A $\beta$ aggregation and neuritic plaque deposition in postmortem brain tissue. <b>2012</b> , 26, 8-16	93
1497	Neuroimaging in dementias. <b>2012</b> , 25, 473-9	19
1496	The neuropsychological profile of Alzheimer disease. <b>2012</b> , 2, a006171	309
1495	Injury markers predict time to dementia in subjects with MCI and amyloid pathology. <b>2012</b> , 79, 1809-16	110
1494	Pathologic lesions in neurodegenerative diseases. <b>2012</b> , 107, 1-40	16
1493	Validation of the route map recall test for getting lost behavior in Alzheimer's disease patients. <b>2012</b> , 27, 781-9	2
1492	Imaging approaches for dementia. <b>2012</b> , 33, 1836-44	18
1491	Lessons Learned in Eastern Europe. <b>2012</b> , 99-103	

1490	Activities of daily living: where do they fit in the diagnosis of Alzheimer's disease?. <b>2012</b> , 2, 483-491	95
1489	Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough. <b>2012</b> , 4, 343-357	10
1488	Demenzdiagnostik mit der Amyloid-PET. <b>2012</b> , 35, 82-92	3
1487	Demenz: Was kann der Radiologe sagen?. <b>2012</b> , 02, 131-148	0
1486	Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects. <b>2012</b> , 53, 378-84	250
1485	Prediction of amyloid- $\beta$ pathology in amnesic mild cognitive impairment with neuropsychological tests. <b>2013</b> , 33, 451-62	27
1484	Hippocampal atrophy rate using an expectation maximization classifier with a disease-specific prior. <b>2012</b> ,	1
1483	Abnormalities of connected speech in semantic dementia vs Alzheimer's disease. <b>2012</b> , 26, 847-866	55
1482	Alzheimer disease: biomarker trajectories across stages of Alzheimer disease. <b>2012</b> , 8, 299-300	19
1481	Picture agnosia as a characteristic of posterior cortical atrophy. <b>2012</b> , 68, 34-41	3
1480	Identifying the neural correlates of executive functions in early cerebral microangiopathy: a combined VBM and DTI study. <b>2012</b> , 32, 1869-78	23
1479	Immunotherapy for Alzheimer's disease: from anti- $\beta$ -amyloid to tau-based immunization strategies. <b>2012</b> , 4, 213-38	106
1478	Temporal order memory assessed during spatiotemporal navigation as a behavioral cognitive marker for differential Alzheimer's disease diagnosis. <b>2012</b> , 32, 1942-52	52
1477	Brain imaging in Alzheimer disease. <b>2012</b> , 2, a006213	336
1476	Geographical variation in dementia: systematic review with meta-analysis. <b>2012</b> , 41, 1012-32	102
1475	Neurochemical biomarkers in Alzheimer's disease and related disorders. <b>2012</b> , 5, 335-48	15
1474	Improvement of the detection of neurodegenerative Alzheimer's disease through a specific surface chemistry applied onto the inner surface of the titration well. <b>2012</b> , 23, 1951-61	2
1473	Stem Cells and Cancer Stem Cells, Volume 2. <b>2012</b> ,	

1472	Skeleton-based gyri sulci separation for improved assessment of cortical thickness. <b>2012,</b>	1
1471	Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease. <b>2012, 78, 379-86</b>	117
1470	Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: head-to-head comparison. <b>2012, 53, 592-600</b>	73
1469	Practical guidelines for the recognition and diagnosis of dementia. <b>2012, 25, 367-82</b>	96
1468	Alzheimer's disease: genetic polymorphisms and rate of decline. <b>2012, 33, 84-9</b>	28
1467	Combining structural brain changes improves the prediction of Alzheimer's disease and mild cognitive impairment. <b>2012, 33, 318-26</b>	16
1466	Diagnostic accuracy of statistical pattern recognition of electroencephalogram registration in evaluation of cognitive impairment and dementia. <b>2012, 34, 51-60</b>	40
1465	Alternate-form reliability of the Montreal cognitive assessment screening test in a clinical setting. <b>2012, 33, 379-84</b>	72
1464	Applicability of the CANTAB-PAL computerized memory test in identifying amnesic mild cognitive impairment and Alzheimer's disease. <b>2012, 34, 83-9</b>	49
1463	Volumetric analysis of the pons, cerebellum and hippocampi in patients with Alzheimer's disease. <b>2012, 34, 224-34</b>	13
1462	Application of the VSRAD, a specific and sensitive voxel-based morphometry, to comparison of entorhinal cortex atrophy between dementia with Lewy bodies and Alzheimer's disease. <b>2012, 34, 328-31</b>	14
1461	Cerebrospinal fluid levels of $\beta$ -amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. <b>2012, 69, 98-106</b>	459
1460	Clinico-pathological correlations of the most common neurodegenerative dementias. <b>2012, 3, 68</b>	23
1459	P300 and neuropsychological assessment in mild cognitive impairment and Alzheimer dementia. <b>2012, 3, 172</b>	47
1458	Cognitive decline and dementia in the oldest-old. <b>2012, 3, e0026</b>	35
1457	Biomarkers for dementia diagnosis: differentiating DLB and FTD may be difficult. <b>2012, 83, 1037</b>	1
1456	Is the Folstein's Mini-Mental test an aphasia test?. <b>2012, 19, 221-8</b>	7
1455	Behavioral Neurobiology of Aging. <b>2012,</b>	

1454	Recognition memory deficits in mild cognitive impairment. <b>2012</b> , 19, 608-19	33
1453	Slowing of information processing in Alzheimer disease: motor as well as cognitive factors. <b>2012</b> , 25, 175-85	4
1452	Analysis of grey matter in thalamus and basal ganglia based on EEG $\beta/\alpha$ frequency ratio reveals specific changes in subjects with mild cognitive impairment. <b>2012</b> , 4, e00103	17
1451	Identifying earlier Alzheimer's disease: insights from the preclinical and prodromal phases. <b>2012</b> , 10, 158-60	12
1450	Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with Alzheimer's disease: a systematic review and meta-analysis. <b>2012</b> , 38, 1-17	203
1449	Structural neuroimaging of concomitant depressive symptoms in amnesic mild cognitive impairment: a pilot study. <b>2012</b> , 2, 573-88	8
1448	Added Diagnostic Value of (11)C-PIB-PET in Memory Clinic Patients with Uncertain Diagnosis. <b>2012</b> , 2, 610-21	38
1447	From Morris Water Maze to computer tests in the prediction of Alzheimer's disease. <b>2012</b> , 10, 153-7	44
1446	Impairments of auditory scene analysis in Alzheimer's disease. <b>2012</b> , 135, 190-200	50
1445	Executive deficits are related to the inferior frontal junction in early dementia. <b>2012</b> , 135, 201-15	79
1444	PSEN1 mutation carriers present lower cerebrospinal fluid amyloid- $\beta$ 42 levels than sporadic early-onset Alzheimer's disease patients but no differences in neuronal injury biomarkers. <b>2012</b> , 30, 605-16	6
1443	The Alzheimer myth and biomarker research in dementia. <b>2012</b> , 31 Suppl 3, S203-9	30
1442	Searching for predictive blood biomarkers: misfolded p53 in mild cognitive impairment. <b>2012</b> , 9, 1191-7	13
1441	Medial Temporal Lobe Volumes in Amnesic Mild Cognitive Impairment and Late-life Depression: Research Synthesis. <b>2012</b> , 8, 208-226	
1440	Differences in cognitive functions. <b>2012</b> , 7, 1-6	
1439	Diagnostic Tools: Fluid Biomarkers for Alzheimer's Disease. <b>2012</b> , 71-79	
1438	Optimizing the diagnosis of early Alzheimer's disease in mild cognitive impairment subjects. <b>2012</b> , 32, 969-79	28
1437	New MRI markers for Alzheimer's disease: a meta-analysis of diffusion tensor imaging and a comparison with medial temporal lobe measurements. <b>2012</b> , 29, 405-29	112



1436	Amyloid- $\beta$ and cognition in aging and Alzheimer's disease: molecular and neurophysiological mechanisms. <b>2013</b> , 33 Suppl 1, S79-86	32
1435	Brain perfusion SPECT imaging and acetazolamide challenge in vascular cognitive impairment. <b>2012</b> , 33, 571-80	11
1434	Temporal integration of 3D coherent motion cues defining visual objects of unknown orientation is impaired in amnesic mild cognitive impairment and Alzheimer's disease. <b>2012</b> , 28, 885-96	14
1433	MRI- and PET-Based Imaging Markers for the Diagnosis of Alzheimer's Disease. <b>2012</b> , 80-114	
1432	Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents. <b>2012</b> , 91, 315-20	11
1431	Alzheimer's disease: a clinical practice-oriented review. <b>2012</b> , 3, 63	43
1430	Rethinking Alzheimer's disease. <b>2012</b> , 3, 45	5
1429	Validation of AclarusDx's blood-based transcriptomic signature for the diagnosis of Alzheimer's disease. <b>2012</b> , 32, 169-81	44
1428	Association of K832R and R952K SNPs of Wilson's disease gene with Alzheimer's disease. <b>2012</b> , 29, 913-9	44
1427	Comparison of four verbal memory tests for the diagnosis and predictive value of mild cognitive impairment. <b>2012</b> , 2, 120-31	43
1426	The role of MRI in the early diagnosis of Alzheimer's disease or other dementias in persons with mild cognitive impairment (MCI). <b>2012</b> ,	5
1425	Neuropathological Basis of Alzheimer's Disease and Alzheimer's Disease Diagnosis. <b>2012</b> , 49-70	1
1424	Magnetic resonance imaging in Alzheimer's disease: from diagnosis to monitoring treatment effect. <b>2012</b> , 9, 1198-209	10
1423	Estimation of the risk of conversion of mild cognitive impairment of Alzheimer type to Alzheimer's disease in a south Brazilian population-based elderly cohort: the PALA study. <b>2012</b> , 24, 674-81	16
1422	Biomarker und Demenz. <b>2012</b> , 6, 201-212	
1421	Mild cognitive impairment (MCI) twenty years on. <b>2012</b> , 24, 1-5	30
1420	Pitfall Intention Explanation Task with Clue Questions (Pitfall task): assessment of comprehending other people's behavioral intentions in Alzheimer's disease. <b>2012</b> , 24, 1919-26	11
1419	The diagnosis and evaluation of dementia and mild cognitive impairment with emphasis on SPECT perfusion neuroimaging. <b>2012</b> , 17, 176-206	24

1418	Current insights into the pathophysiology of Alzheimer's disease: selecting targets for early therapeutic intervention. <b>2012</b> , 24 Suppl 1, S10-7	22
1417	4e Confrence canadienne consensuelle sur le diagnostic et le traitement de la dñence. <b>2012</b> , 39, S1-S8	
1416	4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia. <b>2012</b> , 39, S1-8	19
1415	Could nutrition prevent the onset of dementia? Current evidence from epidemiological and intervention studies. <b>2012</b> , 2, 305-314	9
1414	Ask The Experts: New diagnostic criteria for Alzheimer's disease. <b>2012</b> , 2, 153-157	
1413	Amyloid-related imaging abnormalities associated with immunotherapy in Alzheimer's disease patients. <b>2012</b> , 7, 395-401	1
1412	Drug Treatments in Development for Alzheimer's Disease. <b>2012</b> , 42, 58-65	4
1411	Epidemiology of dementias and Alzheimer's disease. <b>2012</b> , 43, 600-8	303
1410	Functional dependence and caregiver burden in Alzheimer's disease: a controlled trial on the benefits of motor intervention. <b>2012</b> , 12, 186-92	27
1409	Copper hypothesis in the missing heritability of sporadic Alzheimer's disease: ATP7B gene as potential harbor of rare variants. <b>2012</b> , 29, 493-501	28
1408	Drug repositioning for Alzheimer's disease. <b>2012</b> , 11, 833-46	191
1407	Pin1 contribution to Alzheimer's disease: transcriptional and epigenetic mechanisms in patients with late-onset Alzheimer's disease. <b>2012</b> , 10, 207-11	28
1406	Evaluation of plasma A $\beta$ as predictor of Alzheimer's disease in older individuals without dementia: a population-based study. <b>2012</b> , 28, 231-8	37
1405	EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia. <b>2012</b> , 19, 1159-79	191
1404	EFNS task force: the use of neuroimaging in the diagnosis of dementia. <b>2012</b> , 19, e131-40, 1487-501	90
1403	Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. <b>2012</b> , 79, 897-905	175
1402	Advances in the identification of $\beta$ -secretase inhibitors for the treatment of Alzheimer's disease. <b>2012</b> , 7, 19-37	42
1401	Alzheimer's disease and amyloid: culprit or coincidence?. <b>2012</b> , 102, 277-316	58

1400	Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. <b>2012</b> , 69, 1310-7	142
1399	Imaging cerebral amyloid plaques: clinical perspective. <i>Lancet Neurology, The</i> , <b>2012</b> , 11, 652-3	24.1 4
1398	Making Alzheimer's and dementia research fit for populations. <b>2012</b> , 380, 1441-3	71
1397	Alzheimer's Disease. <b>2012</b> , 865-880	1
1396	Distinct cerebrospinal fluid amyloid-beta peptide signatures in cognitive decline associated with Alzheimer's disease and schizophrenia. <b>2012</b> , 33, 3738-44	25
1395	Nouveau concept de la maladie d'Alzheimer: apport des biomarqueurs. <b>2012</b> , 2012, 7-8	
1394	Interest of CSF biomarker analysis in possible cerebral amyloid angiopathy cases defined by the modified Boston criteria. <b>2012</b> , 259, 2429-33	55
1393	Stereotypic behaviors in degenerative dementias. <b>2012</b> , 259, 2452-9	21
1392	Positive argument for debate in J Neural Transmission: Alzheimer's disease: are we intervening too late? Yes, by years if not decades. <b>2012</b> , 119, 1529-32	6
1391	Family history and APOE-4 genetic risk in Alzheimer's disease. <b>2012</b> , 22, 298-309	33
1390	Neuropsychology of Alzheimer's disease. <b>2012</b> , 43, 686-93	28
1389	Emerging noninvasive biomarkers for early detection of Alzheimer's disease. <b>2012</b> , 43, 663-6	16
1388	Clinical diagnosis in preclinical stage of Alzheimer's disease. <b>2012</b> , 43, 667-70	4
1387	Mild cognitive impairment: disparity of incidence and prevalence estimates. <b>2012</b> , 8, 14-21	319
1386	Global gray matter changes in posterior cortical atrophy: a serial imaging study. <b>2012</b> , 8, 502-12	40
1385	Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults. <b>2012</b> , 8, 520-7	29
1384	Comparison of International Working Group criteria and National Institute on Aging-Alzheimer's Association criteria for Alzheimer's disease. <b>2012</b> , 8, 560-3	41
1383	Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot. <b>2012</b> , 8, 312-36	92

1382	No se puede tapar el sol con las manosâ€”Nuevos criterios diagnÃ³sticos en la enfermedad de Alzheimer. <b>2012</b> , 4, 3-5	
1381	Lack of an association between Paraoxonase 1 gene polymorphisms (Q192R, L55M) and Alzheimer's disease: a meta-analysis. <b>2012</b> , 523, 174-9	19
1380	[Epidemiology of dementia in elderly living in the 3rd borough of Bangui (Central African Republic)]. <b>2012</b> , 105, 388-95	8
1379	[For a new definition of the Alzheimer's disease]. <b>2012</b> , 168, 467-8	1
1378	Influence of Alzheimer disease family history and genetic risk on cognitive performance in healthy middle-aged and older people. <b>2012</b> , 20, 565-73	31
1377	Demencias degenerativas. <b>2012</b> , 16, 1-6	
1376	Demenze degenerative. <b>2012</b> , 14, 1-6	
1375	Les dÃ©mences du sujet jeune. <b>2012</b> , 3, 185-195	3
1374	[The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinical stages, mild cognitive impairment, and dementia]. <b>2012</b> , 168, 471-82	19
1373	EvaluaciÃ³n y diagnÃ³stico del deterioro cognitivo leve. <b>2012</b> , 32, 47-56	6
1372	[Markers of prodromal Alzheimer's disease]. <b>2012</b> , 168, 815-24	
1371	Alzheimer's disease diagnostic criteria: practical applications. <b>2012</b> , 4, 35	29
1370	Alzheimer's disease camouflaged by histrionic personality disorder. <b>2012</b> , 18, 75-9	2
1369	[Diagnostic profile of young-onset dementia before 65 years. Experience of a French Memory Referral Center]. <b>2012</b> , 168, 161-9	6
1368	From genetics to dietetics: the contribution of epidemiology to understanding Alzheimer's disease. <b>2013</b> , 33 Suppl 1, S457-63	17
1367	New diagnostic criteria for Alzheimer's disease and mild cognitive impairment for the practical neurologist. <b>2012</b> , 12, 88-96	28
1366	The French series of autosomal dominant early onset Alzheimer's disease cases: mutation spectrum and cerebrospinal fluid biomarkers. <b>2012</b> , 30, 847-56	94
1365	Fluid biomarkers in Alzheimer disease. <b>2012</b> , 2, a006221	120

1364	Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. <b>2012</b> , 33, 1203-14	278
1363	Discriminant analysis of longitudinal cortical thickness changes in Alzheimer's disease using dynamic and network features. <b>2012</b> , 33, 427.e15-30	137
1362	Preclinical AD Workgroup staging: pathological correlates and potential challenges. <b>2012</b> , 33, 622.e1-622.e16	54
1361	CSF tau markers are correlated with hippocampal volume in Alzheimer's disease. <b>2012</b> , 33, 1253-7	76
1360	Posterior cerebral atrophy in the absence of medial temporal lobe atrophy in pathologically-confirmed Alzheimer's disease. <b>2012</b> , 33, 627.e1-627.e12	58
1359	Structural MRI changes detectable up to ten years before clinical Alzheimer's disease. <b>2012</b> , 33, 825.e25-36	141
1358	Resting state fMRI in Alzheimer's disease: beyond the default mode network. <b>2012</b> , 33, 1564-78	367
1357	Hourly variability of cerebrospinal fluid biomarkers in Alzheimer's disease subjects and healthy older volunteers. <b>2012</b> , 33, 831.e1-9	27
1356	New mutations in MAPT gene causing frontotemporal lobar degeneration: biochemical and structural characterization. <b>2012</b> , 33, 834.e1-6	21
1355	Structural and functional neural correlates of visuospatial information processing in normal aging and amnesic mild cognitive impairment. <b>2012</b> , 33, 2782-97	30
1354	Accent processing in dementia. <b>2012</b> , 50, 2233-44	21
1353	Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes. <b>2012</b> , 18, 69-72	36
1352	Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia. <b>2012</b> , 97, 38-51	127
1351	Changes in activity patterns after the oral administration of brotizolam in institutionalized elderly patients with dementia. <b>2012</b> , 12, 99-105	3
1350	Does retirement affect cognitive functioning?. <b>2012</b> , 31, 490-501	242
1349	Semantic knowledge of newly coined words in mild cognitive impairment and Alzheimer's disease. <b>2012</b> , 25, 263-275	2
1348	Peripheral blood mono-nuclear cells derived from Alzheimer's disease patients show elevated baseline levels of secreted cytokines but resist stimulation with $\beta$ -amyloid peptide. <b>2012</b> , 49, 77-84	23
1347	GSTO1*E155del polymorphism associated with increased risk for late-onset Alzheimer's disease: association hypothesis for an uncommon genetic variant. <b>2012</b> , 506, 203-7	29

1346	Combination of p53(ser15) and p21/p21(thr145) in peripheral blood lymphocytes as potential Alzheimer's disease biomarkers. <b>2012</b> , 516, 226-31	23
1345	Elevated cerebrospinal fluid sphingomyelin levels in prodromal Alzheimer's disease. <b>2012</b> , 516, 302-5	67
1344	Complement activation as a biomarker for Alzheimer's disease. <b>2012</b> , 217, 204-15	48
1343	Increased sensitivity to proactive and retroactive interference in amnesic mild cognitive impairment: new insights. <b>2012</b> , 80, 104-10	8
1342	Dementia: Alzheimer pathology and vascular factors: from mutually exclusive to interaction. <b>2012</b> , 1822, 340-9	50
1341	The use of PIB-PET as a dual pathological and functional biomarker in AD. <b>2012</b> , 1822, 380-5	41
1340	Association rule-based feature selection method for Alzheimer's disease diagnosis. <b>2012</b> , 39, 11766-11774	39
1339	Cognitive functions and serum levels of brain-derived neurotrophic factor in patients with major depressive disorder. <b>2012</b> , 88, 454-9	50
1338	Working memory, attention, and executive function in Alzheimer's disease and frontotemporal dementia. <b>2012</b> , 48, 429-46	165
1337	An electronic walkway can predict short-term fall risk in nursing home residents with dementia. <b>2012</b> , 36, 95-101	40
1336	Alzheimer's disease markers from structural MRI and FDG-PET brain images. <b>2012</b> , 127, 1	13
1335	Word reading threshold and mild cognitive impairment: a validation study. <b>2012</b> , 12, 38	5
1334	The effect of stimulation therapy and donepezil on cognitive function in Alzheimer's disease. A community based RCT with a two-by-two factorial design. <b>2012</b> , 12, 59	8
1333	The epidemiology of mild cognitive impairment (MCI) and Alzheimer's disease (AD) in community-living seniors: protocol of the MemoVie cohort study, Luxembourg. <b>2012</b> , 12, 519	11
1332	Effective diagnosis of Alzheimer's disease by means of large margin-based methodology. <b>2012</b> , 12, 79	4
1331	Preclinical Alzheimer disease: identification of cases at risk among cognitively intact older individuals. <b>2012</b> , 10, 127	37
1330	Serial position effects in Alzheimer's disease, mild cognitive impairment, and normal aging: predictive value for conversion to dementia. <b>2012</b> , 34, 841-52	22
1329	Predictors of cognitive decline in Alzheimer's disease and mild cognitive impairment using the CAMCOG: a five-year follow-up. <b>2012</b> , 24, 948-58	14

1328	CSF biomarkers correlate with cerebral blood flow on SPECT in healthy elderly. <b>2012</b> , 33, 156-63	10
1327	Comparing hippocampal atrophy in Alzheimer's dementia and dementia with lewy bodies. <b>2012</b> , 34, 44-50	33
1326	Upstream transcription factor 1 (USF1) polymorphisms associate with Alzheimer's disease-related neuropathological lesions: Tampere Autopsy Study. <b>2012</b> , 22, 765-75	12
1325	Determining cut-points for Alzheimer's disease biomarkers: statistical issues, methods and challenges. <b>2012</b> , 6, 391-400	45
1324	Diagnosis of Alzheimer's disease. <b>2012</b> , 12-46	
1323	Prevalence of mild cognitive impairment and its subtypes in the Mexican population. <b>2012</b> , 34, 271-81	38
1322	Asymmetric loss of parietal activity causes spatial bias in prodromal and mild Alzheimer's disease. <b>2012</b> , 71, 798-804	19
1321	Increased cerebrospinal fluid levels of double-stranded RNA-dependant protein kinase in Alzheimer's disease. <b>2012</b> , 71, 829-35	45
1320	Judgments about moral responsibility and determinism in patients with behavioural variant of frontotemporal dementia: still compatibilists. <b>2012</b> , 21, 851-64	15
1319	Epileptic Amnesic Syndrome revealing Alzheimer's disease. <b>2012</b> , 102, 206-9	18
1318	Detecting global and local hippocampal shape changes in Alzheimer's disease using statistical shape models. <b>2012</b> , 59, 2155-66	66
1317	Brain imaging in the study of Alzheimer's disease. <b>2012</b> , 61, 505-16	83
1316	EEG markers are associated to gray matter changes in thalamus and basal ganglia in subjects with mild cognitive impairment. <b>2012</b> , 60, 489-96	39
1315	Imaging brain amyloid deposition using grating-based differential phase contrast tomography. <b>2012</b> , 61, 1336-46	62
1314	Resting state FDG-PET functional connectivity as an early biomarker of Alzheimer's disease using conjoint univariate and independent component analyses. <b>2012</b> , 63, 936-46	68
1313	Combining MRI and CSF measures for classification of Alzheimer's disease and prediction of mild cognitive impairment conversion. <b>2012</b> , 62, 229-38	224
1312	A computational neurodegenerative disease progression score: method and results with the Alzheimer's disease Neuroimaging Initiative cohort. <b>2012</b> , 63, 1478-86	148
1311	Assessment of the information provided by the medical specialist on Alzheimer's disease and that retained by the patient caregivers. <b>2012</b> , 27, 453-71	3

1310	Assessment of the information provided by the medical specialist on Alzheimer's disease and that retained by the patient caregivers. <b>2012</b> , 27, 453-471	0
1309	Brain excitability and connectivity of neuronal assemblies in Alzheimer's disease: from animal models to human findings. <b>2012</b> , 99, 42-60	98
1308	Disease-specific expression of the serotonin-receptor 5-HT(2C) in natural killer cells in Alzheimer's dementia. <b>2012</b> , 251, 73-9	16
1307	Patients with Alzheimer disease have elevated intrathecal synthesis of antibodies against tau protein and heavy neurofilament. <b>2012</b> , 252, 100-5	41
1306	GSTM1 null genotype as risk factor for late-onset Alzheimer's disease in Italian patients. <b>2012</b> , 317, 137-40	31
1305	Neurocognitive disorders in DSM 5 project - personal comments. <b>2012</b> , 322, 17-9	6
1304	Hippocampal atrophy in Alzheimer's disease. <b>2012</b> , 2, 197-209	2
1303	Neurological Signs of Ageing. <b>2012</b> , 607-616	2
1302	New and emerging treatments for Alzheimer's disease. <b>2012</b> , 12, 535-43	42
1301	Cognitive decline and amyloid accumulation in patients with mild cognitive impairment. <b>2012</b> , 34, 31-7	9
1300	Use of FDG PET as an imaging biomarker in clinical trials of Alzheimer's disease. <b>2012</b> , 6, 431-9	37
1299	Clinical and research diagnostic criteria for Alzheimer's disease. <b>2012</b> , 22, 23-32,viii	39
1298	Structural neuroimaging in aging and Alzheimer's disease. <b>2012</b> , 22, 33-55, vii-viii	21
1297	De meerwaarde van diffusie gewogen beeldvorming bij de vroegdiagnostiek van de ziekte van Alzheimer. <b>2012</b> , 16, 143-148	
1296	Intraindividual cognitive decline using a brief computerized cognitive screening test. <b>2012</b> , 8, 95-104	48
1295	Influence of emotional content and context on memory in mild Alzheimer's disease. <b>2012</b> , 29, 817-26	23
1294	Advances in Stem Cell Research. <b>2012</b> ,	1
1293	Vascular mild cognitive impairment: concept, definition, and directions for future studies. <b>2012</b> , 24, 113-6	24



1292 Welcher Marker ist am präzisesten?. **2012**, 14, 30-30

1291 Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementia. **2012**, 69, 700-8 110

1290 Amyloid- $\beta$  oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease. **2012**, 29, 171-6 78

1289  $\alpha$ 7 nicotinic acetylcholine receptors in Alzheimer's disease: neuroprotective, neurotrophic or both?. **2012**, 13, 613-22 52

1288 5th conference clinical trials on Alzheimer's disease: October 29-31, 2012, Grimaldi Forum, Convention Center, Monte Carlo. **2012**, 16, 795-872 4

1287 Current epidemiological approaches to the metabolic-cognitive syndrome. **2012**, 30 Suppl 2, S31-75 40

1286 Diseases of the Brain, Head & Neck, Spine 2012-2015. **2012**, 4

1285 Practical lessons from amyloid immunotherapy trials in Alzheimer disease. **2012**, 9, 1126-34 3

1284 Improved classification of Alzheimer's disease data via removal of nuisance variability. **2012**, 7, e31112 35

1283 Beta-amyloid peptides enhance the proliferative response of activated CD4CD28 lymphocytes from Alzheimer disease patients and from healthy elderly. **2012**, 7, e33276 22

1282 MRI-based volumetry correlates of autobiographical memory in Alzheimer's disease. **2012**, 7, e46200 18

1281 Structural MRI in frontotemporal dementia: comparisons between hippocampal volumetry, tensor-based morphometry and voxel-based morphometry. **2012**, 7, e52531 33

1280 Clinical Approach to Diagnosis of Pre-Dementia Alzheimer's Disease (CAD-PAD). **2012**, 2, 332-42 3

1279 Executive Dysfunction in MCI: Subtype or Early Symptom. **2012**, 2012, 936272 32

1278 Test-retest reliability of a new medial temporal atrophy morphological metric. **2012**, 2012, 979804 2

1277 Specific EEG changes associated with atrophy of hippocampus in subjects with mild cognitive impairment and Alzheimer's disease. **2012**, 2012, 253153 36

1276 Reviewing reasons for the decreased CSF Abeta42 concentration in Alzheimer disease. **2012**, 17, 2024-34 31

1275 Automated VOI Analysis in FDDNP PET Using Structural Warping: Validation through Classification of Alzheimer's Disease Patients. **2012**, 2012, 512069 3

1274	Memory complaints associated with seeking clinical care. <b>2012</b> , 2012, 725329	20
1273	Perspectives for multimodal neurochemical and imaging biomarkers in Alzheimer's disease. <b>2013</b> , 33 Suppl 1, S329-47	16
1272	Metals in Alzheimer's disease: a systemic perspective. <b>2012</b> , 17, 451-72	62
1271	Spatial navigation-a unique window into physiological and pathological aging. <b>2012</b> , 4, 16	46
1270	Grey matter and cognitive patterns in cognitive impaired subjects using CSF biomarker cut-offs. <b>2012</b> , 29, 741-9	1
1269	Increase in platelet immunoglobulin in Alzheimer's disease is normalised following cholinesterase inhibitor treatment: preliminary results. <b>2012</b> , 32, 431-6	1
1268	Imaging the onset and progression of Alzheimer's disease: implications for prevention trials. <b>2013</b> , 33 Suppl 1, S305-12	4
1267	Metabolic-cognitive syndrome: metabolic approach for the management of Alzheimer's disease risk. <b>2012</b> , 30 Suppl 2, S1-4	7
1266	Parkinson's Disease. 215-226	
1265	Alzheimer's Disease. 227-241	
1264	Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDT4). <b>2012</b> , 15, 120-6	98
1263	Comparison of xMAP and ELISA assays for detecting cerebrospinal fluid biomarkers of Alzheimer's disease. <b>2012</b> , 31, 439-45	55
1262	[Truth telling of Alzheimer's disease diagnosis]. <b>2012</b> , 140, 811-7	4
1261	Contribution of single photon emission computed tomography to the differential diagnosis of dementia in a memory clinic. <b>2012</b> , 30, 833-45	15
1260	Relationship between structural abnormalities in the cerebellum and dementia, posttraumatic stress disorder and bipolar disorder. <b>2012</b> , 6, 203-211	13
1259	Amyloid imaging with AV45 ((18)F-florbetapir) in a cognitively normal APOE4 duplication carrier. <b>2012</b> , 28, 877-83	4
1258	Yamaguchi Facial Expression-Making Task in Alzheimer's Disease: A Novel and Enjoyable Make-a-Face Game. <b>2012</b> , 2, 248-57	4
1257	Spectral and Non-Linear Analyses of Spontaneous Magnetoencephalographic Activity in Alzheimer's Disease. <b>2012</b> , 3, 299-322	10

1256	Dementia diagnosis differs in men and women and depends on age and dementia severity: data from SveDem, the Swedish Dementia Quality Registry. <b>2012</b> , 33, 90-5	33
1255	Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play. <b>2012</b> , 263, 344-61	166
1254	Diagnosis. <b>2012</b> , 139-191	
1253	Investigation. <b>2012</b> , 107-137	
1252	Cognitive Assessment. <b>2012</b> , 15-65	
1251	Is radiological evaluation as good as computer-based volumetry to assess hippocampal atrophy in Alzheimer's disease?. <b>2012</b> , 54, 1321-30	31
1250	CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. <b>2012</b> , 124, 23-35	138
1249	New and emerging treatments for Alzheimer's disease. <b>2012</b> , 17, 147-56	23
1248	Neuroscience-based Tests for Assessing Cognitive Changes in Normal Aging and in the Prodromal Phase of Alzheimer's Disease. <b>2012</b> , 1, 1-10	
1247	Chronic traumatic encephalopathy: neurodegeneration following repetitive concussive and subconcussive brain trauma. <b>2012</b> , 6, 244-54	328
1246	CSF biomarkers for amyloid and tau pathology in Alzheimer's disease. <b>2012</b> , 47, 1-14	51
1245	Expression of the newly identified gene CAC1 in the hippocampus of Alzheimer's disease patients. <b>2012</b> , 47, 207-18	11
1244	Are biomarkers harmful to recruitment and retention in Alzheimer's disease clinical trials? An international perspective. <b>2012</b> , 16, 346-8	9
1243	Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology. <b>2012</b> , 16, 339-45	31
1242	Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. <b>2012</b> , 39, 621-31	163
1241	The prevalence of CD33 and MS4A6A variant in Chinese Han population with Alzheimer's disease. <b>2012</b> , 131, 1245-9	42
1240	Cerebrospinal fluid $\beta$ -amyloid 1-42 correlates with rate of progression in Alzheimer's disease. <b>2012</b> , 119, 799-804	4
1239	Biomarkers of neurodegeneration - not only Alzheimer's disease and not only cerebrospinal fluid: a guest-editor's introduction. <b>2012</b> , 119, 735-7	

1238	Evaluating the traditional Chinese literature for herbal formulae and individual herbs used for age-related dementia and memory impairment. <b>2012</b> , 13, 299-312	38
1237	Cued recall and other cognitive tasks to facilitate dementia recognition in primary care. <b>2012</b> , 60, 130-5	13
1236	Performances on Rey Auditory Verbal Learning Test and Rey Complex Figure Test in a healthy, elderly Danish sample--reference data and validity issues. <b>2012</b> , 53, 26-31	16
1235	CERAD-neuropsychological battery in screening mild Alzheimer's disease. <b>2012</b> , 125, 16-23	57
1234	Dementia, stroke, and vascular risk factors; a review. <b>2012</b> , 7, 61-73	136
1233	Non-pharmacological interventions on cognitive functions in older people with mild cognitive impairment (MCI). <b>2012</b> , 54, 175-80	71
1232	The role of n-3 dietary polyunsaturated fatty acids in brain function and ameliorating Alzheimer's disease: Opportunities for biotechnology in the development of nutraceuticals. <b>2012</b> , 1, 159-166	12
1231	2002-2012. <i>Lancet Neurology, The</i> , <b>2012</b> , 11, 395	24.1
1230	Klaus Fassbender. <i>Lancet Neurology, The</i> , <b>2012</b> , 11, 395	24.1
1229	Underuse of diagnostic codes for specific dementias in the Veterans Affairs New England healthcare system. <b>2012</b> , 60, 910-5	22
1228	Alzheimer CSF biomarkers in routine clinical setting. <b>2012</b> , 125, 416-23	27
1227	Nonlinear dimensionality reduction combining MR imaging with non-imaging information. <b>2012</b> , 16, 819-30	44
1226	Medial prefrontal functional connectivity--relation to memory self-appraisal accuracy in older adults with and without memory disorders. <b>2012</b> , 50, 603-11	40
1225	Optimisation of the quantification of glutamine synthetase and myelin basic protein in cerebrospinal fluid by a combined acidification and neutralisation protocol. <b>2012</b> , 381, 1-8	4
1224	Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression. <b>2012</b> , 19, 1561-7	99
1223	Applying the new research diagnostic criteria: MRI findings and neuropsychological correlations of prodromal AD. <b>2012</b> , 27, 127-34	33
1222	Diffusion tensor imaging of the hippocampus and verbal memory performance: the RUN DMC study. <b>2012</b> , 33, 542-51	36
1221	Entorhinal cortex atrophy differentiates Parkinson's disease patients with and without dementia. <b>2012</b> , 27, 727-34	39

1220	Amyloid- $\beta$ imaging with PET in Alzheimer's disease: is it feasible with current radiotracers and technologies?. <b>2012</b> , 39, 202-8	27
1219	Predictive value of dopamine transporter SPECT imaging with [ $^{111}\text{In}$ ]PE2I in patients with subtle parkinsonian symptoms. <b>2012</b> , 39, 242-50	22
1218	Position paper of the Italian Society for the study of Dementias (SINDEM) on the proposal of a new lexicon on Alzheimer disease. <b>2012</b> , 33, 201-8	3
1217	Neuroanatomic changes and their association with cognitive decline in mild cognitive impairment: a meta-analysis. <b>2012</b> , 217, 115-25	53
1216	Progress in Alzheimer's disease. <b>2012</b> , 259, 201-11	71
1215	The development of effective biomarkers for Alzheimer's disease: a review. <b>2013</b> , 28, 331-40	36
1214	Comparison of entorhinal cortex atrophy between early-onset and late-onset Alzheimer's disease using the VSRAD, a specific and sensitive voxel-based morphometry. <b>2013</b> , 28, 372-6	13
1213	Prolonged rock climbing activity induces structural changes in cerebellum and parietal lobe. <b>2013</b> , 34, 2707-14	33
1212	Improved prediction of Alzheimer's disease with longitudinal white matter/gray matter contrast changes. <b>2013</b> , 34, 2775-85	12
1211	Does posterior cortical atrophy on MRI discriminate between Alzheimer's disease, dementia with Lewy bodies, and normal aging?. <b>2013</b> , 25, 111-9	21
1210	Conclusion: Place of Cognitive Screening Instruments: Test Characteristics and Suspected Diagnosis. <b>2013</b> , 219-238	3
1209	(18)F-florbetaben A $\beta$ imaging in mild cognitive impairment. <b>2013</b> , 5, 4	40
1208	Apraxia and Alzheimer's disease: review and perspectives. <b>2013</b> , 23, 234-56	48
1207	Straightforward synthesis of PET tracer precursors used for the early diagnosis of Alzheimers disease through Suzuki-Miyaura cross-coupling reactions. <b>2013</b> , 69, 7345-7353	7
1206	Is AD a homogeneous nosologic entity? Yes. <b>2013</b> , 120, 1467-73	
1205	Blood and plasma-based proteomic biomarker research in Alzheimer's disease. <b>2013</b> , 101-102, 1-17	88
1204	Novel disease-modifying therapeutics for the treatment of Alzheimer's disease. <b>2013</b> , 6, 423-42	7
1203	Dementing Disorders. <b>2013</b> , 641-674	

1202	Progress in Alzheimer's disease research in the last year. <b>2013</b> , 260, 1936-41	10
1201	Progress towards a consensus on biomarkers for Alzheimer's disease: a review of peripheral analytes. <b>2013</b> , 7, 641-62	16
1200	Resting state cortical EEG rhythms in Alzheimer's disease: toward EEG markers for clinical applications: a review. <b>2013</b> , 62, 223-36	93
1199	How to design nutritional intervention trials to slow cognitive decline in apparently healthy populations and apply for efficacy claims: a statement from the International Academy on Nutrition and Aging Task Force. <b>2013</b> , 17, 619-23	8
1198	Gait variability at fast-pace walking speed: a biomarker of mild cognitive impairment?. <b>2013</b> , 17, 235-9	82
1197	Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement. <b>2013</b> , 17, 54-63	24
1196	Analysis of multiple phenotypes in genome-wide genetic mapping studies. <b>2013</b> , 14, 151	23
1195	Early detection of memory impairment in people over 65 years old consulting at Health Examination Centers for the French health insurance: the EVATEM protocol. <b>2013</b> , 13, 55	16
1194	NG2 cells, a new trail for Alzheimer's disease mechanisms?. <b>2013</b> , 1, 7	37
1193	ATP7B variants as modulators of copper dyshomeostasis in Alzheimer's disease. <b>2013</b> , 15, 515-22	48
1192	The applause sign in cortical and cortical-subcortical dementia. <b>2013</b> , 260, 1099-103	20
1191	Nutrition and neurodegeneration: epidemiological evidence and challenges for future research. <b>2013</b> , 75, 738-55	116
1190	The therapeutics of Alzheimer's disease: where we stand and where we are heading. <b>2013</b> , 74, 328-36	91
1189	A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. <b>2013</b> , 40, 104-14	148
1188	Isoform transition from four-repeat to three-repeat tau underlies dendrosomatic and regional progression of neurofibrillary pathology. <b>2013</b> , 125, 565-79	40
1187	Word list and story recall elicit different patterns of memory deficit in patients with Alzheimer's disease, frontotemporal dementia, subcortical ischemic vascular disease, and Lewy body dementia. <b>2013</b> , 37, 99-107	28
1186	Different demographic, genetic, and longitudinal traits in language versus memory Alzheimer's subgroups. <b>2013</b> , 37, 137-46	8
1185	Resting metabolic connectivity in Alzheimer's disease. <b>2013</b> , 1, 271-278	7

1184	The epidemiology of delirium: challenges and opportunities for population studies. <b>2013</b> , 21, 1173-89	76
1183	Uridine prodrug improves memory in Tg2576 and TAPP mice and reduces pathological factors associated with Alzheimer's disease in related models. <b>2013</b> , 36, 637-57	14
1182	Apport des biomarqueurs cognitifs dans le diagnostic de la maladie d'Alzheimer. <b>2013</b> , 4, 53-58	
1181	Quantifying an amyloid $\beta$ model for Alzheimer's disease. <i>Lancet Neurology, The</i> , <b>2013</b> , 12, 327-8	24.1 1
1180	Impact of molecular imaging on the diagnostic process in a memory clinic. <b>2013</b> , 9, 414-21	137
1179	Diffusion tensor magnetic resonance imaging for single subject diagnosis in neurodegenerative diseases. <b>2013</b> , 136, 2253-61	49
1178	The nucleus basalis of Meynert: a new target for deep brain stimulation in dementia?. <b>2013</b> , 37, 2676-88	98
1177	Beyond amyloid: getting real about nonamyloid targets in Alzheimer's disease. <b>2013</b> , 9, 452-458.e1	41
1176	Clinical stages of patients with Alzheimer disease treated in specialist clinics in Spain. The EACE study. <b>2013</b> , 28, 477-487	1
1175	Personalized medicine in Alzheimer's disease and depression. <b>2013</b> , 36, 616-23	14
1174	Cerebral amyloid PET imaging in Alzheimer's disease. <b>2013</b> , 126, 643-57	79
1173	Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer's disease: a selective review. <b>2013</b> , 5, 58	114
1172	Structural Magnetic Resonance Imaging as a Biomarker for the Diagnosis, Progression, and Treatment of Alzheimer Disease. <b>2013</b> , 87-129	1
1171	Personalized medicine strategies for managing patients with parkinsonism and cognitive deficits. <b>2013</b> , 62 Suppl 1, S27-9	7
1170	Deciphering logopenic primary progressive aphasia: a clinical, imaging and biomarker investigation. <b>2013</b> , 136, 3474-88	121
1169	Mild Cognitive Impairment. <b>2013</b> , 77-95	1
1168	How early can we predict Alzheimer's disease using computational anatomy?. <b>2013</b> , 34, 2815-26	67
1167	Potential blood biomarker for disease severity in the Taiwanese population with Alzheimer's disease. <b>2013</b> , 28, 75-83	27

1166	Molecular neuroimaging in degenerative dementias. <b>2013</b> , 32, 301-309	2
1165	Trait'sur la maladie d'Alzheimer. <b>2013</b> ,	
1164	Memory loss during lenalidomide treatment: a report on two cases. <b>2013</b> , 14, 41	10
1163	Computer-aided diagnostic reporting of FDG PET for the diagnosis of Alzheimer's disease. <b>2013</b> , 1, 279-288	2
1162	One-year repeated cycles of cognitive training (CT) for Alzheimer's disease. <b>2013</b> , 25, 421-6	24
1161	Evaluation of the efficacy of a cognitive rehabilitation treatment on a group of Alzheimer's patients with moderate cognitive impairment: a pilot study. <b>2013</b> , 25, 403-9	4
1160	Multiagent imaging of the brain. <b>2013</b> , 1, 365-376	2
1159	Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. <i>Lancet Neurology, The</i> , <b>2013</b> , 12, 957-65	24.1 389
1158	Alzheimer disease: from biomarkers to diagnosis. <b>2013</b> , 169, 744-51	15
1157	Aphasia(s) in Alzheimer. <b>2013</b> , 169, 680-6	2
1156	Biomarkers of Alzheimer's disease: the present and the future. <b>2013</b> , 169, 719-23	11
1155	Memory, fluency, and orientation (MEFO): A five-minute screening test for cognitive decline. <b>2013</b> , 28, 400-407	1
1154	Type 2 diabetes and cognitive compromise: potential roles of diabetes-related therapies. <b>2013</b> , 42, 489-501	33
1153	Integrating discretization and association rule-based classification for Alzheimer's disease diagnosis. <b>2013</b> , 40, 1571-1578	26
1152	Manual segmentation certification platform. <b>2013</b> ,	1
1151	A PET study of discrimination of cerebral glucose metabolism in Alzheimer's disease and mild cognitive impairment. <b>2013</b> ,	1
1150	Predicting Alzheimer disease with $\beta$ -amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing. <b>2013</b> , 74, 905-13	158
1149	An improved fast marching method and its application in Alzheimer's disease. <b>2013</b> , 23, 346-352	



1148	Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome. <b>2013</b> , 5, 1	202
1147	Modeling the course of Alzheimer's disease to improve clinical trials: symposium report. <b>2013</b> , 5, 29	2
1146	Definitions of dementia and predementia states in Alzheimer's disease and vascular cognitive impairment: consensus from the Canadian conference on diagnosis of dementia. <b>2013</b> , 5, S2	81
1145	Clinical applications of neuroimaging in patients with Alzheimer's disease: a review from the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. <b>2013</b> , 5, S3	20
1144	Role of emerging neuroimaging modalities in patients with cognitive impairment: a review from the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. <b>2013</b> , 5, S4	14
1143	Cortical sources of resting state EEG rhythms are sensitive to the progression of early stage Alzheimer's disease. <b>2013</b> , 34, 1015-35	50
1142	A retrospective survey on rotated drawing in persons with mild cognitive impairment or degenerative dementia. <b>2013</b> , 27, 1300-15	3
1141	Relative preservation of the recognition of positive facial expression "happiness" in Alzheimer disease. <b>2013</b> , 25, 105-10	23
1140	Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative. <b>2013</b> , 34, 62-72	40
1139	Visual ratings of atrophy in MCI: prediction of conversion and relationship with CSF biomarkers. <b>2013</b> , 34, 73-82	38
1138	Apolipoprotein E $\epsilon$ 4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. <b>2013</b> , 34, 1-12	167
1137	Dementia and neuroimaging. <b>2013</b> , 260, 685-91	11
1136	Behavioral and psychological symptoms of dementia: factor analysis and relationship with cognitive impairment. <b>2013</b> , 69, 76-82	17
1135	Applause sign in Alzheimer's disease: relationships to cognitive profile and severity of illness. <b>2013</b> , 260, 172-5	14
1134	Improving dementia care: the role of screening and detection of cognitive impairment. <b>2013</b> , 9, 151-9	153
1133	Clinical use of brain volumetry. <b>2013</b> , 37, 1-14	73
1132	Introduction to Cognitive Screening Instruments: Rationale, Desiderata, and Assessment of Utility. <b>2013</b> , 1-14	5
1131	Revisiting the framework of the National Institute on Aging-Alzheimer's Association diagnostic criteria. <b>2013</b> , 9, 594-601	35

1130	Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. <b>2013</b> , 2, 356-65	227
1129	A new assessment for episodic memory. Episodic memory test and caregiver's episodic memory test. <b>2013</b> , 28, 488-496	1
1128	The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER): study design and progress. <b>2013</b> , 9, 657-65	267
1127	Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. <b>2013</b> , 9, e-1-16	330
1126	Meta-analysis based SVM classification enables accurate detection of Alzheimer's disease across different clinical centers using FDG-PET and MRI. <b>2013</b> , 212, 230-6	76
1125	[Clinical stages of patients with Alzheimer disease treated in specialist clinics in Spain. The EACE study]. <b>2013</b> , 28, 477-87	3
1124	Establishing the psychometric underpinning of cognition measures for clinical trials of Alzheimer's disease and its precursors: a new approach. <b>2013</b> , 9, S56-60	9
1123	Structural and Functional Magnetic Resonance Imaging: Mild Cognitive Impairment and Alzheimer Disease. <b>2013</b> , 8, 407-30	1
1122	Diffusion tensor imaging measures of normal appearing white matter in patients who are aging, or have amnesic mild cognitive impairment, or Alzheimer's disease. <b>2013</b> , 20, 1089-94	17
1121	Molecular neuroimaging in degenerative dementias. <b>2013</b> , 32, 301-9	3
1120	Increased CNV-region deletions in mild cognitive impairment (MCI) and Alzheimer's disease (AD) subjects in the ADNI sample. <b>2013</b> , 102, 112-22	21
1119	Sensitivity and specificity of ventromedial prefrontal cortex tests in behavioral variant frontotemporal dementia. <b>2013</b> , 9, S84-94	50
1118	Imaging markers for Alzheimer disease: which vs how. <b>2013</b> , 81, 487-500	173
1117	The ELISA-measured increase in cerebrospinal fluid tau that discriminates Alzheimer's disease from other neurodegenerative disorders is not attributable to differential recognition of tau assembly forms. <b>2013</b> , 33, 923-8	9
1116	Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trials. <b>2013</b> , 9, S45-55	64
1115	Prospective interest of molecular neuroimaging in Alzheimer's disease. <b>2013</b> , 169, 9-13	
1114	Translational proteomics in Alzheimer's disease and related disorders. <b>2013</b> , 46, 480-6	17
1113	Alzheimer's disease and mortality in traditional long-term care facilities. <b>2013</b> , 56, 437-41	4

1112	Previously not recognized deletion in presenilin-1 (p.Leu174del.) in a patient with early-onset familial Alzheimer's disease. <b>2013</b> , 544, 115-8	8
1111	Impaired cerebral glucose metabolism in prodromal Alzheimer's disease differs by regional intensity normalization. <b>2013</b> , 534, 12-7	21
1110	Research and standardization in Alzheimer's trials: reaching international consensus. <b>2013</b> , 9, 160-8	16
1109	Functional plasticity in Alzheimer's disease: effect of cognitive training on language-related ERP components. <b>2013</b> , 51, 1638-48	23
1108	L'imagerie cérébrale des plaques amyloïdes : le point de vue du clinicien. <b>2013</b> , 4, 59-63	
1107	Risk and resilience: A new perspective on Alzheimer's disease. <b>2013</b> , 1, 47-55	2
1106	[A new assessment for episodic memory. Episodic memory test and caregiver's episodic memory test]. <b>2013</b> , 28, 488-96	6
1105	Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. <b>2013</b> , 9, 438-44	111
1104	MIRIAD--Public release of a multiple time point Alzheimer's MR imaging dataset. <b>2013</b> , 70, 33-6	70
1103	Índice de discriminabilidad en memoria de reconocimiento en deterioro cognitivo leve amnésico y demencia tipo Alzheimer leve. Un estudio preliminar. <b>2013</b> , 5, 241-249	
1102	Genetic interactions associated with 12-month atrophy in hippocampus and entorhinal cortex in Alzheimer's Disease Neuroimaging Initiative. <b>2013</b> , 34, 1518.e9-18	30
1101	Modeling disease progression via multi-task learning. <b>2013</b> , 78, 233-48	129
1100	Screening for predementia AD: time-dependent operating characteristics of episodic memory tests. <b>2013</b> , 80, 1307-14	78
1099	Effects of acetylcholinesterase inhibitors and memantine on resting-state electroencephalographic rhythms in Alzheimer's disease patients. <b>2013</b> , 124, 837-50	60
1098	Does tip-of-the-tongue for proper names discriminate amnesic mild cognitive impairment?. <b>2013</b> , 25, 627-34	20
1097	Introduction. <b>2013</b> , 25, 174-5	8
1096	Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET. <b>2013</b> , 70, 423-33	39
1095	Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid- $\beta$ (1-42) and $\beta$ proteins as Alzheimer disease biomarkers. <b>2013</b> , 59, 903-16	117

1094	Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series. <b>2013</b> , 9, 677-86	43
1093	Neurodegenerative Diseases. <b>2013</b> , 151-173	1
1092	Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. <i>Lancet Neurology, The</i> , <b>2013</b> , 12, 514-24	24.1 108
1091	Diagnosis and management of Alzheimer's disease: past, present and future ethical issues. <b>2013</b> , 110, 102-13	73
1090	Correlations between serum levels of beta amyloid, cerebrospinal levels of tau and phospho tau, and delayed response tasks in young and aged cynomolgus monkeys ( <i>Macaca fascicularis</i> ). <b>2013</b> , 42, 137-46	13
1089	A prediction model to calculate probability of Alzheimer's disease using cerebrospinal fluid biomarkers. <b>2013</b> , 9, 262-8	18
1088	Immunotherapy against amyloid pathology in Alzheimer's disease. <b>2013</b> , 333, 50-4	36
1087	International Work Group criteria for the diagnosis of Alzheimer disease. <b>2013</b> , 97, 363-8	55
1086	The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease. <b>2013</b> , 97, 369-76	47
1085	Clinical trials in predementia stages of Alzheimer disease. <b>2013</b> , 97, 439-57	37
1084	Applying the IWG research criteria in clinical practice: feasibility and ethical issues. <b>2013</b> , 97, 477-84	9
1083	Lipid raft disarrangement as a result of neuropathological progresses: a novel strategy for early diagnosis?. <b>2013</b> , 245, 26-39	37
1082	Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. <b>2013</b> , 9, S72-83	157
1081	Striatal dopamine transporter binding does not correlate with clinical severity in dementia with Lewy bodies. <b>2013</b> , 54, 1072-6	27
1080	SOD2 in mitochondrial dysfunction and neurodegeneration. <b>2013</b> , 62, 4-12	157
1079	Geriatric syndromes--vascular disorders?. <b>2013</b> , 45, 265-73	39
1078	Diagnosis and management of dementia in older people. <b>2013</b> , 41, 43-46	3
1077	A direct morphometric comparison of five labeling protocols for multi-atlas driven automatic segmentation of the hippocampus in Alzheimer's disease. <b>2013</b> , 66, 50-70	44

1076	The impact of alcohol on Alzheimer's disease: a systematic review. <b>2013</b> , 17, 133-46	60
1075	Regional magnetic resonance imaging measures for multivariate analysis in Alzheimer's disease and mild cognitive impairment. <b>2013</b> , 26, 9-23	137
1074	Aripiprazole in the treatment of Alzheimer's disease. <b>2013</b> , 14, 459-74	39
1073	Type 2 diabetes as a risk factor for Alzheimer's disease: the confounders, interactions, and neuropathology associated with this relationship. <b>2013</b> , 35, 152-60	199
1072	[Memory, fluency, and orientation: a five-minute screening test for cognitive decline]. <b>2013</b> , 28, 400-7	8
1071	Effects of the apolipoprotein E $\epsilon$ allele on functional MRI during n-back working memory tasks in healthy middle-aged adults. <b>2013</b> , 34, 1197-202	26
1070	Tip-of-the-tongue for proper names in non-amnesic mild cognitive impairment. <b>2013</b> , 26, 409-420	3
1069	Linkage disequilibrium and haplotype analysis of the ATP7B gene in Alzheimer's disease. <b>2013</b> , 16, 3-10	41
1068	MRI and cerebrospinal fluid biomarkers for predicting progression to Alzheimer's disease in patients with mild cognitive impairment: a diagnostic accuracy study. <b>2013</b> , 3,	56
1067	Can the DSM-5 framework enhance the diagnosis of MCI?. <b>2013</b> , 81, 2045-50	18
1066	Connected speech as a marker of disease progression in autopsy-proven Alzheimer's disease. <b>2013</b> , 136, 3727-37	146
1065	Reversible parietal hypometabolism in late-onset psychosis. <b>2013</b> , 25, E32-3	1
1064	Leichte kognitive Störung. <b>2013</b> , 7, 9-20	
1063	Cerebrospinal fluid tau levels predict prognosis in non-inherited frontotemporal dementia. <b>2014</b> , 13, 224-9	20
1062	[Assessing activities of daily living in patients with epilepsy]. <b>2013</b> , 81, 452-8	6
1061	What Neuropsychiatrists Would Like to See in DSM-5. <b>2013</b> , 25, 6-11	1
1060	Neuroimaging in neurodegenerative dementias. <b>2012</b> , 32, 347-60	15
1059	Recognition performance differentiates between elderly patients in the long term course of secondary progressive multiple sclerosis and amnesic mild cognitive impairment. <b>2013</b> , 19, 799-805	14

1058	SPION-enhanced magnetic resonance imaging of Alzheimer's disease plaques in APP/PS-1 transgenic mouse brain. <b>2013</b> , 34, 349-65	65
1057	Challenges of diagnosing dementia in the oldest old population. <b>2013</b> , 68, 1103-11	32
1056	MEG delta mapping along the healthy aging-Alzheimer's disease continuum: diagnostic implications. <b>2013</b> , 35, 495-507	38
1055	Relating memory to functional performance in normal aging to dementia using hierarchical Bayesian cognitive processing models. <b>2013</b> , 27, 16-22	13
1054	A biased competition account of attention and memory in Alzheimer's disease. <b>2013</b> , 368, 20130062	25
1053	The PredictAD project: development of novel biomarkers and analysis software for early diagnosis of the Alzheimer's disease. <b>2013</b> , 3, 20120072	19
1052	Dysexecutive versus amnesic Alzheimer disease subgroups: analysis of demographic, genetic, and vascular factors. <b>2013</b> , 27, 218-25	23
1051	Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. <b>2013</b> , 27, 4-15	86
1050	Biomarkers in Alzheimer's disease with a special emphasis on event-related oscillatory responses. <b>2013</b> , 62, 237-73	52
1049	Neither Body nor Brain: Comparing Preventive Attitudes to Prostate Cancer and Alzheimer's Disease. <b>2013</b> , 19, 61-91	7
1048	Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. <b>2013</b> , 54, 476-90	179
1047	Central effects of cholinesterase inhibitors in Alzheimer's disease: insights from advanced neuroimaging. <b>2013</b> , 5, 441-452	
1046	Impaired visual recognition memory predicts Alzheimer's disease in amnesic mild cognitive impairment. <b>2013</b> , 35, 291-9	50
1045	Verbal and visuospatial span in logopenic progressive aphasia and Alzheimer's disease. <b>2013</b> , 19, 247-53	34
1044	Association between EEG abnormalities and CSF biomarkers in a memory clinic cohort. <b>2013</b> , 36, 319-28	20
1043	Current guidelines for dementia screening: shortcomings and recommended changes. <b>2013</b> , 3, 565-573	10
1042	Effects of a combined aquatic-nonaquatic training program on static and dynamic balance in elderly men. <b>2013</b> , 61, 1417-9	3
1041	Genetics of Alzheimer's disease. <b>2013</b> , 2013, 254954	59

1040	Drug repositioning: an opportunity to develop novel treatments for Alzheimer's disease. <b>2013</b> , 6, 1304-21	33
1039	Quantitative proteomic analysis of the hippocampus in the 5XFAD mouse model at early stages of Alzheimer's disease pathology. <b>2013</b> , 36, 321-34	27
1038	Development of a brain MRI-based hidden Markov model for dementia recognition. <b>2013</b> , 12 Suppl 1, S2	12
1037	Recovery from possible late-onset Alzheimer's dementia? Evidence from a longitudinal community-based age-cohort study. <b>2013</b> , 61, 1415-7	2
1036	Detection of memory impairment in a community-based system: a collaborative study. <b>2013</b> , 38, 89-96	1
1035	Communicative competence in Alzheimer's disease: metaphor and sarcasm comprehension. <b>2013</b> , 28, 69-74	29
1034	Auditory cortical function during verbal episodic memory encoding in Alzheimer's disease. <b>2013</b> , 73, 294-302	13
1033	Cognitive decline in adults with amnesic mild cognitive impairment and high amyloid- $\beta$ prodromal Alzheimer's disease?. <b>2013</b> , 33, 1167-76	30
1032	Positron emission tomography radioligands for in vivo imaging of A $\beta$ plaques. <b>2013</b> , 56, 89-95	47
1031	Pre-progression rates in Alzheimer's disease revisited. <b>2013</b> , 35, 451-4	4
1030	CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies. <b>2013</b> , 127, 681-90	43
1029	Disease-modifying therapy for Alzheimer's disease: Challenges and hopes. <b>2013</b> , 1, 49-54	9
1028	Biomarker-driven therapeutic management of Alzheimer's disease: establishing the foundations. <b>2014</b> , 95, 67-77	17
1027	CSF prion protein concentration and cognition in patients with Alzheimer disease. <b>2013</b> , 7, 229-34	10
1026	Dementia: Disclosure of results to participants in dementia research. <b>2013</b> , 9, 608-9	2
1025	The Diagnosis of Mild Cognitive Impairment due to Alzheimer's Disease: Recommendations from the National Institute on Aging-Alzheimer's Association Workgroups on Diagnostic Guidelines for Alzheimer's Disease. <b>2013</b> , 11, 96-106	36
1024	Computerized adaptation of The Placing Test for early detection of both mild cognitive impairment and Alzheimer's disease. <b>2013</b> , 35, 846-56	10
1023	Polymorphism -116C/G of human X-box-binding protein 1 promoter is associated with risk of Alzheimer's disease. <b>2013</b> , 19, 229-34	37

1022	Sensitivity and specificity of diagnostic accuracy in Alzheimer's disease: a synthesis of existing evidence. <b>2013</b> , 28, 337-47	20
1021	The impact of age and Alzheimer's disease risk factors on memory performance over time. <b>2013</b> , 9, 115-124	1
1020	Disease state fingerprint in frontotemporal degeneration with reference to Alzheimer's disease and mild cognitive impairment. <b>2013</b> , 35, 727-39	16
1019	Visuospatial memory and neuroimaging correlates in mild cognitive impairment. <b>2013</b> , 35, 75-90	24
1018	Cognitive assessment in Parkinson's disease. 53-64	
1017	Imaging and behavior in Parkinson's disease: functional imaging. 89-96	
1016	Diagnosis and biomarkers: CSF. 97-108	
1015	Improved volumetric measurement of brain structure with a distortion correction procedure using an ADNI phantom. <b>2013</b> , 40, 062303	19
1014	Impact of the 2008-2012 French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: the PLM Study. <b>2013</b> , 34, 297-305	42
1013	Memory for past public events depends on retrieval frequency but not memory age in Alzheimer's disease. <b>2014</b> , 38, 379-90	10
1012	Sensitivity to change of composite and frequency scores of the Neuropsychiatric Inventory in mild to moderate dementia. <b>2013</b> , 25, 431-8	10
1011	Urgence gériatrique: le syndrome confusionnel. <b>2013</b> , 8, 1-5	
1010	Arguments against the biomarker-driven diagnosis of AD. <b>2013</b> , 25, 177-81	8
1009	The utility of the new research diagnostic criteria for Alzheimer's disease. <b>2013</b> , 25, 175-7	8
1008	Commentary. <b>2013</b> , 25, 181-4	1
1007	Poor cognitive outcome in shunt-responsive idiopathic normal pressure hydrocephalus. <b>2013</b> , 72, 1-8;discussion 8	83
1006	[An alternative word-list for the Free and cued selective reminding test (FCSRT): list presentation and reliability study]. <b>2013</b> , 11, 317-22	1
1005	Brain [18F]FDDNP binding and glucose metabolism in advanced elderly healthy subjects and Alzheimer's disease patients. <b>2013</b> , 36, 311-20	17



1004	Cortical florbetapir-PET amyloid load in prodromal Alzheimer's disease patients. <b>2013</b> , 3, 43	29
1003	The AD-CSF-index discriminates Alzheimer's disease patients from healthy controls: a validation study. <b>2013</b> , 36, 67-77	43
1002	A longitudinal follow-up of 550 mild cognitive impairment patients: evidence for large conversion to dementia rates and detection of major risk factors involved. <b>2013</b> , 34, 769-80	118
1001	Neuroimaging-based biomarkers in psychiatry: clinical opportunities of a paradigm shift. <b>2013</b> , 58, 499-508	68
1000	Evaluation of Anosognosia in Alzheimer's Disease Using the Symptoms of Early Dementia-11 Questionnaire (SED-11Q). <b>2013</b> , 3, 351-9	10
999	[An autopsy case of Alzheimer's disease presenting with corticobasal syndrome]. <b>2013</b> , 53, 814-20	1
998	Alzheimer's Disease - An Update. <b>2013</b> , 28, 52-58	3
997	Mild cognitive impairment. Part 2: Biological markers for diagnosis and prediction of dementia in Alzheimer's disease. <b>2013</b> , 35, 284-94	14
996	Proteomic data show an increase in autoantibodies and alpha-fetoprotein and a decrease in apolipoprotein A-II with time in sera from senescence-accelerated mice. <b>2013</b> , 46, 417-25	0
995	Neurodegenerative disorders. 23-71	
994	Symptoms of Early Dementia-11 Questionnaire (SED-11Q): A Brief Informant-Operated Screening for Dementia. <b>2013</b> , 3, 131-42	10
993	The role of cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis. where are we now?. <b>2013</b> , 8, 70-8	3
992	Diffusion tensor imaging surpasses cerebrospinal fluid as predictor of cognitive decline and medial temporal lobe atrophy in subjective cognitive impairment and mild cognitive impairment. <b>2013</b> , 33, 723-36	80
991	Prediction of mild cognitive impairment that evolves into Alzheimer's disease dementia within two years using a gene expression signature in blood: a pilot study. <b>2013</b> , 35, 611-21	12
990	Fronto-striatal atrophy correlates of neuropsychiatric dysfunction in frontotemporal dementia (FTD) and Alzheimer's disease (AD). <b>2013</b> , 7, 75-82	16
989	Diagnosis and treatment of dementia in primary care. <b>2013</b> , 56, 1104	13
988	Targeted recruitment using cerebrospinal fluid biomarkers: implications for Alzheimer's disease therapeutic trials. <b>2013</b> , 34, 431-7	7
987	Neuropsychiatric symptoms and severity of dementia. <b>2013</b> , 7, 171-175	

986	Hereditary and sporadic beta-amyloidoses. <b>2013</b> , 18, 1202-26	6
985	Mild cognitive impairment. Part 1: clinical characteristics and predictors of dementia. <b>2013</b> , 35, 178-85	34
984	Predicting AD conversion: comparison between prodromal AD guidelines and computer assisted PredictAD tool. <b>2013</b> , 8, e55246	28
983	Dissociating memory networks in early Alzheimer's disease and frontotemporal lobar degeneration - a combined study of hypometabolism and atrophy. <b>2013</b> , 8, e55251	49
982	The genetic variation of SORCS1 is associated with late-onset Alzheimer's disease in Chinese Han population. <b>2013</b> , 8, e63621	13
981	Faster cognitive and functional decline in Dysexecutive versus amnesic Alzheimer's subgroups: a longitudinal analysis of the National Alzheimer's Coordinating Center (NACC) database. <b>2013</b> , 8, e65246	14
980	Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction. <b>2013</b> , 8, e66877	41
979	Early indications of future cognitive decline: stable versus declining controls. <b>2013</b> , 8, e74062	23
978	Cut-off scores of a brief neuropsychological battery (NBACE) for Spanish individual adults older than 44 years old. <b>2013</b> , 8, e76436	43
977	Blood amyloid beta levels in healthy, mild cognitive impairment and Alzheimer's disease individuals: replication of diastolic blood pressure correlations and analysis of critical covariates. <b>2013</b> , 8, e81334	30
976	Investigating the association of ApoE genotypes with blood-brain barrier dysfunction measured by cerebrospinal fluid-serum albumin ratio in a cohort of patients with different types of dementia. <b>2013</b> , 8, e84405	15
975	Abnormal platelet amyloid- $\beta$ protein precursor (A $\beta$ PP) metabolism in Alzheimer's disease: identification and characterization of a new A $\beta$ PP isoform as potential biomarker. <b>2013</b> , 35, 285-95	15
974	Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer's disease cerebral metabolic signature. <b>2013</b> , 36, 401-8	15
973	Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review. <b>2013</b> , 5, 25	11
972	Effects of hemochromatosis and transferrin gene mutations on peripheral iron dyshomeostasis in mild cognitive impairment and Alzheimer's and Parkinson's diseases. <b>2013</b> , 5, 37	22
971	Integrative EEG biomarkers predict progression to Alzheimer's disease at the MCI stage. <b>2013</b> , 5, 58	95
970	EEG upper/low alpha frequency power ratio relates to temporo-parietal brain atrophy and memory performances in mild cognitive impairment. <b>2013</b> , 5, 63	31
969	Mismatch negativity (MMN) amplitude as a biomarker of sensory memory deficit in amnesic mild cognitive impairment. <b>2013</b> , 5, 79	38

968	Brain-wide slowing of spontaneous alpha rhythms in mild cognitive impairment. <b>2013</b> , 5, 100	45
967	Aging-related episodic memory decline: are emotions the key?. <b>2013</b> , 7, 2	30
966	Perspectives on episodic-like and episodic memory. <b>2013</b> , 7, 33	70
965	Increase of theta frequency is associated with reduction in regional cerebral blood flow only in subjects with mild cognitive impairment with higher upper alpha/low alpha EEG frequency power ratio. <b>2013</b> , 7, 188	19
964	Cognitive Dysfunction and Dementia in Primary Sjögren's Syndrome. <b>2013</b> , 2013, 501327	14
963	The in vivo topography of cortical changes in healthy aging and prodromal Alzheimer's disease. <b>2013</b> , 62, 67-80	5
962	Alzheimer's Disease: A Clinical Perspective. <b>2013</b> ,	
961	References. 578-670	
960	. <b>2013</b> ,	1
959	Free and cued recall memory in Parkinson's disease associated with amnesic mild cognitive impairment. <b>2014</b> , 9, e86233	28
958	A systematic review of biomarkers for disease progression in Alzheimer's disease. <b>2014</b> , 9, e88854	36
957	Early life socioeconomic circumstance and late life brain hyperintensities--a population based cohort study. <b>2014</b> , 9, e88969	18
956	Hippocampal spatial position evaluation on MRI for research and clinical practice. <b>2014</b> , 9, e115174	7
955	[Episodic memory in Alzheimer's disease: decline in recollection and familiarity?]. <b>2014</b> , 30, 784-9	2
954	Currently Available Biomarkers and Strategies for the Validation of Novel Candidates for Neurochemical Dementia Diagnostics in Alzheimer's Disease and Mild Cognitive Impairment. <b>2014</b> , 2014, 1-15	2
953	Shared mechanisms of neurodegeneration in Alzheimer's disease and Parkinson's disease. <b>2014</b> , 2014, 648740	95
952	Accuracy of cerebrospinal fluid A $\beta$ (1-42) for Alzheimer's disease diagnosis: a systematic review and meta-analysis. <b>2014</b> , 40, 443-54	10
951	Cerebrospinal fluid apolipoprotein E concentration and progression of Alzheimer's disease. <b>2015</b> , 43, 1229-36	8

950	Tip-of-the-Tongue in Mild Cognitive Impairment (MCI). 116-143	2
949	Network-based biomarkers in Alzheimer's disease: review and future directions. <b>2014</b> , 6, 12	45
948	Biomarker-based diagnosis of mild cognitive impairment due to Alzheimer's disease: how and what to tell. A kickstart to an ethical discussion. <b>2014</b> , 6, 41	13
947	Behavioral variant frontotemporal dementia patients do not succumb to the Allais paradox. <b>2014</b> , 8, 287	6
946	Oxidized DJ-1 as a possible biomarker of Parkinson's disease. <b>2014</b> , 54, 138-44	47
945	Role of cerebrospinal fluid biomarkers in clinical trials for Alzheimer's disease modifying therapies. <b>2014</b> , 18, 447-56	11
944	Pronounced impairment of everyday skills and self-care in posterior cortical atrophy. <b>2015</b> , 43, 381-4	21
943	Alzheimer biomarkers and clinical Alzheimer disease were not associated with increased cerebrovascular disease in a memory clinic population. <b>2014</b> , 11, 40-6	4
942	Role of Cardiovascular Comorbidity and Depressive Symptoms on One-Year Clinical Progression of Alzheimer's Disease (AD) in a Population of Italian Elderly. <b>2014</b> , 17,	
941	Different adenosine A2A receptor expression in peripheral cells from elderly patients with vascular dementia and Alzheimer's disease. <b>2014</b> , 40, 45-9	14
940	High-Dimensional Medial Lobe Morphometry: An Automated MRI Biomarker for the New AD Diagnostic Criteria. <b>2014</b> , 2014, 278096	1
939	Understanding the complexities of functional ability in Alzheimer's disease: more than just basic and instrumental factors. <b>2014</b> , 11, 357-66	12
938	APOE- $\epsilon$ allele for the diagnosis of Alzheimer's and other dementia disorders in people with mild cognitive impairment in a community setting. <b>2014</b> ,	4
937	APOE- $\epsilon$ allele for the diagnosis of Alzheimer's and other dementia disorders in people with mild cognitive impairment in a primary care setting. <b>2014</b> ,	4
936	APOE- $\epsilon$ allele for the diagnosis of Alzheimer's and other dementia disorders in people with mild cognitive impairment in a secondary care setting. <b>2014</b> ,	4
935	Functional MRI in Alzheimer's Disease. <b>2014</b> ,	1
934	Operationalization of Global Alzheimer's Disease Trials. <b>2014</b> , 159-177	0
933	Alzheimer's Dementia From a Bilingual/Bicultural Perspective: A Case Study. <b>2014</b> , 36, 55-64	2

932	Cerebrospinal fluid $\beta$ -synuclein in the differential diagnosis of parkinsonian syndromes. <b>2014</b> , 9, 525-532	7
931	Biomarkers in drug safety evaluation. <b>2014</b> , 923-945	3
930	Can cardiac resynchronization therapy improve cognitive function? A systematic review. <b>2014</b> , 37, 520-30	9
929	Amyloid imaging in Alzheimer's disease: a literature review. <b>2014</b> , 18, 723-40	8
928	Immune responses in rapidly progressive dementia: a comparative study of neuroinflammatory markers in Creutzfeldt-Jakob disease, Alzheimer's disease and multiple sclerosis. <b>2014</b> , 11, 170	29
927	Personality, Alzheimer's disease and behavioural and cognitive symptoms of dementia: the PACO prospective cohort study protocol. <b>2014</b> , 14, 110	13
926	Biomarkers in biological fluids for dementia with Lewy bodies. <b>2014</b> , 6, 72	24
925	Long-term inflammation increases risk of common mental disorder: a cohort study. <b>2014</b> , 19, 149-50	76
924	Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. <b>2014</b> , 10, 405-19	70
923	Advances in MRI biomarkers for the diagnosis of Alzheimer's disease. <b>2014</b> , 8, 1151-69	33
922	Three-dimensional quantitative imaging of telomeres in buccal cells identifies mild, moderate, and severe Alzheimer's disease patients. <b>2014</b> , 39, 35-48	29
921	Plasma prion protein concentration and progression of Alzheimer disease. <b>2014</b> , 8,	2
920	Gadolinium-based contrast agents targeted to amyloid aggregates for the early diagnosis of Alzheimer's disease by MRI. <b>2014</b> , 87, 843-61	40
919	The Epidemiology and Prevention of Alzheimer's Disease and Projected Burden of Disease. <b>2014</b> , 3-20	
918	Posterior AD-type pathology: cognitive subtypes emerging from a cluster analysis. <b>2014</b> , 2014, 259358	7
917	Screening for cognition and behaviour changes in ALS. <b>2014</b> , 15, 9-14	305
916	Measuring decline in prodromal AD: a pike to hike. <b>2014</b> , 85, 358	1
915	Patients with mild cognitive impairment display reduced auditory event-related delta oscillatory responses. <b>2014</b> , 2014, 268967	20

914	Intérêt des marqueurs biologiques dans l'approche psychiatrique de la maladie d'Alzheimer. <b>2014</b> , 201-216	
913	A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysis. <b>2014</b> , 2014, 785039	37
912	The Regulatory Environment Surrounding Alzheimer's Disease Research. <b>2014</b> , 119-127	0
911	Peripheral blood mononuclear cells as a laboratory to study dementia in the elderly. <b>2014</b> , 2014, 169203	45
910	Serum calreticulin is a negative biomarker in patients with Alzheimer's disease. <b>2014</b> , 15, 21740-53	15
909	The characterization of biological rhythms in mild cognitive impairment. <b>2014</b> , 2014, 524971	21
908	Structural model for estimating the influence of cognitive reserve on cognitive performance in adults with subjective memory complaints. <b>2014</b> , 29, 245-55	30
907	Cognitive function in midlife and beyond: physical and cognitive activity related to episodic memory and executive functions. <b>2014</b> , 79, 263-78	14
906	Prominent effects and neural correlates of visual crowding in a neurodegenerative disease population. <b>2014</b> , 137, 3284-99	25
905	White matter integrity and cognition in Parkinson's disease: a cross-sectional study. <b>2014</b> , 4, e003976	31
904	Acupuncture for patients with Alzheimer's disease: a systematic review protocol. <b>2014</b> , 4, e005896	8
903	Subjective cognitive impairment subjects in our clinical practice. <b>2014</b> , 4, 419-30	25
902	Amyloid deposition is decreasing in aging brains: an autopsy study of 1,599 older people. <b>2014</b> , 82, 326-31	28
901	[Decreasing dementia incidence rates? Implications for public health and prevention]. <b>2014</b> , 41, 407-9	3
900	Nonamyloid PET biomarkers and Alzheimer's disease: current and future perspectives. <b>2014</b> , 9, 597-613	2
899	Influence of age, disease onset and ApoE4 on visual medial temporal lobe atrophy cut-offs. <b>2014</b> , 275, 317-30	54
898	A postmortem study to compare agonist and antagonist 5-HT1A receptor-binding sites in Alzheimer's disease. <b>2014</b> , 20, 930-4	18
897	Medial temporal lobe atrophy scores translated to clinical practice: editorial comment on 'influence of age, disease onset and ApoE4 on visual medial temporal lobe atrophy cut-offs'. <b>2014</b> , 275, 331-3	12

896	18F-FDG PET and perfusion SPECT in the diagnosis of Alzheimer and Lewy body dementias. <b>2014</b> , 55, 1959-65	130
895	Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. <b>2014</b> , 275, 251-83	437
894	Do the Cambridge Neuropsychological Test Automated Battery episodic memory measures discriminate amnesic mild cognitive impairment?. <b>2014</b> , 29, 602-9	16
893	Characteristics of the default mode functional connectivity in normal ageing and Alzheimer's disease using resting state fMRI with a combined approach of entropy-based and graph theoretical measurements. <b>2014</b> , 101, 778-86	72
892	Saccade deficits in amnesic mild cognitive impairment resemble mild Alzheimer's disease. <b>2014</b> , 39, 2000-13	49
891	Annual research review: Current limitations and future directions in MRI studies of child- and adult-onset developmental psychopathologies. <b>2014</b> , 55, 659-80	32
890	Piloting and validation of a novel self-administered online cognitive screening tool in normal older persons: the Cognitive Function Test. <b>2014</b> , 29, 198-206	23
889	9th Key symposium introduction: updating Alzheimer's disease diagnosis implications for prevention and treatment. <b>2014</b> , 275, 202-3	2
888	Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. <b>2014</b> , 1, 534-43	78
887	Visual memory profiling with CANTAB in mild cognitive impairment (MCI) subtypes. <b>2014</b> , 29, 1040-8	7
886	Association between cell-bound blood amyloid- $\beta$ (1-40) levels and hippocampus volume. <b>2014</b> , 6, 56	8
885	Establishing robust cognitive dimensions for characterization and differentiation of patients with Alzheimer's disease, mild cognitive impairment, frontotemporal dementia and depression. <b>2014</b> , 29, 624-34	14
884	Value of serum nonceruloplasmin copper for prediction of mild cognitive impairment conversion to Alzheimer disease. <b>2014</b> , 75, 574-80	75
883	Using a virtual environment to assess cognition in the elderly. <b>2014</b> , 18, 271-279	10
882	Amyloid-beta 42 adsorption following serial tube transfer. <b>2014</b> , 6, 5	31
881	Modulation of $\beta$ -amyloid by a single dose of GSK933776 in patients with mild Alzheimer's disease: a phase I study. <b>2014</b> , 6, 19	25
880	A diagnostic scale for Alzheimer's disease based on cerebrospinal fluid biomarker profiles. <b>2014</b> , 6, 38	31
879	Preclinical Alzheimer's disease. <b>2014</b> , 24, 117-121	

878	Advances in imaging-genetic relationships for Alzheimer's disease: clinical implications. <b>2014</b> , 4, 73-81	4
877	Neuropsychiatric symptoms in the prodromal stages of dementia. <b>2014</b> , 27, 230-5	36
876	Imaging biomarkers for amyloid: a new generation of probes and what lies ahead. <b>2014</b> , 26, 703-7	1
875	Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?. <b>2014</b> , 27, 128-37	76
874	Evidence of the sensitivity of the MoCA alternate forms in monitoring cognitive change in early Alzheimer's disease. <b>2014</b> , 37, 95-103	33
873	Neuroinflammation and $\beta$ amyloid deposition in Alzheimer's disease: in vivo quantification with molecular imaging. <b>2014</b> , 37, 1-18	19
872	The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. <b>2014</b> , 71, 961-70	372
871	Alzheimer's Disease. <b>2014</b> , 122-127	5
870	Clinical and Cognitive Correlates of Structural Hippocampal Change in "At-Risk" Older Adults. <b>2014</b> , 27, 67-76	11
869	Screening older Latinos for dementia in the primary care setting. <b>2014</b> , 20, 848-55	9
868	Using magnetic resonance imaging in diagnosing dementia: a Dutch outpatient memory clinics survey. <b>2014</b> , 38, 281-5	2
867	A pilot study on utility of Malayalam version of Addenbrooke's Cognitive Examination in detection of amnesic mild cognitive impairment: A critical insight into utility of learning and recall measures. <b>2014</b> , 17, 420-5	16
866	Correlation between both morphologic and functional changes and anxiety in Alzheimer's disease. <b>2014</b> , 38, 153-60	11
865	Is HCRTR2 a genetic risk factor for Alzheimer's disease?. <b>2014</b> , 38, 245-53	16
864	Dementia. <b>2014</b> , 70-92	
863	The unbearable lightness of MCI. <b>2014</b> , 26, 353-9	6
862	Is the MWT-A Suitable for the Estimation of Premorbid Intelligence Level?. <b>2014</b> , 27, 33-39	5
861	Cortical sources of resting state electroencephalographic alpha rhythms deteriorate across time in subjects with amnesic mild cognitive impairment. <b>2014</b> , 35, 130-42	47



860	Comparison between clinical diagnosis and CSF biomarkers of Alzheimer disease in elderly patients with late onset psychosis: Helsinki Old Age Psychosis Study (HOPS). <b>2014</b> , 22, 908-16	9
859	Distinct pattern of hypometabolism and atrophy in preclinical and predementia Alzheimer's disease. <b>2014</b> , 35, 1973-81	38
858	Reduced FDG-PET brain metabolism and executive function predict clinical progression in elderly healthy subjects. <b>2014</b> , 4, 45-52	78
857	In vivo type 1 cannabinoid receptor availability in Alzheimer's disease. <b>2014</b> , 24, 242-50	42
856	An evaluation of deficits in semantic cueing and proactive and retroactive interference as early features of Alzheimer's disease. <b>2014</b> , 22, 889-97	52
855	Biomarkers in amyloid- $\beta$ immunotherapy trials in Alzheimer's disease. <b>2014</b> , 39, 189-201	54
854	Neurology at the Bedside. <b>2014</b> ,	1
853	Comparison between PET template-based method and MRI-based method for cortical quantification of florbetapir (AV-45) uptake in vivo. <b>2014</b> , 41, 836-43	28
852	Biomarker modelling of early molecular changes in Alzheimer's disease. <b>2014</b> , 18, 213-27	4
851	Insight on AV-45 binding in white and grey matter from histogram analysis: a study on early Alzheimer's disease patients and healthy subjects. <b>2014</b> , 41, 1408-18	15
850	Awareness of cognitive deficits and clinical competence in mild to moderate Alzheimer's disease: their relevance in clinical practice. <b>2014</b> , 35, 385-90	14
849	Souvenaid <sup>®</sup> : a new approach to management of early Alzheimer's disease. <b>2014</b> , 18, 291-9	16
848	Dementia in middle-aged patients with schizophrenia. <b>2014</b> , 39, 809-22	7
847	Gold nanoparticle-based immuno-PCR for detection of tau protein in cerebrospinal fluid. <b>2014</b> , 406, 137-42	26
846	Alzheimer's and Parkinson's diseases: an environmental proteomic point of view. <b>2014</b> , 104, 24-36	7
845	An algorithmic approach to structural imaging in dementia. <b>2014</b> , 85, 692-8	71
844	Neurodegenerative Diseases. <b>2014</b> ,	2
843	Conceptualizing neuropsychiatric diseases with multimodal data-driven meta-analyses - the case of behavioral variant frontotemporal dementia. <b>2014</b> , 57, 22-37	63

842	Profiles of white matter tract pathology in frontotemporal dementia. <b>2014</b> , 35, 4163-79	84
841	Dementia in Clinical Practice: A Neurological Perspective. <b>2014</b> ,	20
840	A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. <b>2014</b> , 10, 844-52	1219
839	Apport des neurosciences ^ la psychiatrie clinique. <b>2014</b> ,	
838	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. <i>Lancet Neurology, The</i> , <b>2014</b> , 13, 614-29	24.1 1985
837	Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments. <b>2014</b> , 261, 1234-43	29
836	Imaging of the Geriatric Brain. <b>2014</b> , 136-169	
835	Lyme neuroborreliosis and dementia. <b>2014</b> , 41, 1087-93	24
834	Differential Diagnosis: "What Is the Lesion?" <b>2014</b> , 137-269	
833	A meta-analytic review of theory of mind difficulties in behavioural-variant frontotemporal dementia. <b>2014</b> , 56, 53-62	68
832	Attention Disorders After Right Brain Damage. <b>2014</b> ,	29
831	Comparing predictors of conversion to Alzheimer's disease using the disease state index. <b>2014</b> , 13, 200-2	7
830	Glutathione relates to neuropsychological functioning in mild cognitive impairment. <b>2014</b> , 10, 67-75	78
829	Validity of dementia and Alzheimer's disease diagnoses in Finnish national registers. <b>2014</b> , 10, 303-9	75
828	CSF A $\beta$ 1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease. <b>2014</b> , 10, 381-92	53
827	Development and validation of dried matrix spot sampling for the quantitative determination of amyloid $\beta$ peptides in cerebrospinal fluid. <b>2014</b> , 52, 649-55	5
826	Advances in the prevention of Alzheimer's disease and dementia. <b>2014</b> , 275, 229-50	182
825	Diagnostic classification of arterial spin labeling and structural MRI in presenile early stage dementia. <b>2014</b> , 35, 4916-31	65

824	Early neuropsychological detection of Alzheimer's disease. <b>2014</b> , 68, 1192-9	46
823	Concordance between (99m)Tc-ECD SPECT and 18F-FDG PET interpretations in patients with cognitive disorders diagnosed according to NIA-AA criteria. <b>2014</b> , 29, 1079-86	13
822	The evolution of preclinical Alzheimer's disease: implications for prevention trials. <b>2014</b> , 84, 608-22	429
821	Fine particulate matter air pollution and cognitive function among older US adults. <b>2014</b> , 180, 359-66	160
820	The free and cued selective reminding test distinguishes frontotemporal dementia from Alzheimer's disease. <b>2014</b> , 29, 670-9	39
819	MicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research. <b>2014</b> , 37, 629-41	32
818	Nutrition and brain aging: how can we move ahead?. <b>2014</b> , 68, 1245-9	25
817	A comparison of early diagnostic utility of Alzheimer disease biomarkers in magnetic resonance and cerebrospinal fluid. <b>2014</b> , 29, 397-401	
816	Harmonized diagnostic criteria for Alzheimer's disease: recommendations. <b>2014</b> , 275, 204-13	82
815	What is the role of neuroimaging in dementia? A review. <b>2014</b> , 23, 20120015	
814	Cluster subtypes of the Spanish version of the California Verbal Learning Test in a sample of adults with subjective memory complaints. <b>2014</b> , 36, 317-33	6
813	Responsible Innovation 1. <b>2014</b> ,	15
812	Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease. <b>2014</b> , 42, 901-8	79
811	Within-patient correspondence of amyloid- $\beta$ and intrinsic network connectivity in Alzheimer's disease. <b>2014</b> , 137, 2052-64	97
810	Quantitative EEG in Alzheimer's disease: cognitive state, resting state and association with disease severity. <b>2014</b> , 93, 390-7	26
809	Metabolomic profiling of serum in the progression of Alzheimer's disease by capillary electrophoresis-mass spectrometry. <b>2014</b> , 35, 3321-30	82
808	Using direct infusion mass spectrometry for serum metabolomics in Alzheimer's disease. <b>2014</b> , 406, 7137-48	64
807	Clinical workout for the early detection of cognitive decline and dementia. <b>2014</b> , 68, 1186-91	11

806	Escala por interrogatorio de las actividades de la vida diaria: validaci3n y correlaci3n con escalas de severidad de deterioro cognitivo en pacientes con demencia tipo Alzheimer. <b>2014</b> , 6, 137-141	
805	Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease. <b>2014</b> , 10, 421-429.e3	66
804	In vivo measurement of glutamate loss is associated with synapse loss in a mouse model of tauopathy. <b>2014</b> , 101, 185-92	45
803	Detection of volume loss in hippocampal layers in Alzheimer's disease using 7 T MRI: a feasibility study. <b>2014</b> , 5, 341-8	54
802	Hypermetabolic state in the 7-month-old triple transgenic mouse model of Alzheimer's disease and the effect of lipoic acid: a 13C-NMR study. <b>2014</b> , 34, 1749-60	29
801	Significance of subjective memory complaints in the clinical setting. <b>2014</b> , 27, 259-65	27
800	Classifying neurocognitive disorders: the DSM-5 approach. <b>2014</b> , 10, 634-42	337
799	The need for "objective measurements" in FDG and amyloid PET neuroimaging. <b>2014</b> , 2, 331-342	4
798	Health care resource utilisation in primary care prior to and after a diagnosis of Alzheimer's disease: a retrospective, matched case-control study in the United Kingdom. <b>2014</b> , 14, 76	24
797	Circulating biomarkers that predict incident dementia. <b>2014</b> , 6, 6	10
796	Connectome-scale assessments of structural and functional connectivity in MCI. <b>2014</b> , 35, 2911-23	52
795	CR1 is potentially associated with rate of decline in sporadic Alzheimer's disease. <b>2014</b> , 21, 1705-8	7
794	A brief overview of amyloids and Alzheimer's disease. <b>2014</b> , 23, 1315-31	74
793	[Neurocognitive disorders in DSM-5: pervasive changes in the diagnostics of dementia]. <b>2014</b> , 85, 564-70	19
792	[Mild neurocognitive disorder - a disease? Against]. <b>2014</b> , 85, 632-4	0
791	The screening of Alzheimer's patients with CSF biomarkers, modulates the distribution of APOE genotype: impact on clinical trials. <b>2014</b> , 261, 1187-95	9
790	The earlier the better: Alzheimer's prevention, early detection, and the quest for pharmacological interventions. <b>2014</b> , 38, 217-36	18
789	Amyloid imaging in Alzheimer's disease: a potential new era of personalized medicine?. <b>2014</b> , 5,	1

788	Biochemical stages of amyloid- $\beta$ peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer's disease. <b>2014</b> , 137, 887-903	109
787	A comparison of FDG-PET and blood flow SPECT in the diagnosis of neurodegenerative dementias: a systematic review. <b>2014</b> , 29, 551-61	51
786	Patient and carer views on participating in clinical trials for prodromal Alzheimer's disease and mild cognitive impairment. <b>2014</b> , 29, 22-31	23
785	Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease. <b>2014</b> , 42, 777-88	22
784	Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?. <b>2014</b> , 14, 1465-76	50
783	Potential Clinical Applications of PET/MR Imaging in Neurodegenerative Diseases. <b>2014</b> , 55, 475-555	46
782	Pharma-Nutrition. <b>2014</b> ,	
781	Case report of first-episode psychotic symptoms in a patient with early-onset Alzheimer's disease. <b>2020</b> , 20, 128	3
780	Discovery of Chemicals to Either Clear or Indicate Amyloid Aggregates by Targeting Memory-Impairing Anti-Parallel A $\beta$ Dimers. <b>2020</b> , 59, 11491-11500	7
779	Genetic Association of FERMT2, HLA-DRB1, CD2AP, and PTK2B Polymorphisms With Alzheimer's Disease Risk in the Southern Chinese Population. <b>2020</b> , 12, 16	7
778	Correlation Between SIRT2 3'UTR Gene Polymorphism and the Susceptibility to Alzheimer's Disease. <b>2020</b> , 70, 878-886	6
777	Understated Cognitive Impairment Assessed with the Clock-Drawing Test in Community-Dwelling Individuals Aged $\geq$ 50 Years. <b>2020</b> , 21, 1658-1664	4
776	Picornavirus Identified in Alzheimer's Disease Brains: A Pathogenic Path?. <b>2020</b> , 4, 141-146	4
775	Assessment of Alzheimer's Disease Based on Texture Analysis of the Entorhinal Cortex. <b>2020</b> , 12, 176	9
774	Pregabalin as a Treatment for Anxiety in Patients With Dementia With Lewy Bodies: A Case Series. <b>2020</b> , 40, 297-299	1
773	Sex- and age-specific mild cognitive impairment is associated with low hand grip strength in an older Chinese cohort. <b>2020</b> , 48, 300060520933051	5
772	Mild Cognitive Impairment Subtypes and Type 2 Diabetes in Elderly Subjects. <b>2020</b> , 9,	5
771	Lactic acid bacteria feeding reversed the malformed eye structures and ameliorated gut microbiota profiles of <i>Drosophila melanogaster</i> Alzheimer's Disease model. <b>2020</b> ,	6

770	Blood and cerebrospinal fluid biomarkers for Alzheimer's disease. <b>2020</b> , 5, 15-15	2
769	Combining diagnostic memory clinic with rehabilitation follow-up after hip fracture. <b>2020</b> , 11, 603-611	1
768	Study of the Risk and Preventive Factors for Progress of Mild Cognitive Impairment to Dementia. <b>2020</b> , 35, 1533317520925324	2
767	World-Wide FINGERS Network: A global approach to risk reduction and prevention of dementia. <b>2020</b> , 16, 1078-1094	109
766	Bilingualism Is Associated with a Delayed Onset of Dementia but Not with a Lower Risk of Developing it: a Systematic Review with Meta-Analyses. <b>2020</b> , 30, 1-24	14
765	Neuropsychological Contribution to Predict Conversion to Dementia in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease. <b>2020</b> , 74, 785-796	3
764	Earliest amyloid and tau deposition modulate the influence of limbic networks during closed-loop hippocampal downregulation. <b>2020</b> , 143, 976-992	8
763	Disrupted functional connectivity of the locus coeruleus in healthy adults with parental history of Alzheimer's disease. <b>2020</b> , 123, 81-88	7
762	Hippocampal impairment in patients with Essential Tremor. <b>2020</b> , 72, 56-61	7
761	The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases. <b>2020</b> , 20, 421-441	19
760	Prediction of Alzheimer's disease using blood gene expression data. <b>2020</b> , 10, 3485	23
759	US, EU, and Japanese Regulatory Guidelines for Development of Drugs for Treatment of Alzheimer's Disease: Implications for Global Drug Development. <b>2020</b> , 13, 652-664	8
758	Emphasis Learning, Features Repetition in Width Instead of Length to Improve Classification Performance: Case Study-Alzheimer's Disease Diagnosis. <b>2020</b> , 20,	1
757	Analysis of risk factors for depression in Alzheimer's disease patients. <b>2020</b> , 130, 1136-1141	2
756	Magnetic Resonance Texture Analysis in Alzheimer's disease. <b>2020</b> , 27, 1774-1783	12
755	The Role of Free and Cued Selective Reminding Test in Predicting [18F]Florbetaben PET Results in Mild Cognitive Impairment and Mild Dementia. <b>2020</b> , 73, 1647-1659	3
754	Nutritional status assessment in Alzheimer disease and its influence on disease progression. <b>2020</b> ,	
753	Domain-specific contributions of biological sex and sex hormones to what, where and when components of episodic-like memory in adult rats. <b>2020</b> , 52, 2705-2723	2

752	Challenges in Alzheimer's Disease Drug Discovery and Development: The Role of Modeling, Simulation, and Open Data. <b>2020</b> , 107, 796-805	7
751	D-ribose and pathogenesis of Alzheimer's disease. <b>2020</b> , 47, 2289-2299	5
750	Management of mild cognitive impairment (MCI): The need for national and international guidelines. <b>2020</b> , 21, 579-594	33
749	Role of Fluid Biomarkers and PET Imaging in Early Diagnosis and its Clinical Implication in the Management of Alzheimer's Disease. <b>2020</b> , 4, 21-37	15
748	The neural bases of discourse semantic and pragmatic deficits in patients with frontotemporal dementia and Alzheimer's disease. <b>2020</b> , 128, 174-191	4
747	Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer's disease and mild cognitive impairment. <b>2020</b> , 10, 125	21
746	The Effect of Type 2 Diabetes Mellitus on Neuropsychological Symptoms in Chinese Early Alzheimer's Disease Population. <b>2020</b> , 16, 829-836	4
745	A comparison of resting state EEG and structural MRI for classifying Alzheimer's disease and mild cognitive impairment. <b>2020</b> , 215, 116795	15
744	Are cytochrome P4502D6 and apolipoprotein E genotypes associated with long-term cognitive and functional changes in patients treated with donepezil?. <b>2020</b> , 20, 578-584	
743	Blood Amyloid- $\beta$ Oligomerization as a Biomarker of Alzheimer's Disease: A Blinded Validation Study. <b>2020</b> , 75, 493-499	18
742	Cerebrospinal Fluid and MRI Biomarkers in Neurodegenerative Diseases: A Retrospective Memory Clinic-Based Study. <b>2020</b> , 75, 751-765	5
741	Influence of Hypertension on Longitudinal Changes in Brain Glucose Metabolism Was Modified by the APOE4 Allele Among Cognitively Normal Older Individuals. <b>2020</b> , 12, 85	2
740	Path Integration Changes as a Cognitive Marker for Vascular Cognitive Impairment?-A Pilot Study. <b>2020</b> , 14, 131	7
739	The Brain Metabolic Correlates of the Main Indices of Neuropsychological Assessment in Alzheimer's Disease. <b>2020</b> , 10,	2
738	Interaction effect of Alzheimer's disease pathology and education, occupation, and socioeconomic status as a proxy for cognitive reserve on cognitive performance: in vivo positron emission tomography study. <b>2020</b> , 20, 585-593	4
737	Discovery of Chemicals to Either Clear or Indicate Amyloid Aggregates by Targeting Memory-Impairing Anti-Parallel A $\beta$ Dimers. <b>2020</b> , 132, 11588-11597	3
736	Reduced uptake of [11C]-ABP688, a PET tracer for metabolic glutamate receptor 5 in hippocampus and amygdala in Alzheimer's dementia. <b>2020</b> , 10, e01632	7
735	Beta-Amyloid-Dependent miRNAs as Circulating Biomarkers in Alzheimer's Disease: a Preliminary Report. <b>2020</b> , 70, 871-877	7

734	Early diagnosis of Alzheimer's disease: the role of biomarkers including advanced EEG signal analysis. Report from the IFCN-sponsored panel of experts. <b>2020</b> , 131, 1287-1310	61
733	Evaluating Semantic Knowledge Through a Semantic Association Task in Individuals With Dementia. <b>2020</b> , 35, 1533317520917294	2
732	Metabolic Profiles Help Discriminate Mild Cognitive Impairment from Dementia Stage in Alzheimer's Disease. <b>2020</b> , 74, 277-286	4
731	Longitudinal Patterns of the Tip-of-the-Tongue Phenomenon in People With Subjective Cognitive Complaints and Mild Cognitive Impairment. <b>2020</b> , 11, 425	1
730	Managing depressive symptoms in people with mild cognitive impairment and mild dementia with a multicomponent psychotherapy intervention: a randomized controlled trial. <b>2021</b> , 33, 217-231	9
729	The role of transcranial sonography in differentiation of dementia subtypes: an introduction of a new diagnostic method. <b>2021</b> , 42, 275-283	2
728	Neurophysiological and molecular approaches to understanding the mechanisms of learning and memory. <b>2021</b> , 51, 4-23	0
727	Current strategies for the development of fluorescence-based molecular probes for visualizing the enzymes and proteins associated with Alzheimer's disease. <b>2021</b> , 427, 213553	21
726	Dementia with Lewy bodies in first-generation immigrants in a European memory clinic. <b>2021</b> , 121, 219-223	2
725	Retinal changes in Alzheimer's disease- integrated prospects of imaging, functional and molecular advances. <b>2021</b> , 82, 100899	25
724	Predicting the progression of mild cognitive impairment using machine learning: A systematic, quantitative and critical review. <b>2021</b> , 67, 101848	17
723	Episodic Memory Impairment in Parkinson's Disease: Disentangling the Role of Encoding and Retrieval. <b>2021</b> , 27, 261-269	2
722	Relationship between neuropsychiatric symptoms and Alzheimer's disease pathology: An in vivo positron emission tomography study. <b>2021</b> , 36, 598-605	1
721	A multidisciplinary approach to insanity assessment as a way to reduce cognitive biases. <b>2021</b> , 319, 110652	4
720	Routine assessment of cognitive function in older patients with hypertension seen by primary care physicians: why and how-a decision-making support from the working group on 'hypertension and the brain' of the European Society of Hypertension and from the European Geriatric Medicine Society. <b>2021</b> , 39, 90-100	7
719	Automatic multispectral MRI segmentation of human hippocampal subfields: an evaluation of multicentric test-retest reproducibility. <b>2021</b> , 226, 137-150	4
718	Comparing fluid biomarkers of Alzheimer's disease between African American or Black African and white groups: A systematic review and meta-analysis. <b>2021</b> , 421, 117270	5
717	Circulating inflammatory cytokine levels correlates with cognitive impairment. <b>2021</b> , 12, 66-71	1



716	Narrative Review of Sensory Changes as a Biomarker for Alzheimer's Disease. <b>2021</b> , 23, 223-230	3
715	36-month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease. <b>2021</b> , 17, 29-40	32
714	Cerebral Small Vessel Disease Influences Hippocampal Subfield Atrophy in Mild Cognitive Impairment. <b>2021</b> , 12, 284-292	10
713	Cognitive assessment tools for mild cognitive impairment screening. <b>2021</b> , 268, 1615-1622	22
712	In vivo synaptic density relates to glucose metabolism at rest in healthy subjects, but is strongly modulated by regional differences. <b>2021</b> , 41, 1978-1987	9
711	Analysis of Risk Factors in Dementia Through Machine Learning. <b>2021</b> , 79, 845-861	1
710	Significance of nanosomes for diagnosis of Alzheimer's disease. <b>2021</b> , 499-510	
709	Metabolic Abnormalities in Patients with Chronic Disorders of Consciousness. <b>2021</b> , 12, 386-403	4
708	Differential patterns of gray matter volumes and associated gene expression profiles in cognitively-defined Alzheimer's disease subgroups. <b>2021</b> , 30, 102660	3
707	Altered Gut Microbial Metabolites in Amnesic Mild Cognitive Impairment and Alzheimer's Disease: Signals in Host-Microbe Interplay. <b>2021</b> , 13,	23
706	Accelerated inflammatory aging in Alzheimer's disease and its relation to amyloid, tau, and cognition. <b>2021</b> , 11, 1965	9
705	Biomarker testing in MCI patients-deciding who to test. <b>2021</b> , 13, 14	0
704	Alzheimer's Disease. <b>2021</b> , 1-30	
703	Automated quantitative MRI volumetry reports support diagnostic interpretation in dementia: a multi-rater, clinical accuracy study. <b>2021</b> , 31, 5312-5323	8
702	Curcumin. <b>2021</b> , 49-63	
701	Alzheimer's Patient Analysis Using Image and Gene Expression Data and Explainable-AI to Present Associated Genes. <b>2021</b> , 70, 1-7	7
700	A computational Monte Carlo simulation strategy to determine the temporal ordering of abnormal age onset among biomarkers of Alzheimer's disease. <b>2021</b> , PP,	1
699	Category-specific verb-semantic deficits in Alzheimer's disease: Evidence from static and dynamic action naming. <b>2021</b> , 38, 1-26	3

- 698 The hippocampal region is necessary for text comprehension and memorization: a combined VBM/DTI study in neuropsychological patients. **2021**, 15, 2367-2376
- 697 rs12785878 T>C Polymorphism Is Associated With an Increased Risk of Early Onset of Alzheimer's Disease in Chinese Population. **2021**, 12, 583695 0
- 696 Significant effects of cholinesterase inhibitors on tau pathology in the Alzheimer's disease continuum: An in vivo positron emission tomography study. **2021**, 36, 1274-1283 1
- 695 20 Jahre "Zehn-Wort-Merkliste mit Imaginations-Einspeicherhilfe" **2021**, 24, 110-115
- 694 Comprehensive classification models based on amygdala radiomic features for Alzheimer's disease and mild cognitive impairment. **2021**, 15, 2377-2386 2
- 693 Plasma and cerebrospinal fluid ABeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting. **2021**, 2, CD010945 4
- 692 An optimized MRI and PET based clinical protocol for improving the differential diagnosis of Geriatric Depression and Alzheimer's Disease.
- 691 Blood Methylation Is Associated With Hippocampal Volume in Subjective Cognitive Decline With Apolipoprotein E  $\epsilon$  Non-carriers. **2021**, 13, 632382 2
- 690 Machine Learning Profiling of Alzheimer's Disease Patients Based on Current Cerebrospinal Fluid Markers and Iron Content in Biofluids. **2021**, 13, 607858 3
- 689 Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer's Disease and Other Neurological Disorders. **2021**, 15, 647783 1
- 688 Hippocampal and Amygdalar Morphological Abnormalities in Alzheimer's Disease Based on Three Chinese MRI Datasets. **2020**, 17, 1221-1231 0
- 687 The Free and Cued Selective Reminding Test Predicts Braak Stage. **2021**, 80, 175-183 3
- 686 Diagnosis of Mild Cognitive Impairment Using Cognitive Tasks: A Functional Near-Infrared Spectroscopy Study. **2020**, 17, 1145-1160 4
- 685 Subjective age, depressive symptoms, and cognitive functioning across five domains. **2021**, 43, 310-323 1
- 684 The Diagnostic Value of Exosome-Derived Biomarkers in Alzheimer's Disease and Mild Cognitive Impairment: A Meta-Analysis. **2021**, 13, 637218 7
- 683 The Contribution of Ocular Biomarkers in the Differential Diagnosis of Alzheimer's Disease versus Other Types of Dementia and Future Prospects. **2021**, 80, 493-504 4
- 682 Exploring new avenues for modifying course of progression of Alzheimer's disease: The rise of natural medicine. **2021**, 422, 117332 0
- 681 Evidence of Neurovascular Un-Coupling in Mild Alzheimer's Disease through Multimodal EEG-fNIRS and Multivariate Analysis of Resting-State Data. **2021**, 9, 3

680	ROSE: A Retinal OCT-Angiography Vessel Segmentation Dataset and New Model. <b>2021</b> , 40, 928-939	40
679	Proteomics Landscape of Alzheimer's Disease. <b>2021</b> , 9,	2
678	Comprehensive Visual Rating Scale on Magnetic Resonance Imaging: Application to Prodromal Alzheimer Disease. <b>2021</b> , 25, 39-44	
677	Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer's disease (MCI and dementia) in primary care: a review and synthesis. <b>2021</b> , 290, 310-334	15
676	Alzheimer's Dementia: The Emerging Role of Positron Emission Tomography. <b>2021</b> , 1073858421997035	
675	Bi-Temporal Anodal Transcranial Direct Current Stimulation during Slow-Wave Sleep Boosts Slow-Wave Density but Not Memory Consolidation. <b>2021</b> , 11,	0
674	Research diagnostic criteria for Alzheimer's disease: findings from the LipiDiDiet randomized controlled trial. <b>2021</b> , 13, 64	1
673	Biomarker in der Frñdiagnostik der Demenz? âPPro. <b>2021</b> , 48, 62-63	0
672	Stages of Objective Memory Impairment Predict Alzheimer's Disease Neuropathology: Comparison with the Clinical Dementia Rating Scale-Sum of Boxes. <b>2021</b> , 80, 185-195	2
671	The Efficacy of Cognitive-Communicative Intervention in Mild Cognitive Impairment: A Systematic Review and Meta-Analysis. <b>2021</b> , 17, 147-167	
670	Analyzing Brain Morphology in Alzheimer's Disease Using Discriminative and Generative Spiral Networks.	1
669	Disrupted White Matter Networks from Subjective Memory Impairment to Amnestic Mild Cognitive Impairment. <b>2021</b> ,	1
668	Distinctive alteration of presynaptic proteins in the outer molecular layer of the dentate gyrus in Alzheimer's disease. <b>2021</b> , 3, fcab079	1
667	A method for diagnosis support of mild cognitive impairment through EEG rhythms source location during working memory tasks. <b>2021</b> , 66, 102499	2
666	LeSCoD: a new clinical scale for the detection of Lewy body disease in neurocognitive disorders. <b>2021</b> , 268, 3886-3896	
665	A Review of Brain Atrophy Subtypes Definition and Analysis for Alzheimer's Disease Heterogeneity Studies. <b>2021</b> , 80, 1339-1352	6
664	Influence of COMT polymorphism in cognitive performance on dementia in community-dwelling elderly Mexican (SADEM study). <b>2021</b> , 36, 1223-1229	0
663	Interoception Primes Emotional Processing: Multimodal Evidence from Neurodegeneration. <b>2021</b> , 41, 4276-4292	15

662	T217-Phosphorylation Exacerbates Tau Pathologies and Tau-Induced Cognitive Impairment. <b>2021</b> , 81, 1403-1418	2
661	Cognitive and Structural Correlates of Conversational Speech Timing in Mild Cognitive Impairment and Mild-to-Moderate Alzheimer's Disease: Relevance for Early Detection Approaches. <b>2021</b> , 13, 637404	1
660	A hemicyanine based fluorescence turn-on sensor for amyloid fibril detection in the far-red region. <b>2021</b> , 328, 115322	2
659	An Effective Brain Imaging Biomarker for AD and aMCI: ALFF in Slow-5 Frequency Band. <b>2021</b> ,	1
658	Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer's disease. <b>2021</b> , 13, 84	10
657	Cerebrovascular Disease and Cognitive Outcome in Patients with Cardiac Disease. <b>2021</b> , 41, 463-472	1
656	Serum Levels of Clusterin, PKR, and RAGE Correlate with Amyloid Burden in Alzheimer's Disease. <b>2021</b> , 80, 1067-1077	4
655	Alzheimer's disease. <b>2021</b> , 397, 1577-1590	245
654	Classification of neurological diseases using multi-dimensional CSF analysis. <b>2021</b> , 144, 2625-2634	6
653	Biomarqueurs du liquide cfbrosional. <b>2021</b> , 12, 165-179	0
652	Pharmacological intervention in oxidative stress as a therapeutic target in neurological disorders. <b>2021</b> ,	1
651	Donanemab in Early Alzheimer's Disease. <b>2021</b> , 384, 1691-1704	176
650	History in perspective: How Alzheimer's Disease came to be where it is?. <b>2021</b> , 1758, 147342	2
649	Astrocyte Biomarkers in Alzheimer Disease: A Systematic Review and Meta-analysis. <b>2021</b> ,	23
648	Saccadic Eye Movement in Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review and Meta-Analysis. <b>2021</b> , 1	5
647	MicroRNA-4422-5p as a Negative Regulator of Amyloidogenic Secretases: A Potential Biomarker for Alzheimer's Disease. <b>2021</b> , 463, 108-115	3
646	Diagnostic accuracy of virtual cognitive assessment and testing: Systematic review and meta-analysis. <b>2021</b> , 69, 1429-1440	10
645	Pharmacological treatment of hypertension in people without prior cerebrovascular disease for the prevention of cognitive impairment and dementia. <b>2021</b> , 5, CD004034	1

644	Memory awareness in patients with Major Depressive Disorder. <b>2021</b> , 137, 411-418		1
643	Biomarkers and Tools for Predicting Alzheimer's Disease at the Preclinical Stage. <b>2021</b> ,		4
642	PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research. <b>2021</b> , 13, 624330		5
641	Novel PSEN1 and PSEN2 Mutations Identified in Sporadic Early-onset Alzheimer Disease and Posterior Cortical Atrophy. <b>2021</b> , 35, 208-213		1
640	Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. <i>Lancet Neurology, The</i> , <b>2021</b> , 20, 484-496	24.1	86
639	Transcranial Magnetic Stimulation as a Diagnostic and Therapeutic Tool in Various Types of Dementia. <b>2021</b> , 10,		1
638	Alpha peak frequency is linked to episodic memory impairment in pathological aging.		
637	Longitudinal Cognitive and Physical Training Effectiveness in MCI, Based on the Experience of the Alzheimer's Hellas Day Care Centre. <b>2021</b> , 8919887211016057		5
636	Biological diagnosis of Alzheimer's disease and the issue of stigma. <b>2021</b> , 69, 195-207		1
635	Simultaneous Determination of D-amino Acids in Rat Urine by Highperformance Liquid Chromatography-tandem Mass Spectrometry Method: Application to Investigate the Clinical Value of D-amino Acids in the Early Diagnosis of Alzheimer's Disease. <b>2021</b> , 17, 1026-1035		
634	Temporal Ordering of Inflammatory Analytes sTNFR2 and sTREM2 in Relation to Alzheimer's Disease Biomarkers and Clinical Outcomes. <b>2021</b> , 13, 676744		3
633	Multi-cohort profiling reveals elevated CSF levels of brain-enriched proteins in Alzheimer's disease. <b>2021</b> , 8, 1456-1470		3
632	Sex Difference in Network Topology and Education Correlated With Sex Difference in Cognition During the Disease Process of Alzheimer. <b>2021</b> , 13, 639529		1
631	Reliability and Validity of the Chinese Version of Mild Behavioral Impairment Checklist in Mild Cognitive Impairment and Mild Alzheimer's Disease. <b>2021</b> , 81, 1141-1149		3
630	Expanded Exploration of the Auditory Naming Test in Patients with Dementia. <b>2021</b> , 81, 1763-1779		0
629	Subjective organization in the episodic memory of individuals with Parkinson's disease associated with mild cognitive impairment. <b>2021</b> ,		
628	Cardiac-induced cerebral pulsatility, brain structure, and cognition in middle and older-aged adults. <b>2021</b> , 233, 117956		1
627	A Multicomponent Home-Based Intervention for Neuropsychiatric Symptoms in People With Dementia and Caregivers' Burden and Depression: A 6-Month Longitudinal Study. <b>2021</b> , 8919887211023593		0

626	Copper Imbalance in Alzheimer's Disease: Meta-Analysis of Serum, Plasma, and Brain Specimens, and Replication Study Evaluating Gene Variants. <b>2021</b> , 11,	7
625	The changing definition of Alzheimer's disease. <i>Lancet Neurology, The</i> , <b>2021</b> , 20, 414-415	24.1 3
624	Specific White Matter Tracts and Diffusion Properties Predict Conversion From Mild Cognitive Impairment to Alzheimer's Disease. <b>2021</b> , 13, 711579	2
623	An investigation into the commercialisation of initiation schools: A case of Eastern Cape, South Africa. <b>2021</b> , 77,	0
622	A cross-sectional study in healthy elderly subjects aimed at development of an algorithm to increase identification of Alzheimer pathology for the purpose of clinical trial participation. <b>2021</b> , 13, 132	0
621	The potential diagnostic accuracy of circulating microRNAs for Alzheimer's disease: A meta-analysis. <b>2021</b> ,	2
620	Exercise-Mediated Alteration of miR-192-5p Is Associated with Cognitive Improvement in Alzheimer's Disease. <b>2021</b> , 1-8	1
619	The complexity of Alzheimer's disease: an evolving puzzle. <b>2021</b> , 101, 1047-1081	7
618	Identification of two pathogenic mutations in SORL1 in early-onset Alzheimer's disease. <b>2021</b> , 89, 243-248	1
617	When Does Alzheimer's Disease Really Start? The Role of Biomarkers. <b>2021</b> , 19, 355-364	
616	A Graph Theory Approach to Clarifying Aging and Disease Related Changes in Cognitive Networks. <b>2021</b> , 13, 676618	3
615	Prediction of differentially expressed microRNAs in blood as potential biomarkers for Alzheimer's disease by meta-analysis and adaptive boosting ensemble learning. <b>2021</b> , 13, 126	8
614	CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. <b>2021</b> , 9,	2
613	Serum apelin-13 levels and total oxidant/antioxidant status of patients with Alzheimer's disease. <b>2021</b> , 4, 201-205	1
612	Calibrating Mini-Mental State Examination Scores to Predict Misdiagnosed Dementia Patients. <b>2021</b> , 11, 8055	0
611	Revealing the Influences of Sex Hormones and Sex Differences in Atrial Fibrillation and Vascular Cognitive Impairment. <b>2021</b> , 22,	3
610	Fasu-Net: Fast Alzheimer's Disease Screening with Undersampled MRI Using Convolutional Neural Networks. <b>2021</b> , 11, 2301-2311	
609	Decreased Alpha Peak Frequency Is Linked to Episodic Memory Impairment in Pathological Aging. <b>2021</b> , 13, 711375	0

608	A novel CT-based automated analysis method provides comparable results with MRI in measuring brain atrophy and white matter lesions. <b>2021</b> , 63, 2035-2046	1
607	The Clinical Spectrum of Young Onset Dementia Points to Its Stochastic Origins. <b>2021</b> , 5, 663-679	0
606	Serum Metabolites Differentiate Amnesic Mild Cognitive Impairment From Healthy Controls and Predict Early Alzheimer's Disease via Untargeted Lipidomics Analysis. <b>2021</b> , 12, 704582	0
605	Ginkgo Biloba Extract Is Comparable With Donepezil in Improving Functional Recovery in Alzheimer's Disease: Results From a Multilevel Characterized Study Based on Clinical Features and Resting-State Functional Magnetic Resonance Imaging. <b>2021</b> , 12, 721216	1
604	Time to Diagnosis in Young Onset Alzheimer's Disease: A Population-Based Study from Central Norway. <b>2021</b> , 82, 965-974	3
603	FEOBV-PET to quantify cortical cholinergic denervation in AD: Relationship to basal forebrain volumetry. <b>2021</b> , 31, 1077-1081	0
602	Mechanism of the Fibroblast Growth Factor 23/ $\beta$ Klotho Axis in Peripheral Blood Mononuclear Cell Inflammation in Alzheimer's Disease. <b>2021</b> , 1-14	0
601	Multimodal mechanisms of human socially reinforced learning across neurodegenerative diseases. <b>2021</b> ,	8
600	Progression along data-driven disease timelines is predictive of Alzheimer's disease in a population-based cohort. <b>2021</b> , 238, 118233	0
599	A passive and objective measure of recognition memory in Alzheimer's disease using Fastball memory assessment. <b>2021</b> , 144, 2812-2825	0
598	Differential neural structures, intrinsic functional connectivity, and episodic memory in subjective cognitive decline and healthy controls. <b>2021</b> , 105, 159-173	0
597	Machine learning methods for predicting progression from mild cognitive impairment to Alzheimer's disease dementia: a systematic review. <b>2021</b> , 13, 162	7
596	Novel insights into the relationship between cerebellum and dementia: A narrative review as a toolkit for clinicians. <b>2021</b> , 70, 101389	2
595	Improving the Methodology for Identifying Mild Cognitive Impairment in Intellectually High-Functioning Adults Using the NIH Toolbox Cognition Battery. <b>2021</b> , 12, 724888	0
594	Genotyping and Plasma/Cerebrospinal Fluid Profiling of a Cohort of Frontotemporal Dementia-Amyotrophic Lateral Sclerosis Patients. <b>2021</b> , 11,	0
593	Effects of baseline serum uric acid and apolipoprotein E4 on longitudinal cognition and cerebral metabolism. <b>2021</b> , 106, 223-231	2
592	Visual short-term memory impairments in presymptomatic familial Alzheimer's disease: A longitudinal observational study. <b>2021</b> , 162, 108028	2
591	Skeleton-based human action evaluation using graph convolutional network for monitoring Alzheimer's progression. <b>2021</b> , 119, 108095	5

590	Exploration of potential circulating micro-RNA as biomarker for Alzheimer's disease. <b>2021</b> , 30, 100968	0
589	Dual-Tasking or Concurrent Multitasking. <b>2022</b> , 377-386	
588	Vascular Dementia and Cognitive Impairment. <b>2022</b> , 221-236.e8	1
587	Operational aspects of deep learning solutions for Alzheimer's disease. <b>2022</b> , 151-173	0
586	Comparison of Word-Writing Performance according to the Degree of Cognitive Decline: Focused on Patients with Subjective Memory Complaint, Mild Cognitive Impairment, and Alzheimer's Disease. <b>2021</b> , 17, 91-102	1
585	The contribution of mamillary body damage to Wernicke's encephalopathy and Korsakoff's syndrome. <b>2021</b> , 180, 455-475	5
584	Dietary Habits, Selenium, Copper, Zinc and Total Antioxidant Status in Serum in Relation to Cognitive Functions of Patients with Alzheimer's Disease. <b>2021</b> , 13,	12
583	Diagnosis of Alzheimer's Disease in Developed and Developing Countries: Systematic Review and Meta-Analysis of Diagnostic Test Accuracy. <b>2021</b> , 5, 15-30	3
582	Deep Learning-Based Segmentation in Classification of Alzheimer's Disease. <b>2021</b> , 46, 5373-5383	4
581	Brain Resources: How Semantic Cueing Works in Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD). <b>2021</b> , 11,	1
580	Deep brain stimulation in Alzheimer's disease. <b>2021</b> , 159, 69-87	1
579	Changes in the use of psychotropic drugs during the course of Alzheimer's disease: A large-scale longitudinal study of French medical records. <b>2021</b> , 7, e12210	
578	Volumetric MRI demonstrates atrophy of the olfactory cortex in AD. <b>2020</b> , 17, 904-915	4
577	Neuropathology of Alzheimer's Disease and its Variants. 62-91	14
576	Improving Accuracy for Identifying Cognitive Impairment. <b>2011</b> , 923-950	24
575	Encyclopedia of Clinical Neuropsychology. <b>2011</b> , 1707-1710	1
574	Alzheimer's Disease: Clinical Aspects and Treatments. <b>2014</b> , 17-26	1
573	Amyloid PET Imaging: Standardization and Integration with Other Alzheimer's Disease Biomarkers. <b>2018</b> , 1750, 203-212	8



572	Mass Spectrometry-Based Metabolomic Multiplatform for Alzheimer's Disease Research. <b>2018</b> , 1750, 125-137	3
571	Blood-Based Biomarker Screening with Agnostic Biological Definitions for an Accurate Diagnosis Within the Dimensional Spectrum of Neurodegenerative Diseases. <b>2018</b> , 1750, 139-155	10
570	Quantitative approaches to amyloid imaging. <b>2011</b> , 680, 201-25	3
569	Nutrition and Cognitive Decline in Older Persons: Bridging the Gap Between Epidemiology and Intervention Studies. <b>2014</b> , 395-414	2
568	Introduction. <b>2015</b> , 1-17	1
567	GLISTRboost: Combining Multimodal MRI Segmentation, Registration, and Biophysical Tumor Growth Modeling with Gradient Boosting Machines for Glioma Segmentation. <b>2016</b> , 9556, 144-155	41
566	PET in Neurological and Psychiatric Disorders: Technologic Advances and Clinical Applications. <b>2017</b> , 485-535	1
565	Differential Diagnosis: "What Is the Lesion?" <b>2017</b> , 127-262	1
564	Liquordiagnostik. <b>2011</b> , 143-178	2
563	Alzheimer-Demenz. <b>2011</b> , 47-72	1
562	Classification Models for Alzheimer's Disease Detection. <b>2013</b> , 193-202	6
561	PET Tracers for Beta-Amyloid and Other Proteinopathies. <b>2014</b> , 199-212	2
560	Neuroimaging Findings in Mild Cognitive Impairment. <b>2014</b> , 271-307	1
559	Demenz. <b>2017</b> , 1377-1465	1
558	Clinical Manifestations of Neuropsychiatric Disorders. <b>2010</b> , 1-14	1
557	17 Mild cognitive impairment. <b>2009</b> , 187-195	2
556	Pathologic Lesions in Alzheimer Disease and Other Neurodegenerative Diseases—Cellular and Molecular Components. <b>2012</b> , 37-60	0
555	The Use of Biomarkers for Prediction and Prevention of Alzheimer's and Parkinson's Diseases. <b>2013</b> , 95-140	2

554	Longitudinal Neuroimaging Hippocampal Markers for Diagnosing Alzheimer’s Disease. <b>2019</b> , 17, 43	1
553	Potential Neuroregenerative and Neuroprotective Effects of Uridine/Choline-Enriched Multinutrient Dietary Intervention for Mild Cognitive Impairment: A Narrative Review. <b>2021</b> , 10, 43-60	2
552	Dementia Diagnosis. <b>2010</b> , 385-391	1
551	Presentation and Clinical Management of Dementia. <b>2010</b> , 392-401	2
550	Alzheimer’s Disease. <b>2010</b> , 411-420	1
549	Alzheimer’s Disease and Other Dementias. <b>2011</b> , 1038-1047	2
548	Dementias. <b>2012</b> , 1534-1582	4
547	Le Trouble Cognitif L�ger ou Mild Cognitive Impairment. <b>2008</b> , 169-186	1
546	[Late life depression or prodromal Alzheimer’s disease: Which tools for the differential diagnosis?]. <b>2018</b> , 44, 52-58	6
545	Artificial intelligence and neuropsychological measures: The case of Alzheimer’s disease. <b>2020</b> , 114, 211-228	19
544	Ganglion cell layer thinning in prodromal Alzheimer’s disease defined by amyloid PET. <b>2019</b> , 5, 570-578	22
543	Alzheimer’s disease. 80-108	1
542	Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia. <b>2020</b> , 11, 619	37
541	On Short Cuts: The Complexity of Studying the Early Diagnosis and Prevention of Alzheimer’s Disease. <b>2016</b> , 41-61	3
540	Biomarkers for Alzheimer’s Disease: Searching for the Missing Link Between Biology and Clinic. <b>2016</b> , 63-82	6
539	Understanding Cognitive Screening Tools: Navigating Uncertainty in Everyday Clinical Practice. <b>2016</b> , 123-139	4
538	Mental Disorders Across the Life Span and the Role of Executive Function Networks. <b>2012</b> , 245-268	1
537	Pathophysiological subtypes of Alzheimer’s disease based on cerebrospinal fluid proteomics. <b>2020</b> , 143, 3776-3792	16

536	Cognitive profiles in persons with depressive disorder and Alzheimer's disease. <b>2020</b> , 2, fcaa206	4
535	Alterations in resting-state network dynamics along the Alzheimer's disease continuum: a combined MEG-PET/MR approach.	2
534	A Practical Alzheimer Disease Classifier via Brain Imaging-Based Deep Learning on 85,721 Samples.	4
533	Data-driven detection of latent atrophy factors related to phenotypical variants of posterior cortical atrophy.	1
532	A comparison of resting state EEG and structural MRI for classifying Alzheimer's disease and mild cognitive impairment.	2
531	Mild Cognitive Impairment. <b>2016</b> , 22, 404-18	189
530	Nutritional status, survival and mortality in Alzheimer patients - a cross-sectional study. 7, 137	1
529	Preliminary Study for a Multicenter Study of Alzheimer's Disease Cerebrospinal Fluid Biomarkers. <b>2013</b> , 12, 1	7
528	Risk Factors for Post-Lumbar Puncture Headache in a Study of Alzheimer's Disease Biomarkers. <b>2015</b> , 14, 12	2
527	Different Cortical Thinning Patterns Depending on Their Prognosis in Individuals with Subjective Cognitive Decline. <b>2019</b> , 18, 113-121	3
526	Alzheimer's Disease Diagnosis Using Misfolding Proteins in Blood. <b>2020</b> , 19, 1-18	4
525	Non-conjugated small molecule FRET for differentiating monomers from higher molecular weight amyloid beta species. <b>2011</b> , 6, e19362	31
524	Metabolite profiling of Alzheimer's disease cerebrospinal fluid. <b>2012</b> , 7, e31501	122
523	Epigenetic regulation of fatty acid amide hydrolase in Alzheimer disease. <b>2012</b> , 7, e39186	45
522	Robust automated detection of microstructural white matter degeneration in Alzheimer's disease using machine learning classification of multicenter DTI data. <b>2013</b> , 8, e64925	77
521	Enhanced Chemokine Receptor Expression on Leukocytes of Patients with Alzheimer's Disease. <b>2013</b> , 8, e66664	25
520	Famous landmark identification in amnesic mild cognitive impairment and Alzheimer's disease. <b>2014</b> , 9, e105623	9
519	Right anterior insula: core region of hallucinations in cognitive neurodegenerative diseases. <b>2014</b> , 9, e114774	31

518	Depressive symptoms are associated with analgesic use in people with Alzheimer's disease: Kuopio ALSOVA study. <b>2015</b> , 10, e0117926	10
517	Untargeted metabolomic analysis of human plasma indicates differentially affected polyamine and L-arginine metabolism in mild cognitive impairment subjects converting to Alzheimer's disease. <b>2015</b> , 10, e0119452	105
516	Gaussian Mixture Models and Model Selection for [18F] Fluorodeoxyglucose Positron Emission Tomography Classification in Alzheimer's Disease. <b>2014</b> , 10, e0122731	25
515	A First Tetraplex Assay for the Simultaneous Quantification of Total $\beta$ Synuclein, Tau, $\beta$ Amyloid42 and DJ-1 in Human Cerebrospinal Fluid. <b>2016</b> , 11, e0153564	6
514	Macular Ganglion Cell -Inner Plexiform Layer Thickness Is Associated with Clinical Progression in Mild Cognitive Impairment and Alzheimers Disease. <b>2016</b> , 11, e0162202	52
513	Rheumatoid Arthritis Was Negatively Associated with Alzheimer's Disease: A Population-Based Case-Control Study. <b>2016</b> , 11, e0168106	15
512	Prediction and classification of Alzheimer disease based on quantification of MRI deformation. <b>2017</b> , 12, e0173372	74
511	The association of visual memory with hippocampal volume. <b>2017</b> , 12, e0187851	8
510	Modulation of functional activity and connectivity by acupuncture in patients with Alzheimer disease as measured by resting-state fMRI. <b>2018</b> , 13, e0196933	40
509	Quantifying cognitive resilience in Alzheimer's Disease: The Alzheimer's Disease Cognitive Resilience Score. <b>2020</b> , 15, e0241707	6
508	Endpoints for Pre-Dementia AD Trials: A Report from the EU/US/CTAD Task Force. <b>2015</b> , 2, 128-135	24
507	Cognitive/Clinical Endpoints for Pre-Dementia AD Trials. <b>2015</b> , 2, 82-84	7
506	Defining Disease Modifying Therapy for Alzheimer's Disease. <b>2017</b> , 4, 109-115	34
505	Alzheimer's Disease Composite Score: A Post-Hoc Analysis Using Data from the LipiDiDiet Trial in Prodromal Alzheimer's Disease. <b>2019</b> , 6, 232-236	7
504	Two Novel Mutations and a Mutation in in Early-onset Alzheimer's Disease. <b>2019</b> , 10, 908-914	6
503	The Epidemiological Scale of Alzheimer's Disease. <b>2015</b> , 7, 657-66	40
502	Association of MS4A6A, CD33, and TREM2 gene polymorphisms with the late-onset Alzheimer's disease. <b>2019</b> , 9, 219-225	6
501	Pathophysiology and management of alzheimer's disease: an overview. <b>2018</b> , 7,	14

500	The Value of Long-Term EEG in the Diagnosis of Epilepsy in Alzheimer’s Disease. <b>2016</b> , 4,	1
499	Moving from neurodegenerative dementias, to cognitive proteinopathies, replacing "where" by "what" <b>2020</b> , 14, 237-242	5
498	[The therapeutic potential of acetyl-L-carnitine in the treatment of cognitive and depressive disorders in the elderly]. <b>2018</b> , 118, 37-45	2
497	Recent Developments in Diffusion Tensor Imaging of Brain. <b>2015</b> , 1, 1-12	2
496	APOE Gene polymorphism among Jordanian Alzheimer’s patients with relation to lipid profile. <b>2018</b> , 23, 29-34	8
495	Advances in our Understanding of the Pathophysiology, Detection and Management of Cerebral Amyloid Angiopathy. <b>2012</b> , 7, 134-139	14
494	Diagnostic performance of new and classic CSF biomarkers in age-related dementias. <b>2019</b> , 11, 2420-2429	12
493	Dysfunctional interactions between the default mode network and the dorsal attention network in subtypes of amnesic mild cognitive impairment. <b>2019</b> , 11, 9147-9166	14
492	Application of Generalized Split Linearized Bregman Iteration algorithm for Alzheimer’s disease prediction. <b>2020</b> , 12, 6206-6224	4
491	White matter degeneration in subjective cognitive decline: a diffusion tensor imaging study. <b>2016</b> , 7, 54405-54414	37
490	Interaction between PPAR $\alpha$ and SORL1 gene with Late-Onset Alzheimer’s disease in Chinese Han Population. <b>2017</b> , 8, 48313-48320	4
489	Relationship of polymorphisms and haplotype in interleukin-16 and adiponectin gene with late-onset Alzheimer’s disease risk. <b>2017</b> , 8, 79157-79164	1
488	Aberrant pattern of regional cerebral blood flow in Alzheimer’s disease: a voxel-wise meta-analysis of arterial spin labeling MR imaging studies. <b>2017</b> , 8, 93196-93208	12
487	Biothiols and oxidative stress markers and polymorphisms of and genes in Alzheimer’s disease patients. <b>2018</b> , 9, 35207-35225	20
486	Hyphenated Mass Spectrometry Techniques in the Diagnosis of Amyloidosis. <b>2019</b> , 26, 104-120	1
485	Genetic Variants and Oxidative Stress in Alzheimer’s Disease. <b>2020</b> , 17, 208-223	12
484	YKL-40 as a Potential Biomarker and a Possible Target in Therapeutic Strategies of Alzheimer’s Disease. <b>2017</b> , 15, 906-917	37
483	Differential patterns of hypoperfusion in subtypes of mild cognitive impairment. <b>2008</b> , 2, 20-8	26

482	Longitudinal Magnetic Resonance Imaging as a Potential Correlate in the Diagnosis of Alzheimer Disease: Exploratory Data Analysis. <b>2020</b> , 5, e14389	3
481	Early detection of Alzheimer's disease: new diagnostic criteria. <b>2009</b> , 11, 135-9	52
480	Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. <b>2009</b> , 11, 111-28	567
479	Imaging in Alzheimer's disease. <b>2009</b> , 11, 191-9	27
478	Large-scale functional brain network abnormalities in Alzheimer's disease: insights from functional neuroimaging. <b>2009</b> , 21, 63-75	92
477	Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. <b>2009</b> , 21, 117-28	95
476	Non-Verbal Episodic Memory Deficits in Primary Progressive Aphasias are Highly Predictive of Underlying Amyloid Pathology. <b>2016</b> , 51, 367-76	26
475	Brain Volume Predicts Behavioral and Psychological Symptoms in Alzheimer's Disease. <b>2020</b> , 73, 1343-1353	8
474	Quality Reporting of Radiomics Analysis in Mild Cognitive Impairment and Alzheimer's Disease: A Roadmap for Moving Forward. <b>2020</b> , 21, 1345-1354	9
473	Differences in Cerebral Structure Associated With Depressive Symptoms in the Elderly With Alzheimer's Disease. <b>2020</b> , 12, 107	5
472	Medical Informatics Platform (MIP): A Pilot Study Across Clinical Italian Cohorts. <b>2020</b> , 11, 1021	3
471	Absolute SPECT/CT quantification of cerebral uptake of 99mTc-HMPAO for patients with neurocognitive disorders. <b>2016</b> , 55, 158-65	4
470	Efficacy of the combined use of donepezil with either quetiapine or sodium valproate in patients with Alzheimer's disease with behavioral and psychological symptoms of dementia, and their effects on vascular endothelial growth factors. <b>2021</b> , 21, 10	2
469	Neuroprotective effect of CPCGI on Alzheimer's disease and its mechanism. <b>2020</b> , 21, 115-122	2
468	Expression levels of the $\alpha 7$ nicotinic acetylcholine receptor in the brains of patients with Alzheimer's disease and their effect on synaptic proteins in SH-SY5Y cells. <b>2020</b> , 22, 2063-2075	12
467	Quelques réflexions sur le diagnostic de la maladie d'Alzheimer. <b>2009</b> , 32 / n° 128-129, 143	2
466	Maladie d'Alzheimer: un autre regard. <b>2010</b> , 86, 49	1
465	How close is the stem cell cure to the Alzheimer's disease: Future and beyond?. <b>2012</b> , 7, 66-71	6

464	Rate of early onset Alzheimer’s disease: a systematic review and meta-analysis. <b>2015</b> , 3, 38	47
463	Coexistence of Cerebral Microbleeds and Amyloid Pathology in Patients with Cognitive Complaints. <b>2020</b> , 16, 83-89	8
462	Neuroimaging Approaches for Elderly Studies. <b>2015</b> , 47-86	2
461	[Biomarkers in spinal fluid of patients with dementia]. <b>2011</b> , 131, 2235-8	2
460	The Memory Clinic--outpatient assessment when dementia is suspected. <b>2011</b> , 131, 2254-7	49
459	[Biomarkers of dementia]. <b>2011</b> , 131, 2218	3
458	Diagnosis of dementia--automatic quantification of brain structures. <b>2012</b> , 132, 1747-51	11
457	□Amyrin Ameliorates Alzheimer’s Disease-Like Aberrant Synaptic Plasticity in the Mouse Hippocampus. <b>2020</b> , 28, 74-82	7
456	Biomarker-Based Prediction of Progression to Dementia: F-18 FDG-PET in Amnesic MCI. <b>2019</b> , 67, 1310-1317	7
455	Use of curcumin in diagnosis, prevention, and treatment of Alzheimer’s disease. <b>2018</b> , 13, 742-752	94
454	Prevalence of cerebrospinal fluid Alzheimer disease-like pattern in atypical dementias. <b>2012</b> , 01, 45-50	2
453	Spanish Version of Test MIS (*) with Delayed Memory Recall Normative Values and Results in a Population with Mild Cognitive Impairment. <b>2015</b> , 04, 45-61	2
452	DTI and Structural MRI Classification in Alzheimer’s Disease. <b>2012</b> , 02, 12-20	27
451	&lt;i>Ratanasampil</i> (Tibetan Medicine, RNSP) Reduces &lt;i>□</i>-Amyloid Protein (Aβ) and Pro-Inflammatory Factor Levels and Improves Cognitive Functions in Mild-to-Moderate Alzheimer’s Disease (AD) Patients Living at High Altitude. <b>2012</b> , 02, 82-91	2
450	White Matter Changes in Alzheimer’s Disease Revealed by Diffusion Tensor Imaging with TBSS. <b>2015</b> , 05, 58-65	4
449	Validation of the dementia care assessment packet-instrumental activities of daily living. <b>2013</b> , 10, 238-45	2
448	Structural MRI and Amyloid PET Imaging for Prediction of Conversion to Alzheimer’s Disease in Patients with Mild Cognitive Impairment: A Meta-Analysis. <b>2017</b> , 14, 205-215	12
447	Severe periodontitis with tooth loss as a modifiable risk factor for the development of Alzheimer, vascular, and mixed dementia: National Health Insurance Service-National Health Screening Retrospective Cohort 2002-2015. <b>2020</b> , 50, 303-312	8

- 446 Avidity of antineurocytoskeletal antibodies in Alzheimer's disease patients. **2017**, 161, 179-186 4
- 445 Association of impaired fasting glucose and Type 2 Diabetes Mellitus with brain volume changes in Alzheimer's Disease patients analyzed by MRI: a retrospective study. **2020**, 8, e9801 3
- 444 Predicting MMSE Score from Finger-Tapping Measurement. **2022**, 294-304
- 443 Validation of ICMR Neurocognitive Toolbox for Dementia in the Linguistically Diverse Context of India. **2021**, 12, 661269 1
- 442 Disturbance of phylogenetic layer-specific adaptation of human brain gene expression in Alzheimer's disease. **2021**, 11, 20200
- 441 Cognitive Deficits Associated With Dysphagia in Patients With Dementia. **2021**, 27, 650-652
- 440 Clinical, Neuropsychological, and Neuroimaging Characteristics of Amyloid- positive vs. Amyloid-negative Patients with Clinically Diagnosed Alzheimer's Disease and Amnesic Mild Cognitive Impairment. **2021**, 18, 523-532 1
- 439 Electroencephalography as a Non-Invasive Biomarker of Alzheimer's Disease: A Forgotten Candidate to Substitute CSF Molecules?. **2021**, 22, 1
- 438 Nutritional status assessment in Alzheimer disease and its influence on disease progression. **2021**, 0
- 437 Efficacy and safety of Kami-guibi-tang for mild cognitive impairment: a pilot, randomized, double-blind, placebo-controlled trial. **2021**, 21, 251 1
- 436 Resting-state functional reorganisation in Alzheimer's disease and amnesic mild cognitive impairment: protocol for a systematic review and meta-analysis. **2021**, 11, e049798 1
- 435 [Cerebrospinal fluid amyloid beta and tau protein: biomarkers for Alzheimer's disease]. **2008**, 65, 901-5
- 434 Le diagnostic de la maladie d'Alzheimer : lâpport de la recherche prèclinique. **2008**, 192, 345-361
- 433 Identifying memory loss disorders. **2008**, 2008,
- 432 Diagnostik und Therapie demenzieller Syndrome (ICD-10 F0). **2009**, 1-22
- 431 fMRI in Neurodegenerative Diseases: From Scientific Insights to Clinical Applications. **2009**, 657-680
- 430 Neurological disease. **2009**, 1095-1183
- 429 Neuroimaging Biomarkers in Alzheimer's Disease. **2009**, 3-15



428 1 Ziekteconcept en classificatie. **2009**, 7-12

427 Proteases In ðAmyloid Metabolism: Potential Therapeutic Targets Against Alzheimerâs Disease. **2009**, 385-402

426 Genetics. **2009**, 51-64

425 Bibliographie. **2009**, 337-358

424 Imaging CNS Disease States: Alzheimerâs Disease. **2010**, 303-318

423 Chapitre 2. Le rle de l'Imagerie Molculaire dans le diagnostic des dmences. **2009**, 31-41

422 Klinik der Demenzen. **2010**, 60-76

1

421 Disorders of higher cortical visual function. **2010**, 339-362

420 Knowledge-Based Discrimination in Alzheimerâs Disease. **2010**, 89-96

419 Analysis of Magnetic Resonance Imaging Data on the Study of Alzheimerâs Disease. **2010**, 20, 1123-1138

418 Clinical Trials on Cognitive Drugs. 1

417 The Search for Biomarkers in Alzheimer's Disease. **2010**, 2, 4

416 Alzheimer's Disease. 269-282

415 Dementia: Clinical Background. **2011**, 5-11

414 Cognitive Domains Affected by Conditions of Ageing and the Role of Neuropsychological Testing. **2010**, 389-396

413 The Nosology of Dementia. **2010**, 201-206

412 Applications of fMRI to Neurodegenerative Disease. **2011**, 639-670

411 Demenz. **2011**, 1240-1319

410 Grundlegendes zur Systematik organischer/symptomatischer psychischer Störungen. **2011**, 1212-1227

409 Encyclopedia of Clinical Neuropsychology. **2011**, 1600-1605

1

408 Sueño, respiración y trastornos neurológicos. **2011**, 436-498

407 Técnicas de neuroimagen en neuropsicología clínica y rehabilitación neuropsicológica. **2011**, 15-e4

406 Labordiagnostik. **2011**, 375-388

405 [New diagnostic criteria for Alzheimer disease]. **2011**, 131, 2224-5

404 Neuropsychologische Diagnostik bei Alzheimerkrankheit im Frühstadium: Status quo und Zukunftstrends. **2011**, 59, 95-102

4

403 Disease-Specific Cerebrospinal Fluid Investigations. 175-197

402 Adult Neurogenesis in Etiology and Pathogenesis of Alzheimer's Disease. **2012**, 259-265

401 Dementia. **2011**, 402-425

400 Altered mental state in the elderly. **2012**, 666-676

399 Histoire naturelle du déclin cognitif au cours des 14 ans précédant le diagnostic de Maladie d'Alzheimer. Résultats issus de l'étude en population PAQUID. **2012**, 173-178

398 Dementia and Alzheimer's Disease. **2012**, 561-582

397 Adult Neurogenesis in Alzheimer's Disease and Therapies. **2012**, 383-393

396 Nuclear Imaging of Neurovascular Disease. **2012**, 235-237

395 Neuroimaging. **2012**, 529-548

394 Neuroimage Classification for Early Diagnosis of Alzheimer's Disease. **2012**, 336-350

393 The Nervous System. **2012**, 599-677

392 Mild cognitive impairment. **2012**, 1534-1539

391 Nicht nur vom Alzheimer-Typ. **2012**, 23, 65-70

390 Imaging Biomarkers for Diagnosis, Prognosis and Treatment of Alzheimer's Disease. **2012**, 103-116

389 Enfermedad de Alzheimer: clínica y tratamiento. **2013**, 157-163

388 Incidental MRI Findings in Patients with Impaired Cognitive Function. **2013**, 68, 17

387 Apport de l'imagerie par résonance magnétique dans la maladie d'Alzheimer. **2013**, 45-61

386 Biomarqueurs du liquide céphalo-rachidien dans la maladie d'Alzheimer. **2013**, 29-43

385 Vers une nouvelle définition de la maladie d'Alzheimer. **2013**, 197, 143-156

o

384 Diagnostic de la maladie d'Alzheimer. **2013**, 3-27

383 La comunicazione della diagnosi di malattia di alzheimer: aspetti clinici ed etico-giuridici. **2013**, 501-523

382 Attention Disorders in Neurodegenerative Conditions. **2014**, 151-158

381 Impact of the IWG/Dubois Criteria for Alzheimer's Disease in Imaging Studies. **2014**, 309-322

380 A Brief Note on Methodology: Pragmatic Diagnostic Accuracy Studies. **2014**, 21-40

2

379 Therapie Psychischer Erkrankungen - Pages 1-91. **2014**, 1-91

378 Diagnosis (2): Dementia Disorders. **2014**, 299-322

377 Investigation. **2014**, 203-248

376 18F-Fluorodeoxyglucose PET Procedures: Health Economic Aspects in Neurology. **2014**, 31-57

375 Dementia Due to Neurodegenerative Disease: Molecular Imaging Findings. **2014**, 185-211

- 374 Cerebrospinal Fluid Biomarkers in Alzheimer's Disease and Frontotemporal Dementia. **2014**, 131-157
- 373 Chapitre 8. La maladie d'Alzheimer et les syndromes apparentés. **2014**, 215
- 372 Quandaries of Responsible Innovation: The Case of Alzheimer's Disease. **2014**, 239-254
- 371 Non-Conventional MRI Techniques as an Alternative Role to the Clinical Diagnosis in Alzheimer's Disease. **2014**, 06, 2712-2723
- 370 Applications of fMRI to Neurodegenerative Disease. **2015**, 465-504
- 369 Methods (1): Participants and Test Methods. **2015**, 19-44
- 368 Group Sparse Representation for Prediction of MCI Conversion to AD. **2015**, 510-519
- 367 [5. Diagnostic imaging for neurodegenerative disease]. **2015**, 71, 380-90
- 366 L'impact du trouble cognitif léger et de la maladie d'Alzheimer sur la recollection et la familiarité. **2015**, 7, 177
- 365 Therapie Psychischer Erkrankungen - Pages e1-e96. **2015**, e1-e96
- 364 Dementias. **2015**, 183-195
- 363 Results. **2015**, 73-114
- 362 Systematik organisch-symptomatischer Störungen. **2015**, 1-15
- 361 Care and Responsibility in Building Futures for Alzheimer's Disease Research. **2016**, 83-99
- 360 Dementia and Bioethics. **2016**, 1-13
- 359 Encyclopedia of Geropsychology. **2016**, 1-13
- 358 Demenz. **2016**, 1-89
- 357 Alzheimer's disease as a neuropathological continuum in clinical practice.. **2016**, 17, 305-309

356 Atypical Alzheimer's Disease, Mixed Dementia, and Amyloid Angiopathy. **2017**, 39-47

355 Mild Cognitive Impairment and Prodromal Alzheimer's Disease. **2017**, 23-26

354 Dementia and Bioethics. **2017**, 141-153

353 Evaluating Alzheimer's Disease Diagnosis Using Texture Analysis. **2017**, 470-481

2

352 Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 13. Auflage. **2017**, 1-111

351 Neuroimaging Approaches for Elderly Studies. **2017**, 1576-1617

350 Encyclopedia of Geropsychology. **2017**, 256-268

349 Encyclopedia of Clinical Neuropsychology. **2017**, 1-4

348 Systematik organisch-symptomatischer Störungen. **2017**, 1351-1364

347 Rethinking dementias. **2017**, 32, 117-118

346 Actualité des facteurs de risque des démences. **2017**, 201, 731-738

345 Assessing robustness of hazard ratio estimates to outcome misclassification in longitudinal panel studies with application to Alzheimer's disease. **2017**, 12, e0190107

1

344 Encyclopedia of Clinical Neuropsychology. **2018**, 1-9

343 Methods. **2018**, 23-44

342 Encyclopedia of Clinical Neuropsychology. **2018**, 2183-2190

341 Gini Based Learning for the Classification of Alzheimer's Disease and Features Identification with Automatic RGB Segmentation Algorithm. **2018**, 92-106

1

340 Clinical Meaningfulness of Biomarker Endpoints in Alzheimer's Disease Research. **2018**, 235-248

339 Cognitive Assessment in Alzheimer's Disease Clinical Trials. **2018**, 1750, 355-362

- 338 Longitudinal Follow-Up of a Population with MCI: Predictive Value of the MIS Test with Delayed Recall for Progression to Dementia. **2018**, 07, 183-196
- 337 Encyclopedia of Clinical Neuropsychology. **2018**, 2335-2338
- 336 Investigation. **2018**, 207-240
- 335 Classifying Alzheimer's disease using probability distribution distance of fractional anisotropy and trace from diffusion tensor imaging in combination with whole-brain segmentations. **2018**, 1 1
- 334 Que penser de lâapproche mdicamenteuse prventive de la maladie dâAlzheimer ?. **2018**, 202, 679-690
- 333 Characteristics of Conversation in Frontotemporal Dementia: Comparison with Dementia of the Alzheimerâ Type. **2018**, 23, 146-159 1
- 332 Reproducible evaluation of classification methods in Alzheimerâ disease: framework and application to MRI and PET data. 2
- 331 Detection and Analysis of Human Brain Disorders. **2019**, 717-726 0
- 330 Imagerie molculaire de demain : quels biomarqueurs et pour quelle maladie ?. **2018**, 202, 1523-1527
- 329 Organische (und symptomatische) psychische Störungen. **2019**, 187-246.e3
- 328 VGF in cerebrospinal fluid, when combined with conventional biomarkers, enhances prediction of conversion from mild cognitive impairment to Alzheimerâ Disease.
- 327 State of the Places of Senile Dementia in the Old Hospice of the City of Lubumbashi. **2019**, 08, 39-46
- 326 Introduction. **2019**, 1-20
- 325 Methods (1): Participants and Test Methods. **2019**, 21-49
- 324 Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 14. Auflage. **2019**, 1-119
- 323 Results (2): Estimates of Diagnostic Accuracy. **2019**, 109-148
- 322 Alzheimer's disease. **2019**, 11, 52-60 2
- 321 The comparisons of blood plasma and cerebrospinal fluid S100B protein concentrations in patients with Alzheimer's disease, amyotrophic lateral sclerosis, and multiple sclerosis. **2019**, 1, 22-27

320	Predicting MMSE Score from Finger-Tapping Measurement.	1
319	Assessment of Memory Impairment in Early Diagnosis of Alzheimer's Disease. <b>2019</b> , 16, 975-985	1
318	Assessing the Impact of Factors that Influence the Ketogenic Response to Varying Doses of Medium Chain Triglyceride (MCT) Oil. <b>2021</b> , 8, 19-28	2
317	Identification of Novel Gene variants in Patients with Alzheimer's Disease by Whole Exome Sequencing. <b>2020</b> , 4, 001-004	0
316	Clinical Topics in Old Age Psychiatry. <b>2020</b> ,	
315	Differential Brain Atrophy Patterns and Neurogenetic Profiles in Cognitively-Defined Alzheimer's Disease Subgroups.	
314	Transfer Learning for Alzheimer's Disease through Neuroimaging Biomarkers: A Systematic Review. <b>2021</b> , 21,	6
313	Genetics of dementia. <b>2020</b> , 127-146	
312	Coenzyme Q and Age-Related Neurodegenerative Disorders: Parkinson and Alzheimer Diseases. <b>2020</b> , 241-268	
311	An investigation into the commercialisation of initiation schools: A case of Eastern Cape, South Africa. <b>2020</b> , 76,	
310	Mild Cognitive Impairment Diagnosis and Detecting Possible Labeling Errors in Alzheimer's Disease with an Unsupervised Learning-based Approach. <b>2020</b> ,	
309	Quo vadis Alois?. <b>2020</b> , 155, 491-493	
308	Bibliographie. <b>2012</b> , 419-430	
307	Bibliographie. <b>2014</b> , 169-195	
306	Sex-specificities in anxiety and depressive symptoms across the lifespan and their links with multimodal neuroimaging. <b>2022</b> , 296, 593-602	0
305	Psychometric Properties of the Clinical Dementia Rating - Sum of Boxes and Other Cognitive and Functional Outcomes in a Prodromal Alzheimer's Disease Population. <b>2021</b> , 8, 151-160	4
304	Blood biomarkers in older subjects with mild behavioral impairment: A cross-sectional study from the memory clinic, all india institute of medical sciences, India. <b>2020</b> , 16, 91	2
303	Encyclopedia of Behavioral Medicine. <b>2020</b> , 617-622	

- 302 Assessment of Linear Discrimination and Nonlinear Discrimination Analysis in Diagnosis Alzheimer's Disease in Early Stages. **2020**, 09, 21-32
- 301 Encyclopedia of Gerontology and Population Aging. **2020**, 1-9
- 300 Brain Network Functional Connectivity in Alzheimer's Disease and Frontotemporal Dementia. **2020**, 385-415 0
- 299 Linking motor speech function and dementia. **2020**, 665-676
- 298 Clinical Usefulness of 18F-FC119S Positron-Emission Tomography as an Auxiliary Diagnostic Method for Dementia: An Open-Label, Single-Dose, Evaluator-Blind Clinical Trial. **2020**, 16, 131-139 1
- 297 Early Detection of Dementia. **2020**, 1963-1988 0
- 296 Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics.
- 295 Symptomatic, Genetic, and Mechanistic Overlaps between Autism and Alzheimer's Disease. **2021**, 11, 2
- 294 Dissecting Digital Card Games to Yield Digital Biomarkers for the Assessment of Mild Cognitive Impairment: Methodological Approach and Exploratory Study. **2021**, 9, e18359 2
- 293 Peptoid Nanosheet-Based Sensing System for the Diagnosis and Surveillance of Amnesic Mild Cognitive Impairment and Alzheimer's Disease. **2021**, 12, 4257-4264 1
- 292 The relationship between hypertension and dementia - a brief overview. **2020**, 13, 22-28 0
- 291 Early Detection of Dementia. 74-106
- 290 Amyloid imaging in Alzheimer's disease: A literature review.
- 289 Laboruntersuchungen. **2009**, 277-284
- 288 Alzheimer-Demenz. **2009**, 43-63 1
- 287 Distinctive alteration of presynaptic proteins in the outer molecular layer of the dentate gyrus in Alzheimer's disease.
- 286 An Operational Definition of 'Abnormal Cognition' to Optimize the Prediction of Progression to Dementia: What Are Optimal Cut-Off Points for Univariate and Multivariate Normative Comparisons?. **2020**, 77, 1693-1703 0
- 285 Neuroimaging Findings in Mild Cognitive Impairment. **2021**, 367-425 1



284	Impact of the New Conceptual Framework of Alzheimer’s Disease in Imaging Studies. <b>2021</b> , 427-451	
283	Perfusion SPECT: Its Role in the Diagnosis and Differential Diagnosis of Alzheimer’s Disease, with Particular Emphasis on Guidelines. <b>2021</b> , 453-468	
282	Voxel-based morphometry focusing on medial temporal lobe structures has a limited capability to detect amyloid $\beta$ an Alzheimer’s disease pathology. <b>2020</b> , 12, 19701-19710	
281	Predicting the Progression of Mild Cognitive Impairment Using Machine Learning: A Systematic, Quantitative and Critical Review.	
280	The Effect of Spinal Cord Injury on Beta-Amyloid Plaque Pathology in TgCRND8 Mouse Model of Alzheimer’s Disease. <b>2020</b> , 17, 576-586	1
279	The Parietal Atrophy Score on Brain Magnetic Resonance Imaging is a Reliable Visual Scale. <b>2020</b> , 17, 534-539	2
278	Psychopharmacology for the clinician: should we treat patients with verymild Alzheimer disease with acholinesterase inhibitor?. <b>2009</b> , 34, 480	
277	Structural neuroimaging in the detection and prognosis of pre-clinical and early AD. <b>2009</b> , 21, 3-12	21
276	Alzheimer’s therapies. <b>2007</b> , 4, 27-30	
275	Current neuroimaging techniques in Alzheimer’s disease and applications in animal models. <b>2012</b> , 2, 386-404	17
274	Advances in designs for Alzheimer’s disease clinical trials. <b>2012</b> , 1, 205-16	22
273	Progression to dementia in a population with amnesic mild cognitive impairment: clinical variables associated with conversion. <b>2012</b> , 27, 49-54	28
272	Early Diagnosis of Alzheimer’s Disease and Mild Cognitive Impairment: Imaging, Biomarkers, and Technology. <b>2009</b> , 33, 18-23	7
271	An update on the diagnosis and management of dementing conditions. <b>2011</b> , 8, e68-87	9
270	Omental transplantation for neurodegenerative diseases. <b>2014</b> , 3, 50-63	8
269	Comparison of two methods for the analysis of CSF A $\beta$ and tau in the diagnosis of Alzheimer’s disease. <b>2014</b> , 3, 143-51	6
268	Are the revised diagnostic criteria for Alzheimer’s disease useful in low- and middle-income countries?. <b>2015</b> , 27, 119-23	3
267	Atrophy and lower regional perfusion of temporo-parietal brain areas are correlated with impairment in memory performances and increase of EEG upper alpha power in prodromal Alzheimer’s disease. <b>2015</b> , 4, 13-27	2

266	Outcomes Assessment in Clinical Trials of Alzheimer's Disease and its Precursors: Ready for Short-term and Long-term Clinical Trial Needs. <b>2017</b> , 14, 22-29	24
265	The borderland between normal aging and dementia. <b>2017</b> , 29, 65-71	5
264	Z-score maps from low-dose F-FDG PET of the brain in neurodegenerative dementia. <b>2018</b> , 8, 239-246	2
263	Detection of Alzheimer's Disease. <b>2018</b> , 91, 291-300	17
262	Delta-Aminolevulinatase dehydratase and glutathione peroxidase activity in Alzheimer's disease: a case-control study. <b>2019</b> , 18, 866-875	
261	Early Detection of Alzheimer's Disease Based on Clinical Trials, Three-Dimensional Imaging Data, and Personal Information Using Autoencoders. <b>2021</b> , 11, 120-130	
260	The prevalence of mild cognitive impairment in Latin America and the Caribbean: a systematic review and meta-analysis. <b>2021</b> , 1-11	4
259	A VNS based framework for early diagnosis of the Alzheimer's disease converted from mild cognitive impairment. 1	
258	Brain structural and functional anomalies associated with simultanagnosia in patients with posterior cortical atrophy. <b>2021</b> , 1	1
257	Bibliographie. 235-241	
256	Les performances des patients âgés au cours de la démence : tentative de dénombrement par le clinicien gériatre. <b>2012</b> , 183-196	
255	Evaluation of Plasma Amyloid Peptides A $\beta$ and A $\beta$ as Diagnostic Biomarker of Alzheimer's Disease, its Association with Different Grades of Clinical Severity and 18F-Fluorodeoxyglucose Positron Emission Tomography Z score in the Indian Population: A Case-Control Study.. <b>2021</b> , 36, 391-397	
254	Prevention of Age-Related Cognitive Impairment, Alzheimer's Disease, and Dementia. <b>2021</b> , 3948-3956	
253	High Prevalence and Low Awareness of Mild Cognitive Impairment in a Suburban Community in Shanghai.. <b>2021</b> , 69, 1693-1700	0
252	Extracting Explainable Assessments of Alzheimer's disease via Machine Learning on brain MRI imaging data. <b>2020</b> ,	3
251	Application of Deep Learning Techniques to Diagnose Mild Cognitive Impairment: Functional Near-Infrared Spectroscopy Study. <b>2021</b> ,	1
250	Effects of repetitive transcranial magnetic stimulation combined with cognitive training on resting-state brain activity in Alzheimer's disease.. <b>2022</b> , 19714009211067409	0
249	Memory Binding Test and Its Associations With Hippocampal Volume Across the Cognitive Continuum Preceding Dementia.. <b>2022</b> , 10731911211069676	1

248	Patterns of Symptom Tracking by Caregivers and Patients With Dementia and Mild Cognitive Impairment: Cross-sectional Study.. <b>2022</b> , 24, e29219	1
247	The Outcome of Patients with Amyloid-Negative Amnestic Mild Cognitive Impairment.. <b>2022</b> ,	
246	Reactive astrogliosis: A friend or foe in the pathogenesis of Alzheimer's disease.. <b>2021</b> ,	2
245	Prediction of Cognitive Progression in Individuals with Mild Cognitive Impairment Using Radiomics as an Improvement of the ATN System: A Five-Year Follow-Up Study.. <b>2022</b> , 23, 89-100	
244	Multi-Modal Feature Selection with Feature Correlation and Feature Structure Fusion for MCI and AD Classification.. <b>2022</b> , 12,	5
243	Fingolimod Rescues Memory and Improves Pathological Hallmarks in the 3xTg-AD Model of Alzheimer's Disease.. <b>2022</b> , 59, 1882	3
242	Can We Use Extract to Treat Alzheimer's Disease? Lessons from Preclinical and Clinical Studies.. <b>2022</b> , 11,	2
241	Mitochondrial complex I abnormalities underlie neurodegeneration and cognitive decline in Alzheimer's disease.. <b>2022</b> ,	1
240	Multimodal Preventive Trial for Alzheimer's Disease: MIND-ADmini Pilot Trial Study Design and Progress.. <b>2022</b> , 9, 30-39	0
239	Predicted Cognitive Conversion in Guiding Early Decision-Tailoring on Patients With Cognitive Impairment.. <b>2021</b> , 13, 813923	
238	Fractalkine levels in patients with vascular dementia, Alzheimer's disease and mild cognitive impairment.. <b>2021</b> ,	
237	Epidemiologic Trends, Social Determinants, and Brain Health: The Role of Life Course Inequalities.. <b>2022</b> , STROKEAHA121032609	1
236	An optimized MRI and PET based clinical protocol for improving the differential diagnosis of geriatric depression and Alzheimer's disease.. <b>2022</b> , 320, 111443	1
235	Development of an MRI contrast agent for both detection and inhibition of the amyloid- $\beta$ fibrillation process.. <b>2022</b> , 12, 5027-5030	
234	Bayesian Spatial Binary Regression for Label Fusion in Structural Neuroimaging. 1-14	
233	Strategic Design of Amyloid- $\beta$ Species Fluorescent Probes for Alzheimer's Disease.. <b>2022</b> ,	0
232	The Volumetric Changes of the Pineal Gland with Age: An Atlas-based Structural Analysis.. <b>2022</b> , 1-31	
231	Salivary gland dysfunction and salivary redox imbalance in patients with Alzheimer's disease.. <b>2021</b> , 11, 23904	4

230	Towards a WPA Position Document on the Human Rights of Older Adults with Mental Health Conditions. <b>2022</b> , 3, 16-21	
229	Risk of conversion from mild cognitive impairment to dementia in low- and middle-income countries: A systematic review and meta-analysis.. <b>2022</b> , 8, e12267	4
228	Prediction of Conversion to Alzheimer’s Disease Using 3D-DWT and PCA. <b>2022</b> , 199-213	
227	Heart rate variability and cognitive performance in adults with cardiovascular risk. <b>2022</b> , 3, 100136	0
226	Use of medium chain triglyceride (MCT) oil in subjects with Alzheimer’s disease: A randomized, double-blind, placebo-controlled, crossover study, with an open-label extension.. <b>2022</b> , 8, e12259	1
225	Predicting diagnosis 4 years prior to Alzheimer’s disease incident.. <b>2022</b> , 34, 102993	3
224	The Evolution of Diagnostic Boundaries of Alzheimer’s Disease and Novel Therapeutic Options. <b>2022</b> , 3, 8-15	
223	Alzheimer Care toward bridging the gap between cure and care in patients with dementia.. <b>2022</b> , 1-10	
222	Profile of cognitive impairment in late-stage Parkinson’s disease.. <b>2022</b> , e32537	0
221	Correlations of frontal resting-state EEG markers with MMSE scores in patients with Alzheimer’s disease. <b>2022</b> , 58,	0
220	Pharmacogenetic Analyses of Therapeutic Effects of Lipophilic Statins on Cognitive and Functional Changes in Alzheimer’s Disease.. <b>2022</b> ,	1
219	Generalized EEG Slowing Across Phasic REM Sleep, Not Subjective RBD Severity, Predicts Neurodegeneration in Idiopathic RBD.. <b>2022</b> , 14, 407-418	0
218	Should Doctors Offer Biomarker Testing to Those Afraid to Develop Alzheimer’s Dementia? : Applying the Method of Reflective Equilibrium for a Clinical Dilemma.. <b>2022</b> , 1	0
217	Radiomics-Based Artificial Intelligence Differentiation of Neurodegenerative Diseases with Reference to the Volumetry.. <b>2022</b> , 12,	0
216	The Clinical Practice for Hippocampal Neurogenesis by Chronobiological Therapy. <b>2022</b> , 4, 42-45	
215	Central Auditory Functions of Alzheimer’s Disease and Its Preclinical Stages: A Systematic Review and Meta-Analysis.. <b>2022</b> , 11,	2
214	Different MMSE domains are associated to cognitive decline and education.. <b>2022</b> , 1-7	0
213	The changing landscape of neuroimaging in frontotemporal lobar degeneration: from group-level observations to single-subject data interpretation.. <b>2022</b> ,	2

212 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase IIb Clinical Study to Evaluate the Safety and Efficacy of DHP1401 in Patients with Mild to Moderate Alzheimer’s Disease Treated with Donepezil: DHP1401 Randomized Trial in Mild to Moderate Alzheimer’s Disease (DRAMA).. **2022,**

211 Diagnostic Accuracy of the Five-Word Test for Mild Cognitive Impairment Due to Alzheimer’s Disease.. **2022, 14, 357-367** 0

210 Lights and Shadows of Cerebrospinal Fluid Biomarkers in the Current Alzheimer’s Disease Framework.. **2022,**

209 Quantification of amyloid PET for future clinical use: a state-of-the-art review.. **2022, 1** 1

208 An Increased Aspartate to Alanine Aminotransferase Ratio Is Associated With a Higher Risk of Cognitive Impairment.. **2022, 9, 780174** 0

207 A Novel Alzheimer’s Disease Detection Approach Using GAN-based Brain Slice Image Enhancement. **2022,** 1

206 The Free and Cued Selective Reminding Test: Discriminative Values in a Naturalistic Cohort.. **2022,**

205 Early Detection of Alzheimer’s Disease Using Bottleneck Transformers. **2022, 18, 1-14**

204 Classification of healthy, Alzheimer and Parkinson populations with a multi-branch neural network. **2022, 75, 103617** 0

203 Using the ATN system as a guide for the neuropsychological assessment of Alzheimer’s disease.. **2022, 1-18** 0

202 Structural and functional abnormalities of olfactory-related regions in subjective cognitive decline, mild cognitive impairment and Alzheimer’s disease. **2021,** 4

201 Modulation of the rat hippocampal-cortex network and episodic-like memory performance following entorhinal cortex stimulation.. **2021,** 1

200 Applications and Challenges of Machine Learning Methods in Alzheimer’s Disease Multi-Source Data Analysis.. **2021, 22, 564-582** 1

199 Distributions of A $\beta$ 42 and A $\beta$ 42/40 in the Cerebrospinal Fluid in View of the Probability Theory.. **2021, 11,** 1

198 Blood-based biomarkers for Alzheimer’s disease. **2021, e14408** 7

197 Repetitive Transcranial Magnetic Stimulation for Alzheimer’s Disease Based on Apolipoprotein E Genotyping: Protocol for a Randomized Controlled Study.. **2021, 13, 758765** 0

196 The borderland between normal aging and dementia. **2017, 29, 65** 8

195 CURVED MULTIFORMAT IMAGING OF STRUCTURAL MRI AS A BIOMARKER FOR PROFILING OF VARIOUS DEMENTIA - AN ALGORITHMIC APPROACH WITH MR/PET.. **2022, 73, 103094**

194 Localization, induction, and cellular effects of tau-phospho-threonine 217.

193 MRS in neurodegenerative disease. 144-160

192 Individualized quality of life measurement in neurodegenerative disorders. 174-187

191 Data\_Sheet\_1.docx. 2020,

190 Image\_1.TIF. 2020,

189 Image\_2.TIF. 2020,

188 Image\_3.TIF. 2020,

187 Image\_4.TIF. 2020,

186 Image\_1.JPEG. 2018,

185 Image\_2.JPEG. 2018,

184 Image\_3.JPEG. 2018,

183 Table\_1.DOCX. 2018,

182 Table\_1.DOCX. 2018,

181 Data\_Sheet\_1.xlsx. 2018,

180 Presentation\_1.pdf. 2018,

179 Table\_1.doc. 2019,

178 Table\_1.docx. 2020,

177 Image\_1.tif. 2019,

176 Table\_1.DOCX. 2019,

175 Table\_1.DOCX. 2020,

174 Data\_Sheet\_1.PDF. 2019,

173 Data\_Sheet\_10.ZIP. 2019,

172 Data\_Sheet\_2.PDF. 2019,

171 Data\_Sheet\_3.PDF. 2019,

170 Data\_Sheet\_4.PDF. 2019,

169 Data\_Sheet\_5.PDF. 2019,

168 Data\_Sheet\_6.pdf. 2019,

167 Data\_Sheet\_7.pdf. 2019,

166 Data\_Sheet\_8.PDF. 2019,

165 Data\_Sheet\_9.zip. 2019,

164 Data\_Sheet\_1.XLS. 2020,

163 Image\_1.TIF. 2020,

162 Table\_1.DOCX. 2020,

161 Table\_1.docx. 2020,

160 Video\_1.MP4. 2020,

159 Video\_2.MP4. 2020,

158 Video\_3.MP4. 2020,

157 Table\_1.XLSX. 2019,

156 Table\_2.XLSX. 2019,

155 Data\_Sheet\_1.doc. 2020,

154 Table\_1.DOCX. 2020,

153 Table\_2.DOCX. 2020,

152 Table\_3.docx. 2020,

151 Data\_Sheet\_1.PDF. 2020,

150 Image\_1.pdf. 2020,

149 Image\_2.pdf. 2020,

148 Image\_3.pdf. 2020,

147 Image\_4.pdf. 2020,

146 Table\_1.docx. 2020,

145 Table\_2.xlsx. 2020,

144 Table\_3.xlsx. 2020,

143 Table\_4.docx. 2020,

142 Table\_5.docx. 2020,

141 Table\_6.docx. 2020,



140 Data\_Sheet\_1.docx. **2020**,

139 Data\_Sheet\_2.zip. **2020**,

138 The retinal ganglion cell layer reflects neurodegenerative changes in cognitively unimpaired individuals.. **2022**, 14, 57 2

137 Advances in the development of new biomarkers for Alzheimer's disease.. **2022**, 11, 25 2

136 The management of dementia worldwide: A review on policy practices, clinical guidelines, end-of-life care, and challenge along with aging population.. **2022**, 16, 0

135 Association of the top 20 Alzheimer's disease risk genes with [F]lortaucipir PET.. **2022**, 14, e12308

134 Season of birth and vulnerability to the pathology of Alzheimer's disease: an in vivo positron emission tomography study.. **2022**,

133 Correlation Between Brain Structure Atrophy and Plasma Amyloid- $\beta$  and Phosphorylated Tau in Patients With Alzheimer's Disease and Amnesic Mild Cognitive Impairment Explored by Surface-Based Morphometry.. **2022**, 14, 816043 1

132 How to use neuroimaging biomarkers in the diagnosis framework of neurodegenerative diseases?. **2022**,

131 AD Resemblance Atrophy Index of Brain Magnetic Resonance Imaging in Predicting the Progression of Mild Cognitive Impairment Carrying Apolipoprotein E- $\epsilon$  Allele.. **2022**, 14, 859492 0

130 A Stacking Framework for Multi-Classification of Alzheimer's Disease Using Neuroimaging and Clinical Features.. **2022**, 0

129 Cognitive functioning in essential tremor without dementia: a clinical and imaging study.. **2022**, 1 0

128 Impaired Affordance Perception as the Basis of Tool Use Deficiency in Alzheimer's Disease. **2022**, 10, 839 0

127 Association of Peripheral Blood Cell Profile With Alzheimer's Disease: A Meta-Analysis. **2022**, 14, 0

126 A novel approach to type 3 diabetes mechanism: The interplay between noncoding RNAs and insulin signaling pathway in Alzheimer's disease.. **2022**, 0

125 Decreased 5-HT binding in mild Alzheimer's disease - a PET study.. **2022**,

124 Association of Circulating Apolipoprotein AI Levels in Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis. **2022**, 14,

123 Differential diagnosis of vascular cognitive impairment. **2022**, 24, 85-89

- 122 Intestinal Microflora Changes in Patients with Mild Alzheimer's Disease in a Chinese Cohort. **2022**, 1-13 0
- 121 Analysis of Genetic Association Between ABCA7 Polymorphism and Alzheimer's Disease Risk in the Southern Chinese Population. 14, 0
- 120 APOE  $\epsilon$  Allele Distribution and Association With Scores of Subjective Cognitive Decline Questionnaire 9 in a Large Chinese Memory Clinic Cohort. **2022**, 16, 0
- 119 Volumetric Assessment of Hippocampus and Subcortical Gray Matter Regions in Alzheimer Disease and Amnesic Mild Cognitive Impairment. **2022**, 35, 95-103 0
- 118 Histoire naturelle et diagnostic de la maladie d'Alzheimer. **2022**, 143-161 0
- 117 Clinical applicability of quantitative atrophy measures on MRI in patients suspected of Alzheimer's disease. 2
- 116 Whole Exome Sequencing Reveals a Novel APOE Mutation in a Patient With Sporadic Early-Onset Alzheimer's Disease. 13, 1
- 115 Investigation of Underlying Association Between Whole Brain Regions and Alzheimer's Disease: A Research Based on an Artificial Intelligence Model. 14, 0
- 114 CT-Detected MTA Score Related to Disability and Behavior in Older People with Cognitive Impairment. **2022**, 10, 1381 0
- 113 Differential Diagnosis Between Alzheimer's Disease-Related Depression and Pseudo-Dementia in Depression: A New Indication for Amyloid- $\beta$  Imaging?. **2022**, 1-7 0
- 112 Comparison of dynamic susceptibility contrast enhanced MR and FDG-PET brain studies in patients with Alzheimer's disease and amnesic mild cognitive impairment. **2022**, 20, 0
- 111 Toward harmonization of strategies for investigating lucidity in AD/ADRD: A preliminary research framework. 0
- 110 Sex-Specific Associations of Diabetes With Brain Structure and Function in a Geriatric Population. 14, 2
- 109 Learning to Recognize Others: The Effect of Vocal Emotions. **2022**, 167-192 0
- 108 Contribution of Memory Tests to Early Identification of Conversion from Amnesic Mild Cognitive Impairment to Dementia. **2022**, 1-13 0
- 107 Dietary Alterations in Impaired Mitochondrial Dynamics Due to Neurodegeneration. 14, 0
- 106 Classification of Alzheimer's Disease Based on Deep Learning of Brain Structural and Metabolic Data. 14, 0
- 105 Alzheimer's Disease Blood Biomarkers Associated With Neuroinflammation as Therapeutic Targets for Early Personalized Intervention. 4, 0

104	Application of diffusion tensor imaging based on automatic fiber quantification in Alzheimer's disease.. <b>2022</b> , 19,	0
103	Grey matter changes on brain MRI in subjective cognitive decline: a systematic review. <b>2022</b> , 14,	
102	Non-Invasive Nasal Discharge Fluid and Other Body Fluid Biomarkers in Alzheimer's Disease. <b>2022</b> , 14, 1532	0
101	Biomarkers for the Diagnosis of Alzheimer's Disease in Clinical Practice: The Role of CSF Biomarkers during the Evolution of Diagnostic Criteria. <b>2022</b> , 23, 8598	0
100	Proteomic Discovery and Validation of Novel Fluid Biomarkers for Improved Patient Selection and Prediction of Clinical Outcomes in Alzheimer's Disease Patient Cohorts. <b>2022</b> , 10, 26	0
99	Ultra-high-resolution time-frequency analysis of EEG to characterise brain functional connectivity with the application in Alzheimer's disease. <b>2022</b> , 19, 046034	
98	Comparing Medial Temporal Atrophy Between Early-Onset Semantic Dementia and Early-Onset Alzheimer's Disease Using Voxel-Based Morphometry: A Multicenter MRI Study. <b>2022</b> , 19,	1
97	Effect of acupuncture with donepezil based on syndrome differentiation on cognitive function in patients with mild-to-moderate Alzheimer's disease: a study protocol for a multicenter randomized controlled trial. <b>2022</b> , 23,	
96	Designing the next-generation clinical care pathway for Alzheimer's disease. <b>2022</b> , 2, 692-703	3
95	Expansion microscopy at one nanometer resolution.	3
94	Biomarker and therapeutic potential of peripheral extracellular vesicles in Alzheimer's disease. <b>2022</b> , 114486	0
93	Exploring Early Physical Examination Diagnostic Biomarkers for Alzheimer's Disease Based on Least Absolute Shrinkage and Selection Operator. <b>2022</b> , 2022, 1-10	0
92	Assessing mild cognitive impairment using object-location memory in immersive virtual environments. <b>2022</b> , 32, 660-678	0
91	A Belief Rule Based Expert System to Diagnose Alzheimer's Disease Using Whole Blood Gene Expression Data. <b>2022</b> , 301-315	0
90	Exosomes as diagnostic tools. <b>2022</b> , 117-144	0
89	Sex and gender differences in dementia. <b>2022</b> , 179-233	0
88	Brain atrophy pattern in patients with mild cognitive impairment: MRI study. <b>2022</b> , 13, 335-348	0
87	The temporal lobes and memory. <b>2022</b> , 319-337	1

86	Association between Subclinical Epileptiform Discharge and the Severity of Cognitive Decline in Alzheimer's Disease: A Longitudinal Cohort Study. <b>2022</b> , 1-8	0
85	Requirements of Scintillation Crystals with the Development of PET Scanners. <b>2022</b> , 12, 1302	0
84	Altered Microcirculation in Alzheimer's Disease Assessed by Machine Learning Applied to Functional Thermal Imaging Data. <b>2022</b> , 9, 492	0
83	Biomarkers for dementia in Latin American countries: Gaps and opportunities.	2
82	Wrist accelerometry for monitoring dementia agitation behaviour in clinical settings: A scoping review. 13,	2
81	Tear Biomarkers in Alzheimer's and Parkinson's Diseases, and Multiple Sclerosis: Implications for Diagnosis (Systematic Review). <b>2022</b> , 23, 10123	2
80	Targeting the cannabinoid system to counteract the deleterious effects of stress in Alzheimer's disease. 14,	0
79	Multipronged diagnostic and therapeutic strategies for Alzheimer's disease.	2
78	Research progress of psychoradiology in geriatric neurodegenerative diseases. <b>2022</b> ,	0
77	Altered functional association and couplings: Effective diagnostic neuromarkers for Alzheimer's disease. 14,	0
76	Synaptic Proteins as Fluid Biomarkers in Alzheimer's Disease: A Systematic Review and Meta-Analysis. <b>2022</b> , 1-13	0
75	Cerebrospinal Fluid Biomarker Profile in TDP-43-Related Genetic Frontotemporal Dementia. <b>2022</b> , 12, 1747	0
74	The Concentration of Fibronectin and MMP-1 in Patients with Alzheimer's Disease in Relation to the Selected Antioxidant Elements and Eating Habits. <b>2022</b> , 11, 6360	0
73	Graph Analysis of Functional Brain Topology Using Minimum Spanning Tree in Subjective Cognitive Decline. <b>2022</b> , 1-11	0
72	Forgetting rate for the familiarity and recollection components of recognition in amnesic mild cognitive impairment: A longitudinal study. 1-13	0
71	Do informant-reported subjective cognitive complaints predict progression to mild cognitive impairment and dementia better than self-reported complaints in old adults? A meta-analytical study. <b>2022</b> , 101772	1
70	Targeting amyloid proteins for clinical diagnosis of neurodegenerative diseases. <b>2022</b> ,	1
69	Fluid biomarkers in Alzheimer's disease. <b>2022</b> ,	0

68 Classification of Alzheimer’s disease and frontotemporal dementia using routine clinical and cognitive measures across multicentric underrepresented samples: A cross sectional observational study. **2023**, 17, 100387 1

67 Una revisión de técnicas básicas de neuroimagen para el diagnóstico de enfermedades neurodegenerativas.. **2018**, 17, 59-90 1

66 Epigenome-Wide Association Study in Peripheral Tissues Highlights DNA Methylation Profiles Associated with Episodic Memory Performance in Humans. **2022**, 10, 2798 0

65 CSF proteome profiling across the Alzheimer’s disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panels. 0

64 Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer’s disease. **2022**, 14, 0

63 Reduced Expression of Voltage-Gated Sodium Channel Beta 2 Restores Neuronal Injury and Improves Cognitive Dysfunction Induced by A $\beta$ 1-42. **2022**, 2022, 1-21 0

62 Sex Difference in General Cognition Associated with Coupling of Whole-brain Functional Connectivity Strength to Cerebral Blood Flow Changes During Alzheimer’s Disease Progression. **2023**, 509, 187-200 0

61 Evolution of the diagnostic frontiers of Alzheimer’s disease and new therapeutic possibilities. **2022**, 122, 38 0

60 Blood Biomarkers for the Diagnosis of Neurodegenerative Dementia: A Systematic Review. 089198872211416 0

59 Association of Subjective Cognitive Decline With Progression to Dementia in a Cognitively Unimpaired Multiracial Community Sample. 10.1212/WNL.0000000000201658 1

58 Effects of preventive interventions on neuroimaging biomarkers in subjects at-risk to develop Alzheimer’s disease: A systematic review. 14, 0

57 Validity of Visuoconstructional Assessment Methods within Healthy Elderly Greek Australians: Quantitative and Error Analysis. 0

56 Effects of Remote Expressive Arts Program in Older Adults with Mild Cognitive Impairment: A Randomized Controlled Trial. **2022**, 1-17 0

55 Decoding the heterogeneity of Alzheimer’s disease diagnosis and progression using multilayer networks. 0

54 Deep brain stimulation of the nucleus basalis of Meynert modulates hippocampal-frontoparietal networks in patients with advanced Alzheimer’s disease. **2022**, 11, 0

53 The use of an individual-based FDG-PET volume of interest approach in mild cognitive impairment: a multi-modality longitudinal follow-up study. 0

52 Trajectories of Cognitive Impairment in Adults Bearing Vascular Risk Factors, with or without Diagnosis of Mild Cognitive Impairment: Findings from a Longitudinal Study Assessing Executive Functions, Memory, and Social Cognition. **2022**, 12, 3017 0

51 Association Between Acoustic Features and Neuropsychological Test Performance in the Framingham Heart Study: Observational Study. **2022**, 24, e42886 0

- 50 Sex-dependent changes in emotional memory associated with cerebral blood flow alterations during Alzheimer's disease progression. ○
- 49 Alzheimer's Disease: Clinical Trials and the Amyloid Hypothesis. **2011**, 40, 304-306 ○
- 48 Theta Frequency is Associated to Morpho-Structural and Perfusional Modifications in Subjects with Mild Cognitive Impairment. **2014**, 1, 3-13 ○
- 47 CSF biomarkers for early-onset Alzheimer's disease in Chinese population from PUMCH dementia cohort. 13, ○
- 46 Eat for better cognition in older adults at risk for Alzheimer's disease. **2023**, 111969 ○
- 45 Localization, induction, and cellular effects of tau phosphorylated at threonine 217 1. ○
- 44 Wechsler memory scale-fourth edition (WMS-IV) in the neuropsychological evaluation of patients diagnosed with probable Alzheimer's disease. 1-8 ○
- 43 A short and simple bedside test to detect cognitive fluctuations in patients with dementia with Lewy bodies.. ○
- 42 Acquired Pedophilia: international Delphi-method-based consensus guidelines. **2023**, 13, ○
- 41 A Novel Framework for Classification of Different Alzheimer's Disease Stages Using CNN Model. **2023**, 12, 469 2
- 40 Rapid progress in neuroimaging technologies fuels central nervous system translational medicine. **2023**, 103485 ○
- 39 Increase of ALCAM and VCAM-1 in the plasma predicts the Alzheimer's disease. 13, ○
- 38 Disruption of mitochondrial respiration and the monoamine neurotransmitter system in Alzheimer's disease. ○
- 37 White matter alterations in amnesic mild cognitive impairment: a tract-based spatial statistics study. ○
- 36 Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer's Disease. **2023**, 1-13 ○
- 35 Robustness of CSF A $\beta$ 42/40 and A $\beta$ 42/P-tau181 measured using fully automated immunoassays to detect AD-related outcomes. ○
- 34 Cerebral blood flow changes induced by high-frequency repetitive transcranial magnetic stimulation combined with cognitive training in Alzheimer's disease. 14, ○
- 33 Dry Chemistry-Based Bipolar Electrochemiluminescence Immunoassay Device for Point-of-Care Testing of Alzheimer-Associated Neuronal Thread Protein. ○

- 32 Dynamic Amyloid and Metabolic Signatures of Delayed Recall Performance within the Clinical Spectrum of Alzheimer’s Disease. **2023**, 13, 232 ○
- 31 Cognitive effects of cilostazol in Alzheimer’s dementia patients with peripheral arterial occlusive disease: A case-control study. ○
- 30 The Effects of SARS-CoV-2 Infection on the Cognitive Functioning of Patients with Pre-Existing Dementia. 1-10 ○
- 29 Comparison of Cognitive Intervention Strategies for Individuals With Alzheimer’s Disease: A Systematic Review and Network Meta-analysis. ○
- 28 Demographic and Neuropsychologic Profiles of Patients with Neurodegenerative Dementia: Results from A Tertiary Referral University Hospital. **2023**, 5, 59-65 ○
- 27 Abnormal white matter changes in Alzheimer’s disease based on diffusion tensor imaging: A systematic review. **2023**, 87, 101911 ○
- 26 Accelerated cognitive decline after the COVID -19 pandemic in a community population of older persons with cognitive impairment: A 4-year time series analysis in the Tokyo Metropolis area. **2023**, 23, 200-204 ○
- 25 SynthSR: A public AI tool to turn heterogeneous clinical brain scans into high-resolution T1-weighted images for 3D morphometry. **2023**, 9, ○
- 24 A novel regulator in Alzheimer’s disease progression: The astrocyte-derived extracellular vesicles. **2023**, 86, 101871 ○
- 23 Particulate matter exposure from motorized traffic and risk of conversion from mild cognitive impairment to dementia: An Italian prospective cohort study. **2023**, 222, 115425 ○
- 22 Investigation of the gait parameters after donepezil treatment in patients with alzheimer’s disease. 1-5 ○
- 21 The multidimensional neurocognitive geometry in Alzheimer’s disease and posterior cortical atrophy. ○
- 20 Finding the falsification threshold of the toxic proteinopathy hypothesis in neurodegeneration. **2023**, 143-154 ○
- 19 Longitudinal changes in participant and informant reports of subjective cognitive complaints are associated with dementia risk. 15, ○
- 18 Neuroimaging studies of acupuncture on Alzheimer’s disease: a systematic review. **2023**, 23, ○
- 17 Beta-Hydroxybutyrate (BHB), Glucose, Insulin, Octanoate (C8), and Decanoate (C10) Responses to a Medium-Chain Triglyceride (MCT) Oil with and without Glucose: A Single-Center Study in Healthy Adults. **2023**, 15, 1148 ○
- 16 Evaluation of the 18F-labeled analog of the therapeutic all-D-enantiomeric peptide RD2 for amyloid imaging. **2023**, 184, 106421 ○
- 15 Predicting Conversion from Subjective Cognitive Decline to Mild Cognitive Impairment and Alzheimer’s Disease Dementia Using Ensemble Machine Learning. **2023**, 1-16 ○

- 14 Involvement of ApoE4 in dementia with Lewy bodies in the prodromal and demented stages: evaluation of the Strasbourg cohort. ○
- 13 Early detection of cognitive decline in Alzheimer's disease using eye tracking. 15, ○
- 12 Enfermedad de Alzheimer. **2023**, 13, 4360-4371 ○
- 11 Ginkgo biloba Extract EGb 761 in the Treatment of Patients with Mild Neurocognitive Impairment: A Systematic Review. Volume 19, 647-660 ○
- 10 Neurodegeneration: Cerebrum. **2013**, 947-947.e19 ○
- 9 Deep learning-based EEG analysis to classify normal, mild cognitive impairment, and dementia: Algorithms and dataset. **2023**, 272, 120054 ○
- 8 Model-based whole-brain perturbational landscape of neurodegenerative diseases. 12, ○
- 7 Directed Functional Brain Connectivity is Altered in Sub-threshold Amyloid- $\beta$  Accumulation in Cognitively Normal Individuals. **2023**, 18, 263310552311616 ○
- 6 The Use of Diffusion Kurtosis Imaging for the Differential Diagnosis of Alzheimer's Disease Spectrum. **2023**, 13, 595 ○
- 5 A short and simple bedside test to detect cognitive fluctuations in patients with dementia with Lewy bodies. ○
- 4 Apraxia and dementia severity in Alzheimer's disease: a systematic review. 1-20 ○
- 3 Structural complexity of brain regions in mild cognitive impairment and Alzheimer's disease. ○
- 2 Validation of automated hippocampus volume assessment using deep learning convolutional neural networks in patients with Alzheimer's disease. ○
- 1 Comprehensive review of task-based neuroimaging studies of cognitive deficits in Alzheimer's disease using electrophysiological methods. **2023**, 88, 101950 ○